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Abstract
The manufacturing of biopharmaceuticals requires substantial investments and necessi-
tates long-term planning. Complicating the task of determining optimal production plans
are large portfolios of products and facilities which limit the tractability of exact solution
methods, and uncertainties & stochastic events which often render plans obsolete when
reality deviates from the expectation. This thesis therefore describes decisional tools that
are able to cope with these complexities.
First, a capacity planning problem for a network of facilities and multiple products was
tackled. Inspired by meta-heuristic approaches to job shop scheduling, a tailored construc-
tion heuristic that builds a production plan based on a sequence — optimised by a genetic
algorithm — of product demands was proposed. Comparisons to a mathematical program-
ming model demonstrated its competitiveness on certain scenarios and its applicability to
a multi-objective problem.
Next, a custom object-oriented model was introduced for a manufacturing scheduling
system that utilised a failure-prone perfusion-based bioprocess. With this, process design
decisions such as cell culture run time and process configuration, and single-product fa-
cility scheduling strategies were evaluated whilst incorporating simulations of stochastic
failure events and uncertain demand.
This model was then incorporated into a larger hyper-heuristic to determine optimal
scheduling policies for a multi-product problem. Various policy representations are tested
and a few policies are adapted from the literature to fit this specific problem. In addition, a
novel policy utilising a look-ahead heuristic is proposed. The benefit of parameter tuning
using evolutionary algorithms is demonstrated and shows that tuned policies perform much
better than a policy that estimates parameters based on service level considerations. In
addition, the disadvantages of relying on a fixed or rigid production sequence policy in the
face of uncertainty is highlighted.
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Chapter 1
Introduction
1.1 Motivation
The production of biopharmaceuticals is an expensive and time-consuming endeav-
our requiring large investments and long-term production planning. The average
cost to bring a new biopharmaceutical to market is estimated at $1.2-1.8 billion
given the high attrition rates (DiMasi and Grabowski, 2007; Paul et al., 2010), and
building large multiproduct manufacturing facilities can take 4-5 years to complete
and costs $40-650 million (Farid, 2007) in addition to the decade-long timeline
required for drug development.
Due to the high cost and long timeframes, biopharmaceutical companies have
to plan production well in advance, often utilising demand forecasts to guide their
decision-making. However, biopharmaceutical production has a number of charac-
teristics that make it challenging to optimise including: interdependent decisions;
multiple conflicting objectives; heterogeneity in product and manufacturing facil-
ity portfolios; options for third-party partnerships or outsourcing; batch and semi-
continuous manufacturing processes; uncertainties in the manufacturing process or
external factors; and product lability (Lim et al., 2006; Lakhdar et al., 2007; George
and Farid, 2008).
Literature in the pharmaceutical or biopharmaceutical industry on planning and
production scheduling is small but growing (Vieira et al., 2015). However, the
models used either are restricted to deterministic problems, only model one mode
of processing, or do not focus on scheduling. In addition, there is a dependence,
in much of the existing literature, on exact solution methods which whilst useful
and powerful, become intractable with increasing problem size. They also may be
1
restricted in their ability to model real-life systems due to simplifying assumptions
made in order to formulate the problem(s).
As a result, there exists a gap to use heuristic, meta-heuristic, and/or hyper-
heuristic techniques to: (i) provide alternative solution approaches to previous
problems by providing improvements in speed or objective value performance, or
a more accurate model of reality; (ii) pose questions and investigate aspects of
biopharmaceutical production planning that have so far not been within the scope
of the current literature; and (iii) deal with the stochastic and uncertain nature of
planning and manufacturing systems.
1.2 Research Questions
The challenges and opportunities described above may be mitigated by process
design & scale-up, planning, strategy, and decision-making which is efficient and
effective (in terms of cost, time and effort). Within this context, the questions posed
by this thesis and which it will attempt to answer include:
• What is a suitable meta-heuristic alternative to exact solution methods to
capacity planning and scheduling for a network of biopharmaceutical manu-
facturing facilities?
– How does the performance of this meta-heuristic compare empirically
with existing approaches?
– What is the scope for providing a decision-maker with ‘equally good’
solutions with different trade-offs regarding multiple conflicting objec-
tives?
• What is the effect on scheduling of uncertainty due to fluctuating demand
and randomly failing processes?
– What process design decisions (i.e., process run time and process con-
figuration) deliver optimum performance in the face of random process
failure?
– Given process configuration and uncertain demand, what is a suitable
strategy to simultaneously determine optimum run times and schedule
manufacturing batches for a single product?
2
• Additionally, given instead, a system of multiple products with uncertain
demand and process failure:
– What are good representations and parameters for scheduling policies
to dynamically allocate facility capacity optimally between products?
– What is the benefit of implementing flexible process run times?
To answer these questions, decision tools based on heuristic, meta-heuristic,
and hyper-heuristic techniques are developed and problem instances are formulated
to test and validate them. These tools can support biopharmaceutical companies in
planning and scheduling decisions.
1.3 Structure of Thesis
This thesis is composed of six more chapters plus some additional appendices and
is structured as described below. The earlier chapters aim to provide necessary
background to the research questions whilst the latter chapters develop the tools
required and tackle these questions head-on.
Chapter 2 on page 5 provides an overview of the biopharmaceutical industry,
detailing the effort required in drug development and describing a typical manu-
facturing process. The aim of this chapter is to demonstrate the opportunities but
also the challenges facing the companies operating in the industry.
Chapter 3 on page 14 delves into a detailed survey on literature related to pro-
duction planning research. This focuses on lot sizing and scheduling models with
purely deterministic or part stochastic components. There are also brief introduc-
tions to the algorithms utilised in this thesis. Additionally, it highlights the gaps in
the planning literature for the biopharmaceutical industry.
In Chapter 4 on page 28, a meta-heuristic is proposed to solve the complex
combinatorial optimisation problem of deterministic scheduling and planning of
multi-site biopharmaceutical manufacturing. This novel proposal is subsequently
compared with an exact solution method from the existing literature in an attempt
to highlight its usefulness in certain scenarios.
A novel hyper-heuristic framework is proposed and developed in Chapter 5 on
page 62 which incorporates a custom object-oriented model simulating schedul-
ing decisions and operational events in semi-continuous perfusion processes. This
3
framework is then evaluated in terms of determining optimal process design and
scheduling decisions in the face of stochastic and uncertain events.
Further to that, Chapter 6 on page 98 uses this framework and tests a range of
scheduling policies on a synthetic case study of a single multi-product facility. In
addition to demonstrating the benefit and robustness of policies compared to more
basic rules, the usefulness of flexible process run times is explored.
Chapter 7 on page 139 wraps up this thesis by revisiting and summarising the
contributions of the thesis while giving an outlook on possible future work.
4
Chapter 2
Background on the
Biopharmaceutical Industry
The biopharmaceutical industry is concerned with the development, manufactur-
ing, and marketing & commercialisation of biopharmaceutical drugs1. These bio-
pharmaceuticals are complex biological molecules which are marketed and com-
mercialised for therapeutic or diagnostic uses. Worldwide sales of biopharmaceuti-
cals totalled $140 billion in 2013 (La Merie Business Intelligence, 2013), growing
to $228 billion in 2016 (Troein, 2017), and represent the fastest growing sector of
the overall pharmaceutical market. Biopharmaceuticals are usually distinguished
from other pharmaceuticals or small molecule drugs which, unlike biopharmaceu-
ticals, can be synthesised chemically and can be described atom-by-atom (Rader,
2005). Biopharmaceuticals require biotechnology methods for manufacture, often
in a host cell organism which often has been genetically engineered to produce the
biopharmaceutical.
A non-exhaustive list of the types of biopharmaceuticals includes vaccines,
gene therapy products, recombinant proteins, cultured cells and tissues, human
blood products, enzymes, and monoclonal antibodies (mAbs). Table 2.1 on the fol-
lowing page lists pharmaceuticals (including small molecule drugs) with the high-
est worldwide revenue in 2017, highlighting the clout of biopharmaceuticals in the
broader market, especially mAbs. A mAb refers to therapeutic antibodies which
are made from a cell line of identical clones sourced from a single unique parent.
Antibodies — which are large protein molecules — have very strong affinity and
1These may also be referred to as biologics.
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6
specificity to targets (antigens) unique to each antibody clone. These antigens can
be pathogenic bacteria, viruses or even cancer cells.
2.1 Drug and Process Development
Biopharmaceutical drug development refers to the process of taking a molecule
from first discovery of the potential therapeutic action to a commercial product on
the market available for use by patients and the healthcare providers administering
them to the patients (see Figure 2.1 on the next page). This drug development
is extremely lengthy (Werner, 2004), expensive (DiMasi and Grabowski, 2007),
complex, and risky (DiMasi et al., 2010). The estimated total capitalised cost for
each new biopharmaceutical molecule to achieve market approval can exceed $1.2
billion (DiMasi and Grabowski, 2007).
Part of this R&D effort takes place on two parallel but interacting and inter-
dependent tracks. On one track is clinical development which involves a series
of clinical trials and essentially aims to ascertain if the therapeutic is safe and if
it works. The other track is process development in which a manufacturing pro-
cess for producing the therapeutic for testing in clinical trials and for commercial
production is designed and undergoes scale-up. Decisions made in clinical devel-
opment affect process development and vice versa. This is because the molecule
that goes through clinical testing comes from the manufacturing process that is
concurrently undergoing development. Due to the complexity of biologics and bi-
ological systems, the molecule’s identity is often linked to (and in part determined
by) its manufacturing process. As a result, process design decisions have to be con-
sistent through development to ensure that it is the same molecule going through all
stages of clinical development. Similarly, decisions made in clinical development
on dosage and method of delivery mean that the manufacturing process will need to
be productive enough and produce the molecule in the correct formulation to match
the clinical efforts. In addition, in the early stages of development, a company will
often need to commit capital towards a facility to house the manufacturing process
without the guarantee that the drug candidate will successfully clear clinical trials.
In the stages of developing a biopharmaceutical, the initial drug discovery
comes before clinical or process development. This drug discovery is composed
of four stages: target identification, target validation, lead identification, and lead
optimisation. This process involves identifying potential targets for therapeutic ac-
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tion that are involved in the model of the disease in question and selecting the most
promising of those targets. Then these targets are used to screen a large number
of molecules to test and identify the molecules (leads) that have specificity for the
target and cause the desired changes to the target. The leads are subsequently op-
timised to improve activity. Selection of the optimal lead or drug candidate moves
the process into clinical development. The potential difficulty or feasibility of man-
ufacturing is often a factor in drug candidate selection.
Clinical development is made up of several different stages. Before any in-
human trials, pre-clinical testing is carried out to assess if the drug candidate is
safe to administer to humans. To commence human clinical trials in the US, an
investigational new drug (IND) application has to be made to and successfully
granted by the regulatory body — the FDA. Usually, between this point and drug
candidate selection, a patent would have been applied for and granted. This patent
protection gives market exclusivity to the patent holder for the molecule for 20
years from the patent application date.
There are three major stages of human clinical trials for drug candidates to go
through. Phase I focuses on the safety of the drug and will involve around ten
healthy subjects. Phase II is the major stumbling block for most drugs as it has
the highest attrition rate (i.e., probability of transition to the next phase is lowest in
Phase II). This is where the efficacy of the drug is determined and tested as well as
further safety studies. Phase III requires up to thousands of volunteer subjects to
determine the range and severity of side effects on a larger sample size, final dose
sizes, as well as further safety and efficacy testing. Results and findings from these
studies are filed and submitted to request regulatory approval in the form of a new
drug application (NDA), which when granted allows the drug to be marketed and
sold.
Process development aims to take the techniques from synthesizing the molecule
at a lab-scale to an economical manufacturing process capable of producing the
therapeutic at commercial scale. The process evolves in stages at intermediate
scales (e.g., pilot-plant scale), progressively increasing and optimising equipment
sizes and productivities. As previously mentioned, clinical manufacturing takes
place concurrently to provide the drug that is used during clinical trials. Ultimately,
process development ensures that the manufacturing process is validated, safe, con-
sistent, and robust whilst also trying to be as economical and cost-effective as pos-
sible. For biologics, in addition to an NDA, a biologic licence application (BLA)
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is required for approval and this BLA is needed for each different manufacturing
facility it is produced in.
This drug development process may take up to 12 years. So that means that a
patent granted at the start of the development process therefore only leaves eight
years of market exclusivity (in this case). Work done on optimising the structure
and development pathway of biopharmaceutical drug portfolios includes the study
by George and Farid (2008).
2.2 Biopharmaceutical Manufacturing
Biopharmaceutical manufacturing is a substantial endeavour as it involves growing
single-cell organisms on a large scale. As experience and expertise has built up in
this area, a lot of biopharmaceuticals especially mAbs have started to adopt more
standardised processes (Fahrner et al., 2001; Shukla et al., 2007).
The bioprocess for manufacturing mAbs is normally a batch process and com-
prises of many steps (unit operations) but can be broadly divided into two main
parts: upstream processing (USP) and downstream processing (DSP). USP is the
part of the manufacturing process where the cells are grown and the biopharmaceu-
tical is actually made (by the cells). DSP separates the biopharmaceutical molecule
from its host cell and removes any impurities from the product stream(s). Bulk
manufacturing ends after DSP, and after that the purified bulk product undergoes
final fill, formulation, and packaging (usually in a secondary facility or location) to
put the molecule in the delivery format that is administered to patients.
USP starts from the expansion and thaw of frozen seed cells in cell banks and
goes on to make the actual drug molecule using cells grown in one or more biore-
actors. The selection of expression system depends on a number of factors (Verma
et al., 1998), and the available choices range from bacterial (e.g., E. coli), yeast,
insect, to mammalian cells (e.g., Chinese hamster ovary (CHO)). Generally, mAbs
are produced in mammalian cells (Farid, 2006) because other cells, like E. coli,
cannot secrete antibodies — this makes the purification process more cumbersome
as the cells have to be broken up to release the antibodies. Also, they may not
be able to carry out post-translational modifications such as glycosylation — this
glycosylation is often necessary for antibody specificity and effector functions, and
also improves half-life.
There are two main types of processing modes in USP: fed-batch and perfusion
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(Chu and Robinson, 2001; Birch, 2003). In fed-batch processes, the bioreactor is
seeded and the cells are grown for a certain period of time (with a few intermittent
feed additions) at which point the entire contents are harvested and passed on to
DSP for purification. Perfusion processes, on the other hand, are semi-continuous.
The bioreactor is seeded as normal and cells are grown for a specified amount
of time (with regular feed additions) until they reach a steady-state cell density —
this period of time is called ramp-up. From this point onwards, regular harvests are
made from the bioreactor (which is replenished by equally regular feed additions);
these harvests can be purified separately, or pooled and/or frozen for later down-
stream processing. As a result, the perfusion processes last significantly longer
than the fed-batch processes — a CHO fed-batch cell culture is typically 14 days
long but a perfusion cell culture can be as long as 60 days. The fed-batch process is
more prevalent in industry, though the industry is showing new interest in perfusion
processes. There are advantages and disadvantages to both processing modes (Chu
and Robinson, 2001; Birch, 2003; Bibila and Robinson, 1995): fed-batch is easier
to control but is less productive, and perfusion offers a smaller facility footprint but
is more susceptible to process contamination and failure.
The unit operations involved in DSP for a platform mAb process generally in-
clude: clarification steps to separate the whole cells from the product stream; multi-
ple chromatography steps; and orthogonal viral clearance steps (FDA, 1998; Sofer
and Lister, 2003) (depending on the cells used). Although most mAb downstream
processing trains tend to consist of the same unit processes, each mAb introduces
unique differences which means process engineers must tune unit operations and
the DSP as a whole to each mAb molecule (Marichal-Gallardo and Alvarez, 2012).
The chromatography unit operations, particularly the affinity chromatography step
which uses Protein A resin for mAbs, have recently been identified as the bottle-
neck (in time and costs) in the overall process (Kelley, 2007) as cell culture titres
have increased. Work done by Allmendinger et al. (2012, 2013) has sought to deal
with this by optimising cost-effective chromatography column-sizing strategies for
mAb manufacture while also incorporating user preferences.
In addition to decisions on equipment sizes and selection of unit operations, it is
possible to choose process configurations where there are multiple staggered biore-
actors to one DSP train. Rouf et al. (2000) investigated the economy of scaling-up a
bioreactor by using multiple units versus one larger bioreactor. This found that the
flowsheet with multiple reactors had a higher return on investment resulting from
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the smaller size of DSP units since DSP accounts for such a large proportion of
processing costs. Multiple reactors however will incur higher equipment purchase
costs even as their DSP is smaller and more utilised.
Manufacturing can take place in a dedicated facility or suite (i.e., a single-
product facility) or in a facility where equipment and resources are shared between
different manufacturing processes (i.e., a multi-product facility (MPF)). Operat-
ing an MPF brings up a few more concerns in addition to those experienced in a
single-product facility. First of all, there needs to be an adequate cleaning and ro-
bust validation procedure to ensure there is no product carryover from one process
to another. Secondly, as well as the potential to cause cross-contamination and
product carryover, the changeovers between different products can be labour and
time intensive (with the extra cleaning and validation). So it may be operationally
beneficial to manufacture in campaigns2, and minimise product changeovers.
2.3 Emerging Trends and Challenges
The unique qualities of biopharmaceuticals and its market bring many varying chal-
lenges to biopharmaceutical companies (Na¨rhi and Nordstro¨m, 2005). As briefly
implied above, these companies face great uncertainty and risk. They have to man-
age uncertain development times and costs, uncertain phase transition probabilities,
and uncertain market forecasts — ideally in a cost-effective and efficient manner.
Biosimilars are a growing trend in the biopharmaceutical industry and pose an
increasing competitive threat to manufacturers of originator biopharmaceuticals.
Biosimilars refer to close copies of branded biologics marketed after the expiration
of the patent and regulatory protection period of the established branded biologic
(Weise et al., 2011). The sales erosion in the first year after generic entry for small
molecule drugs can cause the originator’s unit share to fall to 11% (Grabowski
et al., 2013). It is unlikely that such drastic sales erosion will occur in the bio-
pharmaceutical market. However, new biosimilars are set to reap the benefits and
success of the originator when put in context with the highly profitable, growing
market and potential selling prices 20-30% lower than the originator (Walsh, 2010).
Biopharmaceutical companies are also faced with manufacturing bottlenecks;
2Here a campaign means a long sequence of batches of one product which is uninterrupted by
batches of other products. It has a second similar meaning: after changeover from product b, starting
the first batch of another product, a, can be referred to as starting a campaign of product a (regardless
of how many more batches of a are planned). Both meanings are used interchangeably within context
throughout this thesis.
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strict risk-averse regulation (Eichler et al., 2013); and long, difficult and complex
manufacturing processes (Ransohoff, 2004; McGurk, 2004). There have been re-
cent efforts to improve the productivity and utilisation of bottlenecked chromatog-
raphy processes by introducing semi-continuous chromatography (Mahajan et al.,
2012; Warikoo et al., 2012). Pollock et al. (2013a) evaluate the potential of semi-
continuous chromatography systems for clinical and commercial manufacture.
The pursuit of efficiency and cost-effectiveness is coupled with the increas-
ing need for flexibility (Kelley, 2009) as companies compete for limited resources
whilst bringing their products to market. Legacy facilities were designed and built
to manufacture large amounts of just one blockbuster drug each (i.e., single-product
facilities), and it has been forecast to no longer be the norm (Carson, 2005). Com-
panies designing new facilities will need multi-product facilities that are more flex-
ible — i.e., facilities that are capable of manufacturing several mAbs with diverse
characteristics and process variations. This is to account for several different leads
going through the development process and the inherent uncertainty in which spe-
cific mAb candidates will be approved. A main problem facing MPFs is the risk of
cross-contamination, but this can be mitigated by the correct facility design (GEN,
2006). MPFs require more rigorous cleaning procedures and extra validation costs
between each product campaign but these extra procedures and costs have been
found to still be economically feasible (Sofer and Nystro¨m, 1991). The use of dis-
posable systems further extends the flexibility of an MPF as it reduces the costs and
time related with cleaning validation and product changeover respectively. In ad-
dition, they reduce some running costs by minimising water and reagents used by
clean-in-place (CIP) and sterilization-in-place (SIP) operations. However they in-
cur higher consumables and waste disposal costs. Disposable components that can
be used include but are not limited to single-use bioreactors (up to 2000L scale),
filters, filter housings, pipes, pre-packed columns or membrane adsorbers; dispos-
able technology finds many applications in both MPFs and single-product facilities
(Allison and Richards, 2013; Shukla and Gottschalk, 2013).
Finally, decisions faced by biopharmaceutical companies are interdependent,
i.e., the decision about which drugs to develop depends on the available capacities
and resource needs of the other drugs, and vice versa. At the same time, process
development determines the technical characteristics of the manufacturing process
producing drugs either for clinical development or the commercial market.
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Chapter 3
Literature Review
3.1 Introduction
Production planning aims to make best use of production resources in order to
satisfy production goals or demand over a planning horizon. It is omnipresent in
any manufacturing environment including bioprocessing and the manufacture of
biologics. Determining a good or an optimal production plan is not a new problem
and various approaches exist that tackle it wholly or focus on specific aspects in
order to achieve the stated objectives.
This chapter aims to lay out the current state-of-the art in production planning
research especially in the realm of lot sizing and scheduling and in a pharmaceu-
tical or bioprocessing context. This interfaces between deterministic and stochas-
tic lot-sizing, scheduling, capacity planning, bioprocess optimisation, and prod-
uct cycling problems and solution techniques such as meta- and hyper-heuristics,
simulation-optimisation, and exact methods.
Literature on lot sizing and scheduling, will be discussed first in Section 3.2 on
the following page. This will include descriptions of its deterministic and stochas-
tic types as well as the distinctions between their many variants. Secondly, Sec-
tion 3.3 on page 19 will describe and compare several solution methods and al-
gorithms which have been used in prior work. Following that, relevant research
tackled in a bioprocessing or biopharmaceutical context will be outlined in Sec-
tion 3.4 on page 26, and the conclusion of this chapter will summarise the present
research gaps this thesis attempts to fill.
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3.2 Lot Sizing and Scheduling
Lot sizing models determine the optimal timing and level of production. The sim-
plest of these was formulated by Wagner and Whitin (1958) whereby production
levels for a product on a single machine (or facility) over a finite planning horizon
are determined. Lot sizing models mostly focus on the trade-off between set-up
cost and inventory cost.
Scheduling was defined by Graves (1981) as “. . . the allocation of available
production resources over time to best satisfy some set of criteria”. Framinan
et al. (2014) provided an extensive overview on scheduling systems models, and
algorithms for exact and approximate solutions. Within the context of lot sizing,
scheduling has to do with the precise sequencing and timing of jobs within time
periods. Usually the lot sizing is solved first before the scheduling problem which
is based on the results from the lot sizing model.
Different extensions have been developed and investigated for lot sizing in gen-
eral (Jans and Degraeve, 2008), and also with scheduling considered as part of
the problem (Drexl and Kimms, 1997). One of the main distinctions between the
variants (when using mathematical programming) is whether they are classed as
a ‘small-bucket’ formulation or a ‘big-bucket’ formulation. This refers to the size
of the time periods and how sequencing and scheduling is handled within them.
The former describes models or formulations which can only have at most one
product per machine produced in each time period which effectively determines a
sequence. On the other hand, ‘big-bucket formulations’ may have more than one
product produced on a single machine per time period. As a result, these models
usually do not deal with sequencing or explicit scheduling.
Other characteristics that may differentiate model variants are as follows:
• The planning horizon which determines the length of the production sched-
ule. This can either be finite or infinite.
• A single-level system is one where end products or items are produced di-
rectly from raw materials. Conversely, a multi-level system involves parent-
component relationships among the products. That is, one product serves
as an input or raw material for the processing or production of another, so
demand for one operation (level) is dependent on a prior one.
• The number of products has an important effect on complexity, with single-
product problems significantly simpler than multi-product cases.
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• Capacity or resource constraints can be put on the production operations
leading to capacitated problems. If these constraints are not present, the
problem is said to be uncapacitated.
• Demand is classed as static if it remains constant (or stationary) over the
entire planning horizon and dynamic if it changes with time. In addition, it
may be uncertain or stochastic if not known ahead of time — usually based
on probabilities and probability functions. Otherwise if it is known exactly,
it is deterministic. Related to the number of levels, independent demand
has products where their demands do not depend on the decisions of other
products but dependent demand has products with demands depending on
demands of other products.
• Implementation of setup can take many forms. Usually, changeover (switch-
ing) from one product to another incurs a setup cost and/or setup time. If the
setup applied at the start of production of an item differs based on the pre-
ceding item, this is classed as sequence-dependent setup. In addition (and
specific to mathematical programming), a problem has setup-carryover if
production of an item over two periods only required one setup before pro-
duction in the first period.
• Finally, the flow of inventory may have several constraints. There may be
maximum inventory levels (maximum storage capacity) imposed per prod-
uct, per facility (or machine), globally, or combinations thereof. In addition,
inventory may be perishable. This can either be by defining a maximum
holding time (or shelf-life) or a spoilage rate (i.e., a fraction of inventory
spoils each period and needs to be discarded). Also, inventory shortage may
be allowed in two ways1. Backlogging means that the demand of the cur-
rent period can be delivered in future periods and lost sales means that not
meeting demand at all is allowed.
The rest of the discussion in this chapter will distinguish primarily between
deterministic and stochastic lot sizing and scheduling problems. That is, of the
characteristics just mentioned, the type of demand is what shall be focused on.
1It is possible for both forms of inventory shortage to be used in the same system simultaneously.
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3.2.1 Deterministic Models
As has previously been mentioned, there are several extensions for the lot sizing
and scheduling problem which generally evolved from the economic order quan-
tity (EOQ) problem — a single-product single-item problem with deterministic
stationary demand, infinite planning period, and no capacity constraints (Erlenkot-
ter, 1990).
Some of the deterministic variants include: the economic lot scheduling prob-
lem (ELSP) which has an infinite planning horizon, where products have stationary
demand, and time is continuous (instead of discrete) (Gallego and Shaw, 1997);
the capacitated lot-sizing problem (CLSP), which considers capacity constraints
for the machines and as a ‘large-bucket’ model, allows several items to be pro-
duced per period (Eppen and Martin, 1987); the discrete lot sizing and scheduling
problem (DLSP), where periods are very short, only one product can be made per
period, and if so, the production uses the full capacity (Lasdon and Terjung, 1971);
the proportional lot sizing and scheduling problem (PLSP), in which not more than
two products can be made in a time period (Drexl and Haase, 1995; Drexl and
Kimms, 1997); and the general lot sizing and scheduling problem (GLSP) which
attempts to take take a ‘large-bucket’ model and simultaneously do scheduling by
assigning each lot in a period a unique number to determine a sequence (Fleis-
chmann and Meyr, 1997).
In addition, Potts and Wassenhove (1992) highlighted the close relationship
between scheduling, and lot sizing and scheduling. This idea of a relationship
between lot sizing problems and scheduling models in general was motivation for
two efforts to solve the DLSP as a batching and scheduling problem. Here, each
demand is interpreted as a job and characterised by its size and deadline and must
be processed in one piece without splitting: one by Jordan (1996), and another by
Jordan and Drexl (1998).
Of these deterministic models, CLSPs have received a large share of research
attention and been the subject of several extensive reviews and surveys (Drexl and
Kimms, 1997; Karimi et al., 2003; Jans and Degraeve, 2008).
3.2.2 Stochastic Models
Historically, most research has been on problems that assume deterministic demand
and no randomness or uncertainty in general. However, real-life systems often are
not as simple and suffer from uncertainty either in demand, production rates or
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setup times.
This different class of the problem is termed the stochastic lot scheduling prob-
lem (SLSP). In their review of the SLSP, Sox et al. (1999) made a distinction be-
tween the stochastic economic lot scheduling problem (SELSP) and the stochastic
capacitated lot sizing problem (SCLSP) to be consistent with their deterministic
counterparts. The former assumes continuous time, an infinite horizon, and sta-
tionary demand while the latter assumes a finite planning horizon, discrete time
periods, and may have non-stationary demand. However, Winands et al. (2011)
blurred this by defining the SELSP as allowing finite planning horizons but re-
stricting it to stationary demand.
In addition to these surveys, Aloulou et al. (2014) compiled an extensive bibli-
ography of publications on the non-deterministic lot-sizing problem and classified
them according to the number of products, time-periods, machines, the uncertain
parameters, and the modelling approaches. Li and Ierapetritou (2008) reviewed
the main methodologies that have been developed to address the problem of uncer-
tainty in production scheduling as well as to identify the main challenges in this
area. Ouelhadj and Petrovic (2009) surveyed dynamic scheduling in manufactur-
ing systems, covering the limitations of static schedules and approaches in dynamic
scheduling.
An extension looks at production processes which are prone to random ma-
chine/equipment failure. In the case of equipment failure, corrective maintenance
is done to restore the machine to its ‘normal’ state and any imperfect product items
are either reworked or discarded. Also, preventive maintenance may be carried out
in order to mitigate the occurence of failure events. For example, Liao and Sheu
(2011) presented an economic production quantity (EPQ) model for randomly fail-
ing production process with minimal repair and imperfect maintenance.
In general, a production or control policy is required for the SELSP which
defines decisions to make for the possible states of the system. These decisions are:
whether to continue production of the current product; whether to switch to another
product; or whether to idle the machine. The implication is that finite production
capacity has to be dynamically allocated between products in order to be responsive
to stochastic demands. This adds to the complexity of the problem and means that
determining an optimal control policy is non-trivial (Sox et al., 1999). The critical
aspects of these policies are the lot-sizing decisions and the sequencing decisions.
The lot-sizing decision may either depend on the state of the entire system (i.e., a
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global lot-sizing decision) or just on the stock level of the product currently set up
(i.e., a local lot-sizing decision). In addition, the production sequence can either be
dynamic, fixed with variable cycle length, or fixed with the cycle length fixed as
well (Winands et al., 2011).
Though there are formulations of these stochastic models that can be solved
analytically — e.g., Tempelmeier (2013) and Tempelmeier and Hilger (2015) —
often, to evaluate solutions to the SLSP, stochastic simulation is employed over a
set of specific or random scenarios and instances.
3.3 Solution Approaches
This section will outline the application(s) of popular approaches to both determin-
istic and stochastic versions of the lot sizing and scheduling problem while briefly
describing the algorithms underlying them where necessary.
3.3.1 Exact Methods
Very often, CLSPs are modelled as mixed-integer linear programming (MILP)
problems and solved with software such as IBM’s CPLEX (Ramya et al., 2016;
Dangelmaier and Kaganova, 2013; Walser et al., 1998). However, the CLSP is NP-
hard (Bitran and Yanasse, 1982), and so there is a limit to the size and complexity
of CLSPs that can be tackled with exact mathematical programming methods. Sim-
ilarly, the SELSP can be formulated as a Semi-Markov Decision Process (SMDP)
but this approach does not scale well (Graves, 1980). It is also possible to for-
mulate an SCLSP with service-level constraints as a linearised model and solve
with a standard MIP solver, but this too means prohibitive computation times with
increasing products and time periods (Tempelmeier, 2013).
3.3.2 Heuristics, Meta-Heuristics, and Hyper-Heuristics
For larger and more complex scenarios, various approaches based on meta-heuristics
or heuristic solution approaches have been proposed for both deterministic and
stochastic lot sizing and scheduling problems. These algorithms are invaluable
when problem sizes become intractable to solve with exact methods and computa-
tion costs are prohibitively large.
A heuristic is an algorithm which does not guarantee that the optimal solution
to the problem will be found. They trade optimality for speed in order to gener-
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ate ‘good enough’ solutions in a reasonable time frame. What counts as a ‘good
enough’ solution will depend on the use case or specific problem. For example,
for a problem where it is difficult to manually construct a (feasible) solution, a
‘good enough’ solution is one that is feasible and quickly generated. Similarly, a
heuristic can be said to give a ‘good enough’ solution if subject to a computation or
time budget, the solution is close in quality to known optima or benchmarks. Or in
the case where this information does not exist, the solution improves significantly
on random ones. Heuristics may be implemented by themselves or in conjunction
with other heuristics or optimisation algorithms.
On the other hand, a meta-heuristic is a class of heuristic that does not make
assumptions about the structure or characteristics of the underlying problem that is
to be solved. Meta-heuristics work to efficiently direct the search of a subordinate
heuristic on a larger decision (or search) space. To quote a more pithy definition:
“Metaheuristics are typically high-level strategies which guide an underlying,
more problem specific heuristics, to increase their performance. The main goal is
to avoid the disadvantages of iterative improvement and, in particular, multiple de-
scent by allowing the local search to escape from local optima. This is achieved by
either allowing worsening moves or generating new starting solutions for the local
search in a more “intelligent” way than just providing random initial solutions.
Many of the methods can be interpreted as introducing a bias such that high qual-
ity solutions are produced quickly. This bias can be of various forms and can be
cast as descent bias (based on the objective function), memory bias (based on pre-
viously made decisions) or experience bias (based on prior performance). Many
of the metaheuristic approaches rely on probabilistic decisions made during the
search. But, the main difference to pure random search is that in these algorithms
randomness is not used blindly but in an intelligent, biased form.” (Stu¨tzle, 1998).
Blum and Roli (2003) and Luke (2013) have other definitions of meta-heuristics
and extensive descriptions of many popular algorithms as well as intuitive expla-
nations as to their particular use cases.
In addition to heuristics and meta-heuristics, there have been some applica-
tions of hyper-heuristics to lot sizing and scheduling problems. Hyper-heuristics
are heuristic search methods that attempt to automate the selection or design of sub-
ordinate heuristics to solve hard computational problems (Burke et al., 2013). The
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distinction between a hyper-heuristic and a meta-heuristic is that the latter searches
a solution space (i.e., the search space is comprised of solutions to the problem),
however, the former searches within a space of heuristics.
3.3.2.1 Heuristic solution methods
Variations of construction heuristics have been used for various types of lot sizing
problems — a construction heuristic is one that starts with an ‘empty’ solution and
gradually builds or assembles a complete solution as determined by its algorithm
procedure.
For example, Ho et al. (2006) developed two construction heuristics for the
uncapacitated dynamic lot-sizing problem that are extensions of earlier heuristics
by Silver and Meal (1973), and show that they outperform six other construction
heuristics including the original Silver and Meal heuristic. James and Almada-
Lobo (2011) proposed, along with other heuristics, a MILP-based ‘relax-and-fix’
construction heuristic for the parallel-machine capacitated lotsizing and scheduling
problem with sequence-dependent setups (CLSD-PM). This construction heuristic
solves a sequence of decomposed ‘sub-MILPs’ in order to construct an initial so-
lution for the various search algorithms it is coupled with. Finally, Almada-Lobo
et al. (2007) proposed a five step heuristic for finding good feasible solutions. Each
step of the heuristic is either a forward or backward pass (or a combination of both)
through the schedule.
For the SCLSP, Leachman and Gascon (1988) developed a dynamic cycle
lengths heuristic in a discrete-time model under the assumption of non-stationary
demand and deterministic production and setup times. The first step in their heuris-
tic is the calculation of target cycle lengths in each review period via a determin-
istic approach by using moving averages of the demand forecasts. Graves (1980)
proposed a composite-product heuristic with a composite-product defined as an ag-
gregation of the products in the scenario. Graves then tested this heuristic against
a naive procedure and other heuristics based on (Q,R)2 and (s,S)3 policies using
simulation and showed that the novel composite-product heuristic outperforms the
others. Tempelmeier (2013) focused on discrete time SCLSP models with ran-
dom demands, fixing production periods and fixing lot sizes under service level
2This policy requires that Q items are ordered whenever the inventory position falls to the reorder
point, R (Gallego, 1992).
3This policy dictates that no new orders are made until inventory falls to or below s, at which
point an order is made to restore inventory to the level S (Caplin, 1985).
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constraints. In addition, Tempelmeier and Hilger (2015) proposed linear program-
ming models with non-linear constraints approximated by piecewise linear func-
tions and compared a variant of the Fix-and-Optimise heuristic with the column
generation heuristic proposed by Tempelmeier (2011) on a large number of test
problem instances. Wagner and Smits (2004) described a model for the SELSP
with the objective of minimising long-run average holding and setup costs whilst
fulfilling a given service level. They used a cyclic scheduling approach with cycle
times of each product a multiple of a fundamental cycle (or base period). A local
search algorithm was implemented along with a myopic construction heuristic as
the solution method and compared with deterministic benchmarks and on a large
set of stochastic instances.
3.3.2.2 Evolutionary algorithms and genetic algorithms
Most of the deterministic lot sizing and scheduling meta-heuristic approaches use
evolutionary algorithms (EAs), particularly genetic algorithms (GAs). EAs are a
class of population-based meta-heuristics inspired by biological evolution. They
maintain a population of candidate solutions which are improved by applying one
or more of recombination, reproduction, and mutation operators on them and then
selecting the fittest individuals (Vikhar, 2016; Michalewicz et al., 1997). In ad-
dition, EAs have already demonstrated some promise in dealing with problems
that integrate uncertainty (Jin and Branke, 2005). The most popular of evolution-
ary algorithms are GAs. These GAs generally ‘evolve’ a set candidate solutions,
each represented by a chromosome, over a specified number of generations (or
iterations) to produce high-quality solutions to a search problem (Holland, 1975;
Goldberg and Holland, 1988; Goldberg, 1989). Chromosomes are versatile and
flexible, and can take a wide range of representations e.g., binary or bit strings,
permutations, real-valued numbers, rule-sets, or combinations thereof. The set of
candidate solutions is improved on generationally by mimicking the concept of nat-
ural selection and survival-of-the-fittest. Fitter individuals are generally selected to
be ‘parents’ and be combined in some fashion to create ‘children’ that will make
up the subsequent generation. As these progeny generally share traits with their
parents, mutation operators are applied that make small random changes to them
in order to explore more of the search space.
The GA-based approaches to lot sizing can be broadly divided into approaches
using a direct representation or an indirect representation, where the former ap-
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pears much more often. In a direct representation, the sequence and lot sizes are
directly encoded in the chromosome. The main challenge with such an approach
is that mutations and crossovers can generate infeasible solutions, which is usually
dealt with by discarding those solutions or by special repair operators (O¨zdamar
and Birbil, 1998). Methods with an indirect representation use a mapping function
or heuristic to derive a production plan from a solution’s chromosome. An indi-
rect GA representation has been proposed by Kimms (1999). In Kimms’ paper,
a two-dimensional matrix is used as chromosome, with each entry representing a
rule for selecting the set up state for a machine at the end of a period (e.g., the item
with maximum holding costs, minimum set up cost, maximum depth, maximum
number of predecessors). To compute the fitness value of a chromosome, a con-
struction scheme is called, which constructs the solution backwards, starting from
the end of the planning horizon.
A lot more work has been published on GAs for the job-shop scheduling prob-
lem (JSP), and they typically use a permutation-based representation, and then
apply a construction heuristic to actually construct the schedule based on the per-
mutation (Cheng et al., 1999; Branke and Mattfeld, 2005; Bierwirth and Mattfeld,
1999). A typical construction heuristic is the Giffler-Thompson algorithm (Giffler
and Thompson, 1960), which generates active schedules by iteratively selecting
the job with the highest priority (lowest permutation index) from the set of eligible
jobs, and then scheduling it at the earliest possible time. This approach is used
in work such as Branke and Mattfeld (2005) where the objective is to minimise
tardiness. However, this approach does not directly transfer to biopharmaceutical
capacity planning or lot sizing, because (i) scheduling as early as possible would
lead to excessive storage costs and (ii) the existence of a heterogeneous set of al-
ternative facilities.
3.3.2.3 Other meta-heuristic approaches
Apart from GAs, other meta-heuristic approaches to the deterministic problem in-
clude tabu search (TS) or particle swarm optimisation (PSO), see, e.g., Piperagkas
et al. (2012), and Guner Goren et al. (2008). Ant Colony Optimisation (ACO) has
also been used for uncapacitated and capacitated multi-level problems (Pitakaso
et al., 2007; Almeder, 2010). In both cases, ACO was used to determine produc-
tion decisions from top items to raw materials and a MILP solver is used to calcu-
late the corresponding production and inventory levels. Almada-Lobo and James
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(2010) extended previous work of Almada-Lobo et al. (2007) by using their five-
step heuristic as an initial starting solution for a TS and variable neighbourhood
search meta-heuristic to solve the CLSP with sequence-dependent times and costs.
In the case of a bi-objective CLSP problem, Mehdizadeh et al. (2016) devel-
oped two novel multi-objective meta-heuristic algorithms and compared them with
the non-dominated sorting genetic algorithm II (NSGA-II).
In general, Jans and Degraeve (2007) reviewed and compared meta-heuristic
solution approaches for the CLSP, and there are good introductions to these other
meta-heuristic approaches in Luke (2013), Eberhart et al. (2001), Dorigo and Stu¨tzle
(2010), Glover and Laguna (1999), and by Deb et al. (2000). Usually, TS and ACO
are more suited to combinatorial optimisation problems whilst PSO can be used on
problems that have a real-valued decision space.
3.3.2.4 Hyper-Heuristics
Branke et al. (2016) surveyed the use of hyper-heuristics in generating or designing
reusable construction heuristics for production scheduling. In the indirect GA rep-
resentation proposed by Kimms (1999) (which was mentioned previously), since
the entries in the chromosome represented a rule for selecting set up states, the ap-
proach can be seen as a selection hyper-heuristic as the search space is on potential
rules and not direct solutions to the problem.
Hyper-heuristics may incorporate machine-learning techniques such as Artificial
Neural Networks (ANNs) or genetic programming (GP). GP is an EA technique
where computer programs, usually based on a tree-representation, are searched
for and evolved (Koza, 1992). Burke et al. (2007) have demonstrated automated
heuristic generation with genetic programming. For a complex dynamic schedul-
ing problem, Pickardt et al. (2013) proposed a two-stage hyper-heuristic for the
generation of work centre-specific dispatching rules. This hyper-heuristic com-
prised a genetic program that evolves a composite rule and an EA that searches for
good allocation of rules between the work centres. An ANN is a computing system
that comprises a set of connected nodes (artificial neurons) which can transmit sig-
nals to each other computed as a function of each neuron’s inputs (Haykin, 1994).
The edges connecting neurons have associated weights which determine the con-
nection strength — i.e., it weights the effect of the respective incoming signal in
the computation of a neuron’s output signal. Branke et al. (2015) investigated three
different rule representations for optimising rules to compute priority indices for
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new/arriving jobs in a jobshop environment. In addition to a linear representation,
a feed-forward ANN, and GP with tree-representation was employed.
3.3.3 Simulation Optimisation
For the SELSP simulation optimisation is often used as an alternative approach.
This refers to, as the name suggests, attempts to couple optimisation techniques
with simulation analysis. Its objective is to find decision variables for optimal
system performance with performance being evaluated via simulation. Simulation
optimisation is a powerful technique useful for problems with complex or unknown
structure where uncertainty is present (Amaran et al., 2016) and its applications in-
clude supply-chain management, inventory replenishment, process design, and bio-
process control (Chu et al., 2015; Jalali and Van Nieuwenhuyse, 2015; Caballero,
2015; Renotte and Wouwer, 2003) with heuristics and meta-heuristics often used
as the optimisation algorithm.
Recent work in terms of the multi-item SELSP includes the study by Lo¨hndorf
and Minner (2013) who formulated the problem as a SMDP, and compared dif-
ferent solution approaches including approximate value iteration and global search
on simple production policies that had either fixed or dynamic cycles. They found
that global control policy search outperforms average value iteration on large prob-
lems. For their global search algorithm, Lo¨hndorf and Minner utilised a type of
EA called Covariance Matrix Adaptation Evolution Strategy (CMA-ES) (Hansen
and Ostermeier, 2001). CMA-ES generates individuals by sampling from a multi-
variate normal distribution. Each generation, the underlying distribution is mu-
tated to explore the search space. Dependencies between the different coordinates
in the chromosome vector are described by a covariance matrix which is updated
each generation in order to guide the search to more promising regions. Lo¨hndorf
et al. (2014) then extended that work to consider sequence-dependent setup times.
Both of these papers use meta-heuristics to conduct the global search for control
policies, and both of these papers’ approaches can also be classed as a hyper-
heuristic. Briskorn et al. (2016) presented a fixed cyclic production scheme for
multiple products with control strategies to stabilise the cycle length and consider
sequence-dependent setup times, backlogging with service level constraints, and
limited storage capacity. They used a nested solution approach comprising three
levels utilising iterative and neighbourhood search procedures.
Nourelfath (2011) determined robust production plans for the SCLSP to ensure
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that specified service level is met with high probability. The model accounted for
random machine breakdowns and random repair times independent of product type
and lot size. It did not consider random demand nor preventive maintenance plan-
ning. On the other hand, Purohit and Kumar Lad (2016) presented a mathematical
model to provide an integrated plan incorporating job sequencing, lot sizing, and a
schedule for preventative maintenance which is solved with the use of a simulation-
based GA approach and outperforms previous conventional approaches.
3.4 The Bioprocessing Context
Literature on capacity planning or lot sizing and scheduling in the pharmaceutical
or biopharmaceutical industry represent complicated extensions to the CLSP, with
multiple products and facilities, product-specific manufacturing rates and costs,
multi-stage processing, and perishable products. This also applies to the SLSP
which must also consider semi-continuous processes that are prone to different
types of failure events, as well as variable reactor titres. For the deterministic
problem, they have applied primarily mathematical programming models based on
discrete time-periods which are solved using MILP solver software.
For example, Lakhdar et al. (2005) developed a deterministic mixed-integer
linear program for the planning and scheduling of a multi-product biopharmaceuti-
cal manufacturing facility and later extended it for use with a multi-facility model
where multiple criteria were considered using goal programming (Lakhdar et al.,
2007). Siganporia et al. (2014) also developed a MILP model, in this case to op-
timise an eight-year planning horizon for a mixture of fed-batch and continuous
bioprocesses while considering capacity decisions in a few scenarios with different
demands and bioreactor titres. Siganporia et al. utilised rolling-time horizons to
improve computational performance. Each of these models is based on discrete
time periods and allows only one product to be manufactured in each time-period.
In the case of Lakhdar et al. (2007), where discrete 90 day periods are used, this
means that at most four different campaigns (lots) can be scheduled per year and
facility. As a result, this effectively artificially restricts the search space.
Recently, the work done by Lakhdar et al. (2005), has been extended to alterna-
tive approaches by other authors. First, Vieira et al. (2016) solved a set of example
problems based on a Resource Task Network (RTN) continuous-time single-grid
formulation focusing on addressing specific operational characteristics of biopro-
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cesses. Jankauskas et al. (2017) then used a continuous-time model optimised by
a GA which is underpinned by a dynamic chromosome structure that is allowed to
vary in length.
For problems with stochastic elements considered, Gatica et al. (2003) and
Levis and Papageorgiou (2004) presented a mathematical programming approach
for the capacity planning problem, but with a focus on long-term planning and
capacity investment decisions under clinical trials uncertainty rather than schedul-
ing. Lakhdar et al. (2006) extended their deterministic medium-term planning for-
mulation to include uncertain production rates and dealt with this using chance-
constrained programming. Marques et al. (2017) presented a simulation optimiza-
tion approach combining a MILP model and Monte Carlo simulation procedure to
integrate process design and planning decisions under clinical trial and demand un-
certainty for the pharmaceutical industry. Finally, Pollock et al. (2013b) developed
a discrete-event simulation model focused on investigating the economic benefits
of continuous perfusion culture and single-use technology for a mAb. As part of
this evaluation, stochastic process failure events and their consequences are con-
sidered using simulation. This is then extended by Pollock et al. (2017) to include
an assessment of various integrated continuous process flowsheets.
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Chapter 4
Lot-Sizing & Scheduling for
Biopharmaceuticals
4.1 Introduction
To spread risk, companies usually have a portfolio of various products, and man-
ufacturing takes place across a network of different facilities, including in-house
facilities and outsourced manufacturing at contract manufacturing organisations
(CMOs). The facilities’ capabilities usually vary with respect to the set of products
they can produce and technical, operational and economic characteristics will often
differ between facilities as well as for different products that can be manufactured
on the facility. Furthermore, products have a finite shelf-life and cannot be stored
for very long.
Given the large investments, high costs, and long time-frames they face, bio-
pharmaceutical companies have to plan ahead over a long time horizon, based on
a demand forecast for each time period. It is important that production schedules
are optimised to make best use of the available production capacity, and even small
improvements can have a substantial impact on a company’s profit. Taken together,
these characteristics make biopharmaceutical capacity planning and scheduling
challenging to optimise. The result — a variant of the capacitated lot-sizing prob-
lem — constitutes a complex combinatorial optimisation problem.
Because of the simplifications required to model the problem in a mixed-integer
linear programming (MILP) approach — such as large discrete time periods that
permit the manufacture of only one product in each period on a facility — the solu-
tion potentially suffers from an artificial restriction of the search space. This chap-
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ter describes the development of a more flexible meta-heuristic approach for the
biopharmaceutical lot sizing and scheduling problem, and contrasts it with the pro-
posed mixed-integer programming approach as described by Lakhdar et al. (2007).
The work in this chapter is based on a 2017 publication in Journal of Hueristics
(see Appendix D).
To this end, a genetic algorithm (GA) with an embedded problem-specific con-
struction heuristic is designed which is inspired by previous GA approaches to job
shop scheduling. The GA uses an indirect permutation encoding, i.e., the specifi-
cally developed construction heuristic schedules demands sequentially in the order
prescribed by the chromosome. As will be demonstrated, the use of a GA allows
for a more flexible and realistic model of the real-life problem and avoids some of
the simplifications necessitated by available mathematical programming models.
It is interesting to note that the construction heuristics previously reviewed (see
Chapter 3) operate sequentially in either a forwards or backwards pass through the
schedule, or a combination thereof. Instead, the construction heuristic proposed
here inserts jobs in an order of importance determined by the GA and not neces-
sarily in any chronological order.
The chapter is structured as follows. First, the problem is formally described
in Section 4.2. Section 4.3 describes in more detail the case study used to evaluate
the approach. The GA and the associated construction heuristic are explained in
Section 4.4. The results of the empirical evaluation, including a comparison with
an MILP approach, are reported in Section 4.5. This chapter closes with a section
summarising the major conclusions of the sections preceding it.
4.2 Mathematical Formulation
This section summarises the mathematical formulation used here and introduced
by Lakhdar et al. (2007) to solve a deterministic long-term multi-product schedul-
ing/capacity planning problem on multiple facilities.
4.2.1 Notation
The indices i, p, and t denote individual facilities, products, and time periods re-
spectively. The subsets characterising the facilities being considered are: PIi, the
set of products produced by facility i; IPp, the set of facilities that can produce
product p; and T Ii, the set of time periods in which facility i is available for use.
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Binary Variables
Yipt 1 if product p is produced over period t at facility i; 0
otherwise
Zipt 1 if a new campaign of product p at facility i is started
in period t; 0 otherwise
Integer Variables
Bipt amount of product p produced over period t at facility
i, batches
Continuous Variables
Ipt amount of product p stored over period t, kilograms
Kipt amount of product p produced over period t at facility
i, kilograms
Pro f expected operating profit, RMU1
Spt amount of product p which is sold over period t, kilo-
grams
Tipt production time for product p at time period t at facil-
ity i
T f totit total production time over period t at facility i
Wpt amount of product p wasted over period t, kilograms
∆pt amount of product p which is late over period t, kilo-
grams
1relative monetary units (RMU)
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Parameters
Cp storage capacity of product p, kilograms
Dpt demand of product p at time period t, kilograms
rip production rate of product p at facility i, batches per unit time
Ht available production time horizon over time period t
T maxip maximum production time for product p
T minip minimum production time for product p
ydip yield conversion factor, kilograms per batch
αip lead time for production of first batch of product p at facility i
ζp life time of product p, number of time periods t
υp unit sales price for each kilogram of product p, RMU per kilo-
gram
ηip unit cost for each batch produced of product p in facility i, RMU
per batch
ψp unit cost for each new campaign of product p, RMU
δp unit cost charged as penalty for each late kilogram of product p,
RMU per kilogram
ρp unit cost for each stored kilogram of product p, RMU per kilo-
gram
pi rate of backlog decay
4.2.2 Constraints
4.2.2.1 Production constraints
Constraint (4.1) represents batch processing. The number of batches produced in
facility i of product p at time period t, Bipt , is determined by a continuous produc-
tion rate, rip, production lead time, αip, and production time Tipt . The lead time
allows for the duration of the first batch of a campaign plus the setup and cleaning
time before the first batch commences. Incorporation of lead time is enforced by a
binary variable Zipt .
Bipt = Zipt + rip(Tipt −αipZipt) ∀ i, p ∈ PIi, t ∈ T Ii. (4.1)
Constraint (4.2) converts the number of batches into kilograms produced using
a yield conversion factor ydip which differs for each combination of facility and
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product. Lead time is only avoided in a facility if the same product is manufactured
in the preceding period; this is covered in (4.3), with Yipt being a variable that
specifies whether product p is produced by facility i in time period t. Constraint
(4.4) ensures that at most one product p is manufactured in any given facility i per
time period t.
Kipt = Bipt ydip, ∀ i, p ∈ PIi, t ∈ T Ii. (4.2)
Zipt ≥ Yipt −Yip,t−1, ∀ i, p ∈ PIi, t ∈ T Ii. (4.3)
∑
p∈PIi
Yipt ≤ 1, ∀ i, t ∈ T Ii. (4.4)
4.2.2.2 Timing constraints
Constraints (4.5) and (4.6) represent the appropriate minimum and maximum pro-
duction time constraints. These are only active if Yipt is equal to 1, otherwise the
production times are forced to 0.
T minip Yipt ≤ Tipt , ∀ i, p ∈ PIi, t ∈ T Ii. (4.5)
Tipt ≤min{T maxip ,Ht}Yipt , ∀ i, p ∈ PIi, t ∈ T Ii. (4.6)
4.2.2.3 Storage constraints
The following constraints enforce an inventory balance for production and force
total production to meet product demand. In (4.7), the amount of product p stored
at the end of the time period, Ipt , is equal to the amount stored in the previous pe-
riod, plus the total amount produced across all facilities i, less the amount sold, Spt ,
and the amount of product wasted, Wpt , in the current time period t. Product stored
cannot be negative and should not exceed maximum product storage capacity in
(4.8); and total inventory at any point cannot exceed the global storage capacity in
(4.9).
Ipt = Ip,t−1+∑
i
Kipt −Spt −Wpt , ∀ p ∈ PIi, t ∈ T Ii. (4.7)
0≤ Ipt ≤Cp, ∀ p, t. (4.8)
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0≤∑
p
Ipt ≤CtotP , ∀ t. (4.9)
The duration a product can be stored in inventory is limited by its shelf-life in
(4.10). Stored material will not be left to expire whilst in inventory and this is done
by ensuring that the final product is sold in less than ζp time periods from when it
is first stored.
Ipt ≤
t+ζp
∑
θ=t+1
Spθ , ∀ p, t. (4.10)
4.2.2.4 Backlog constraints
A penalty is incurred for every time period t that a given amount of product p is
late. For a given product p at time t, the amount of product that is late, ∆pt , is
equal to the amount of undelivered product from the previous time period, ∆p,t−1,
multiplied by a factor, pip (which allows for the backlog to decay), plus demand at
time t, Dpt , less the sales at time t, Spt .
∆pt = pip∆p,t−1+Dpt −Spt , ∀ p, t. (4.11)
4.2.3 Objective Functions
4.2.3.1 Single objective
The objective function is to maximise profit, which is the difference between total
revenue (sales in kilogram times price υp), and total operating costs which include
the changeover cost at ψp per setup, storage cost at ρp per kilogram of product,
late delivery penalties of δp per kilogram of product, and batch manufacturing cost
at υip for every product-facility combination. All costs and prices are in relative
monetary units (RMU).
max Profit =∑
p
∑
t∈T Ii
(υpSpt −ρpIpt −δp∆pt − ∑
i∈IPp
(ηipBipt +ψipZipt)). (4.12)
The equations (4.1) – (4.12) comprise the complete formulation of the MILP
problem to be optimised and subsequently compared with the GA approach.
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4.2.3.2 Other objective(s)
In addition to single-objective of maximising profit, there is a second objective of
maximising customer service level (CSL) which is used in multi-objective optimi-
sation(s).
max CSL = (∑
p
∑
t
Spt)/(∑
p
∑
t
Dpt). (4.13)
4.2.4 Formulation Assumptions
This derived formulation assumes (and consequently makes the restriction that) not
more than one product can be manufactured in any given period. As a result, the
MILP requires this to be solved but the GA does not which is an advantage of the
GA approach that will be elaborated on later in Section 4.5.1 of this chapter.
In addition, in any given period, lead times and associated setup costs can be
avoided on a facility if the same product is manufactured in the preceding period.
What this means is, that for the MILP, there could potentially be as much as pe-
riod’s length of time between two batches which are in two different but adjacent
periods. In order to fairly compare with the MILP, the GA is implemented such that
lead times and associated setup costs are accrued if the time between two batches
of the same product is greater than the time period used by the MILP. This maxi-
mum idle time allowed between two batches before setup time and cost is accrued
is referred to as the setup ‘expiration’ period.
4.3 Industrial Case Study
An industrial case study presented by Lakhdar et al. (2007) was used to evaluate
the proposed method. This is anonymized real world data comprising anticipated
market demand and manufacturing facility characteristics. This benchmark prob-
lem features multiple products to be produced on multiple facilities with different
efficiencies and costs, setup times, batch production, perishable inventory, and the
ability to backlog demand.
The demand forecast comprises a time horizon of 15 years and 15 products
(p1 – p15). The forecast indicates yearly market demands, assumed to be fulfilled
at the end of each year (Table 4.1)2. The demand can be scheduled across 10
2Note that the product 1 demand for year 10 in Table 4.1 in Lakhdar et al. (2007) was 63, which
is not consistent with the general trend of the other years, so it was changed to 163.
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facilities (i1 – i10), but not all facilities can produce all 15 products. All facilities
are assumed to be available for the entire time horizon apart from facility 6 (i6)
which is unavailable until Y2, and facility 9 (i9) which is unavailable until Y11.
Of the ten manufacturing facilities, i1, i4, i6, and i9 are in-house facilities while
the rest are owned by CMOs.
Production rates (Table 4.2), manufacturing yields (Table 4.3) and manufactur-
ing costs (Table 4.4) are specified for all facility-product combinations (RMU in
these tables denotes relative monetary unit). The manufacturing yield determines
how many kilograms of a specific product are produced in a batch for a specific
facility. The manufacturing cost of a product is thus also dependent on the yield.
Setup cost and time are incurred when a facility is switching between products. For
consecutive batches of the same product, no setup time/cost is involved.
The setup ‘expiration’ time is 90 days (equal to the discrete time period used by
the MILP) which defines the maximum amount of time that a facility can be idle
without accruing setup times and costs on the subsequent batch produced. This
accounts for the extra equipment preparation activities (cleaning, sterilisation, etc.)
required after prolonged idle time. There is also a restriction on the time a product
may be stored before it has to be thrown away which is the maximum shelf-life.
In the case that the demand cannot be fulfilled in time, it is backlogged, but there
is a backlog penalty for every unit that is not delivered on time. Also, backlogged
demand decays exponentially at a rate of 50% every three months. For example,
if a demand of 100 kg cannot be delivered on time, 6 months later, only 25 kg
could actually be sold, and 75 kg of the demand would have been lost, reducing
the revenue correspondingly.
The case study assumes a fixed sales price, changeover cost, storage cost, and
setup time for all products (Table 4.5)3. The setup time includes the time of pro-
duction of the first batch. In addition, it is assumed that a month is 30 days and,
subsequently, a year is equal to 360 days.
The objective is to maximize the overall profit, calculated as total revenue mi-
nus the cost for production, storage, setups and backlog penalties. Given a set of
heterogeneous facilities with different manufacturing yields, manufacturing cost,
and batch production rates for different products, this takes into account maxi-
mizing the amount of products sold, and minimizing the manufacturing cost, the
3Note that the description by Lakhdar et al. (2007) had some inconsistencies in the units specified,
so in Table 4.5 the units for setup cost, sales price, storage cost and backlog penalty were updated to
be consistent with the other data.
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Table 4.2: Production Rates of Facilities (i1–i10) for Case Study [batch/day]
p1 p2 p3 p4 p5 p6 p7 p8 p9 p10 p11 p12 p13 p14 p15
i1 0.35 0.39 0 0.45 0 0.29 0 0.35 0.25 0.39 0.41 0.39 0 0.12 0.35
i2 0.6 0 0 0.61 0 0.6 0 0.6 0 0.43 0.56 0 0.6 0.6 0.6
i3 0 0 0 0 0 0 0 0 0 0 0 0 0.23 0 0
i4 0 0 0 0.12 0 0 0 0 0 0 0 0 0 0 0
i5 0 0 0 0.45 0 0 0 0.45 0 0.45 0.45 0 0 0.45 0.45
i6 0 0 0 0.45 0 0 0 0.45 0 0.45 0.45 0 0 0.45 0.45
i7 0 0 0 0 0 0 0.45 0 0 0.45 0 0 0 0 0
i8 0 0 0.58 0 0.45 0 0 0 0 0 0 0 0 0 0
i9 0.45 0 0 0.45 0 0.45 0 0 0 0.45 0.45 0 0 0.45 0.49
i10 0.45 0.45 0 0.45 0 0.45 0 0.45 0.45 0.45 0.49 0.45 0.45 0.45 0.45
Table 4.3: Manufacturing Yields of Facilities for Case Study [kg/batch]
p1 p2 p3 p4 p5 p6 p7 p8 p9 p10 p11 p12 p13 p14 p15
i1 10 1 0 8 0 6 0 10 2 9 7 1 0 12 12
i2 9 0 0 8 0 6 0 9 0 8 10 0 10 12 11
i3 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0
i4 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0
i5 0 0 0 10 0 0 0 10 0 8 8 0 0 11 11
i6 0 0 0 12 0 0 0 10 0 8 17 0 0 17 14
i7 0 0 0 0 0 0 10 0 0 10 0 0 0 0 0
i8 0 0 36 0 10 0 0 0 0 0 0 0 0 0 0
i9 10 0 0 12 0 5 0 0 0 8 16 0 0 12 13
i10 9 1 0 12 0 5 0 10 2 8 14 1 10 12 12
Table 4.4: Manufacturing Costs of Facilities for Case Study [RMU/batch]
p1 p2 p3 p4 p5 p6 p7 p8 p9 p10 p11 p12 p13 p14 p15
i1 1 1 0 10 0 3 0 1 1 1 3 1 0 1 1
i2 10 0 0 5 0 2 0 5 0 10 2 0 2 5 2
i3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
i4 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
i5 0 0 0 20 0 0 0 20 0 20 20 0 0 5 20
i6 0 0 0 10 0 0 0 10 0 10 10 0 0 1 10
i7 0 0 0 0 0 0 10 0 0 10 0 0 0 0 0
i8 0 0 1 0 5 0 0 0 0 0 0 0 0 0 0
i9 10 0 0 10 0 10 0 0 0 10 8 0 0 1 10
i10 15 15 0 15 0 15 0 15 15 15 15 15 15 15 15
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Table 4.5: Case Study Parameters
Parameter Value [Unit]
Setup time 14 days
Setup cost 2 RMU/changeover
Setup ‘expiration’ time 90 days
Sales price 2.5 RMU/kg
Storage cost 0.01 RMU/(kg ×period)
Storage period 90 days
Shelf life 2 years
Production time per year 360 days
Backlog decay 0.5 per 3 months
Backlog penalty 0.1 RMU/kg
storage cost, the setup cost, and any backlog penalty.
Lakhdar et al. (2007) used mixed-integer linear programming (MILP) to solve
this problem (described in Section 4.2) and the GA proposed in this chapter is sub-
ject to the same constraints, except that production on each facility is not restricted
to one product per time period. This seemed to be an artificial restriction imposed
only to reduce the modelling complexity of the MILP.
4.4 The Proposed Genetic Algorithm with Construction
Heuristic
For job shop scheduling, many successful GAs use indirect encodings (e.g., Branke
and Mattfeld (2005) and Cheng et al. (1999)), with the GA only searching the
space of permutations of jobs. For evaluation, a schedule is constructed from the
permutation by a construction heuristic, often Giffler-Thompson, which iteratively
selects the job with the highest priority (lowest permutation index) from the set
of eligible jobs, and then schedules it at the earliest possible time. This avoids
infeasible solutions and introduces a desirable heuristic bias, in the sense that it
excludes obviously bad solutions (such as schedules with big gaps) from the search
space. Inspired by this work, an indirect, permutation-based encoding combined
with a construction heuristic is proposed. The construction heuristic, however, had
to be carefully designed for the problem at hand.
The following two subsections first explains the proposed construction heuris-
tic, then provides details on the GA used.
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Product 1
Product 2
Product 3
Product 4
Y1 Y2 Y3 Y4
Facility 1
Facility 2
Demand
due end of
Year 3 to be
scheduled:
Current Schedule
(I): Schedule as late as possible (II): Schedule adjacent to previously scheduled
demand of the same product
(III): Schedule by shifting other demands to left (IV): Schedule by splitting over two facilities
(V): Schedule later than due date by backlogging
and apply a penalty to the demand
(VI): Split over two facilities and schedule the first
part late by backlogging
Facility 2
Facility 2
Facility 2 Facility 2
Facility 2
Facility 2
Facility 1 Facility 1
Facility 1
Facility 1
Figure 4.1: Visualisation of construction heuristic, based on a simple example with
two facilities and four demands. Items (I) — (VI) show the alternatives the heuristic
considers when identifying the most profitable place to insert a new demand into
the schedule. The rectangle representing a demand includes the setup time (so
length varies depending on where the new demand is inserted). Note that just using
(I) or (II), feasible options are found on Facility 1 but not on Facility 2. Therefore
the heuristic will terminate its search on Facility 1 but continue on Facility 2 using
(III), (IV), (V), and (VI).
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4.4.1 Construction Heuristic
The construction heuristic works on the basis of forecasted demands, in this case
demands for each year and product (see Table 4.1). Its task is to schedule the
production to satisfy the demand (referred to as demand from now for the sake
of simplicity) sequentially, in the order prescribed by the GA. When deciding at
what time and what facility to insert a new demand into the schedule, the heuristic
explores a number of different alternatives, and then greedily picks the alternative
that creates the smallest additional cost. So, the heuristic will consider each facility
in which the product may be produced. It then tries to schedule the entire demand
in an uninterrupted way as late as possible to minimise storage cost, and as late as
possible but adjacent to already scheduled demand of the same product to avoid
setup cost and time.
Only if these alternatives are not feasible for a facility, e.g., because a facility
does not have a sufficiently large gap in its schedule, further options are explored
that either move some of the already scheduled demands to make sufficient space
for the new demand, split the demand into two parts and schedule the second part
in another facility, or backlog the demand.
Figure 4.1 provides a simple example based on just two facilities and four prod-
ucts, while Algorithm 1 lays out brief pseudo-code of the construction heuristic.
The six alternatives considered shall now be explained in detail.
(I) Schedule as late as possible. The first alternative considered is to schedule
the entire demand as late as possible but before the due date, as one uninter-
rupted block, which minimizes storage cost at this facility. In the example,
this is possible for Facility 1, see Figure 4.1 (I), but not for Facility 2, since
there is not sufficient uninterrupted capacity available to schedule the entire
demand.
(II) Schedule next to previous demand. To avoid setup times and setup costs,
it may be beneficial to schedule a demand adjacent to the same product al-
ready scheduled. The heuristic picks the latest time slot before the due date
that allows it to link to a previously-scheduled demand of the same product,
and has sufficient available capacity to schedule the entire demand - see Fig-
ure 4.1 item (II). Again, this is only possible on Facility 1, as Facility 2 does
not have sufficient uninterrupted capacity. Note that due to the avoided setup
time, the overall time required to produce the demand is smaller.
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Algorithm 1 Pseudocode of the construction heuristic.
procedure CONSTRUCTION HEURISTIC(job J)
Determine possible time window for J ensuring batches finish before
due date but do not expire before due date
for each facility i do
Gi1 = latest gap that can fit J . (I)
Gi2 = latest gap that fits J and links to job of same product . (II)
if Gi1+Gi2 == {} then
Find latest gap that can fit at least one batch, Gi3
Split J into two parts r1 and r2 such that r1 is largest size that
can fit in Gi3
Gi3 = Gi3+ SECOND FACILITY SEARCH(i,Gi3,r2) . (IV)
Find latest gap
Attempt to enlarge gap by left-shifting already scheduled jobs
without violating shelf-life dependencies, Gi4 . (III)
Gi5 = the first gap past or straddling due date, that is big
enough for penalized job, J′ . (V)
Find earliest gap past or straddling due date that fits at least
one batch, Gi6
Split J′ into two parts r′1 and r
′
2 such that r
′
1 is largest size
that can fit in Gi6
Gi6 = Gi6+ SECOND FACILITY SEARCH(i,Gi6,r′2) . (VI)
end if
end for
Evaluate overall cost for each facility and gap, and pick the one with
minimal cost, min Cost(Gi j) ∀ i, j . Construct and add to schedule
end procedure
procedure SECOND FACILITY SEARCH(facility i, gap G, remainder of job R)
for each facility k 6= i do . The remaining facilities
Fk1 = latest gap that can fit R
Fk2 = latest gap that fits R and links to job of same product
if Fk1+Fk2 == {} then
Fk3 = the first gap past or straddling due date,
that is big enough for penalized remainder of job, R′
end if
end for
Evaluate overall costs, Cost(Fk j) ∀ k, j, and return cheapest option
end procedure
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If, on a particular facility, none of the above two alternative insertion attempts
resulted in a feasible solution, the following options are explored. Specifically, the
steps attempted are: to move already scheduled demands, to split a demand, and to
backlog a demand.
(III) Move previously scheduled demands. Since there was not a sufficiently
long gap in the current schedule to allocate the entire production for the
new demand, one possibility to create a feasible schedule may be to shift
previously-scheduled demands to an earlier time to make space for the new
demand. Thereby, the heuristic identifies the latest gap in the considered
facility before the due date. All conflicting scheduled demands before this
gap are shifted backward in time (towards the start of the planning horizon),
without changing the order, and just enough to make space for the new de-
mand. This can be seen in Figure 4.1 item (III) for Facility 2, where four
previously scheduled demands had to be left-shifted to make space for the
new demand.
(IV) Split demand. Another option to fit the demand may be to split the new
demand. In this alternative, the heuristic will again consider the latest gap
before the due date, and use all available consecutive capacity. Then, it will
attempt to schedule the rest of the demand at each of the other facilities, but
only considering options (I), (II), and (V) (which is described below). An
example is provided in Figure 4.1 item (IV), where only a small fraction of
the demand can be scheduled at Facility 2, and the remainder is then moved
to Facility 1. Note that splitting the demand may cause an additional setup
time and setup cost. A demand can only be split into two i.e., a demand
cannot be split more than once.
(V) Backlog. If the facilities are really busy, it may be best (or the only feasible
option) to backlog the demand. This means that the time slot allocated to
produce the material to meet the demand falls partly or wholly later than
the due date for the demand. As described in the case study, this will result
in a monetary penalty and part of the demand being lost, as is reflected in
Figure 4.1 (V) by the smaller rectangle for the scheduled demand. In order to
reduce the magnitude of the penalty, the heuristic will schedule the demand
as early as possible in a gap that either straddles, or is later than, the due
date. An example is provided in Figure 4.1 item (V).
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(VI) Backlog and split. As a kind of last resort, with this alternative, the heuristic
will combine steps (IV) and (V). As in (IV), the demand is split, but rather
than using the latest gap before the due date, the first part of the demand is
scheduled in the earliest gap after the due date. The remaining portion of
the demand is attempted again to be scheduled in all other facilities, but only
using options (I), (II) or (V). This is illustrated in Figure 4.1 item (VI).
The above alternatives will be evaluated for all the facilities that are capable of
producing the product. Then, the demand is inserted into the schedule according to
the most profitable alternative examined, and the algorithm moves on to schedule
the next demand.
Overall, if there are n facilities, in the worst case the heuristic considers 6n2−
2n alternatives: (n) alternatives for each of the options (I), (II), (III) and (V), and
then 3n(n− 1) alternatives each for option (IV) and option (VI), due to different
possibilities in scheduling the remaining part of a demand in case of a split. This
means that in the worst case the complexity of the construction heuristic is O(mn2),
where m is the number of demands and n the number of facilities. In practice,
however, as will be shown later, in the majority of cases, only options (I) and (II)
are explored per facility.
Note that batch production means that unless the demand is exactly equal to an
integer multiple of the batch size (which itself is different for different facilities) it
is not possible to produce exactly the required demand. In such cases, the number
of produced batches is always rounded up to the minimal integer number of batches
necessary to fulfill the demand. The amount overproduced in such a case is put in
storage, possibly to be used to (partly) fulfill future demand. Before going through
the steps above to insert a demand into the schedule, the construction heuristic
will always check whether the product is in the storage, and try to partially fulfill
the demand from storage. The cost associated with this is storage cost only, as
manufacturing costs are invoked at the time of production, i.e., when a previous
scheduled demand produced that overcapacity. Products left in storage that the
heuristic can not use in later steps are considered lost and have no value.
It is interesting to note that the construction heuristics previously reviewed (see
Chapter 3 on page 14) operate sequentially in either a forwards or backwards pass
through the schedule, or a combination thereof. Instead, the construction heuristic
proposed here inserts jobs in an order of importance determined by the GA and not
necessarily in any chronological order.
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4.4.1.1 Reneging
With reneging, the heuristic has the choice of either producing as much of the
demand as it can or deciding not to produce the whole demand or just a part of it.
This is simultaneously implemented in two ways.
1. Demand reneging: In all options (I)-(VI) the heuristic can decide based on a
cost evaluation, whether it will schedule the entire demand or just fulfil what
it can from storage and renege on the rest of the obligated demand.
2. Split reneging: In options (IV) or (VI), after the job/demand has been split
into two, the heuristic can decide based on a cost evaluation whether to
schedule the second part of the split or renege on it.
The cost evaluation is done by comparing the cost of scheduling the most prof-
itable alternative as normal, CA, and the cost of reneging (i.e., not producing), CR.
The cost of reneging includes the backlog costs and also the lost revenue(s). This
comparison is of the form:
CR < RcCA. (4.14)
Where Rc is an arbitrary coefficient and 0.0 < Rc ≤ 1.0. The comparison is such
that if Equation (4.14) evaluates as true, the heuristic will renege on the demand
(or second part of the split) so manufacturing capacity is not allocated for its pro-
duction. However, as with demands that are scheduled, part of the demand would
still be fulfilled by any existing material in storage.
4.4.2 Genetic Algorithm
The quality of the solution produced by the above construction heuristic is to some
extent dependent on the order in which the demands are inserted into the schedule
since available production capacity is more restricted the later a demand is consid-
ered. By giving priority to certain demands, mainly three situations can be created.
1. Demands of the same product that should be ideally scheduled consecutively
to avoid setup costs, can be assigned similar priorities, making it very likely
that the construction heuristic will link them together.
2. Demands that are best scheduled just before the due date to save storage
cost can be given a high priority. This will lead to the construction heuristic
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scheduling these demands early on, at a time where still a lot of capacity is
available, and the cheapest option just before the due date would be selected.
3. Demands that benefit most from a highly utilised facility (e.g., because all
other facilities are much more expensive), can also be given high priority,
which will lead to early scheduling when this highly demanded facility is
still available.
Optimising this order is left to the GA, which was implemented in JavaTM using
the ECJ library (Version 23) (Luke, 1998). It used a permutation representation of
all the demands to be scheduled, i.e., 225 demands in the industrial case study used
here (the number of elements in Table 4.1). Specifically, each demand was given a
unique ID number (from 1 to 225), and the chromosome is a permutation of these
numbers. The ordering of the numbers on the chromosome determines the order
by which the construction heuristic processes the respective demands (from first
to last position) and thus influences the resulting schedule (see Figure 4.2 on the
previous page). In the cases that reneging was turned on and the coefficients were
being optimised, the chromosome would resemble that which was just described
but two extra genes would be appended to the chromosome. The 226th gene would
correspond to the reneging coefficient for ‘demand reneging’ whilst the 227th gene
would hold the value for that of ‘split reneging’. The range of values allowed
for these two extra genes was 0.0 < x ≤ 1.0 to correspond with the description of
reneging coefficients in Section 4.4.1.1.
Originally, individuals were initialised randomly, but then it was determined
that better solutions are produced if demands from a single year are grouped to-
gether on the chromosome. Unless stated otherwise, the results in this chapter are
thus based on runs where 50% of the population is initialised randomly, whereas
the other 50% only randomise the sequence of demands from the same year, but
maintain the sequence of years (i.e., all demands of a particular year appear in the
permutation before the demands of later years).
The genetic operators shared by both single- and multi-objective optimisations
are as follows. For crossover, the operator used was the Precedence Preserving
Crossover (PPX) proposed by Bierwirth et al. (1996) which ensures that if a de-
mand i is before a demand j in both individuals, this will also be true in the off-
spring. To ensure the absolute precedence relations of two parent permutations, an
empty child is initialised and a vector equal to the lengths of the parent is randomly
filled from the set {1,2} to determine the order in which genes are picked from the
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first and second parent respectively. When a gene is picked from either parent, it
is appended to the child and deleted from both parents. This ends when both par-
ents are empty and the child contains all the genes. In the case that genes 226 and
227 were included in the chromosome, one of each was picked from either parent
(with equal probability) to be in the resultant child of the PPX procedure. Selec-
tion of potential parents for crossover was done using stochastic universal sam-
pling (SUS). SUS is a fitness proportionate selection method that has minimum
spread and zero bias (Baker, 1987). Compared with standard fitness proportionate
roulette selection where there is a single pointer indicating the ‘winner’, SUS has
N equally spaced pointers where N is the number of samples to keep. This gives
members of the population with weaker fitness a chance to be chosen by sampling
the population at evenly spaced intervals. The mutation operator used was shift
mutation, which iterates through every element of the permutation and, with prob-
ability pm = 0.02, removes a demand and re-inserts it at a new random position.
The reneging coefficient genes were mutated also with the same probability but
with Gaussian mutation and a standard deviation σ = 0.1.
The operators and parameters specific to either one of single- or multi-objective
optimisation runs are described separately below. In either case, for fitness eval-
uation, the GA called the construction heuristic described in Section 4.4.1 which
builds a schedule by inserting demands iteratively in the order prescribed by the
solution’s chromosome.
4.4.2.1 Single objective
In the single objective case the actual fitness is the overall profit of the resulting
schedule, i.e., revenue minus storage, production, setup cost and backlog penalty.
This objective function is Equation (4.12) defined in Section 4.2. Experiments
with different population sizes and mutation rates showed that results were rather
insensitive to the parameter settings (see Table 4.6).
For the rest of the chapter, the GA parameters used were: a population size of
30, and generational reproduction with elite of 6. The algorithm was run for 1500
generations, and all results are based on averages over 50 runs (unless otherwise
stated). These, and the other parameters used were chosen based on preliminary
experiments and rules-of-thumb for evolutionary computation practice.
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Table 4.6: Profit performance for base case (in RMU) ± std. err. for three different
population sizes and mutation rates.
Population Size Mutation Rate
0.01 0.02 0.03
20 66612 ± 0.9 66601 ± 1.0 66594 ± 0.9
30 66613 ± 0.8 66604 ± 0.9 66593 ± 0.9
60 66612 ± 0.8 66603 ± 0.8 66592 ± 0.8
4.4.2.2 Multiple objectives
In addition to the single-objective of maximising profit, investigations were con-
ducted into multi-objective optimisation. The other objective considered was CSL.
This multi-objective optimisation maximised both profit and CSL, and there-
fore was a bi-objective optimisation. The profit objective is as described previously
and the CSL is likewise described in Section 4.2 as Equation (4.13) on page 34.
The optimisation algorithm used was the non-dominated sorting genetic algorithm
II (NSGA-II) which was also implemented in JavaTM using the ECJ library (Luke,
1998). The evolution parameters were such that a population size of 150 was run
for 300 generations with a 0.9 crossover probability for 50 separate runs. These pa-
rameters were chosen after preliminary experiments to give a suitably sized Pareto
set and enable clear visualisations of the attainment surfaces.
4.5 Empirical Evaluation
4.5.1 Comparison with Mathematical Programming
The algorithm was run on the case study described in Section 4.3, and results for
this are reported in Table 4.7 on the next page as “Standard case/GA Model”. As it
turns out, the case study has ample production capacity, which is due to modelling
the option of outsourcing production at higher cost as additional facilities. To see
how the algorithm would perform in a more loaded scenario, variations of the case
study were also tested where the demand is increased in each year by a factor of 2
or 3, and the results of these experiments are reported in Table 4.7 as well.
To judge the performance of the proposed algorithm, it was compared with
the MILP implementation as described by Lakhdar et al. (2007) and replicated in
Section 4.2. However, there is one important difference that deserves discussion.
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The MILP model has variables that specify how much is produced for each facil-
ity, product and time period. It thus requires the problem to be broken down into
discrete time periods, and it allows for at most one product to be produced in a
particular facility and time period. The choice of the length of a time period is
somewhat arbitrary, but has huge implications. If the time period is chosen very
large, then most demands would require only a fraction of a time period to be pro-
duced. The facility would then be idle in the remaining part of the time period,
leading to poor solutions. On the other hand, if the length of a time period is cho-
sen to be rather short, because the number of batches to be produced is integer,
often a fraction of the time period remains unused (e.g., if a time period is 5 days,
and producing a batch takes 3 days, only one batch can be produced in each time
period and 2 days in each time period remain unused — up to the point where a
time period is too short for even one batch and there is no feasible solution). Fur-
thermore, reducing the length of the time period increases the number of variables
and constraints quite significantly, with corresponding drastic implications on run-
ning time. Some experimenting concluded that the 90 day period used by Lakhdar
et al. (2007) indeed performs well, and all results are based on this time granularity.
In contrast to the MILP model, the GA can work with arbitrary time periods,
and even continuous time, without any implications on running time. In this im-
plementation, the smallest time unit was chosen to be a single day. This allows a
model closer to reality than the mathematical programming implementation. As a
result, the GA sometimes is able to produce solutions with a higher profit than the
MILP approach, even if MILP is run to optimality. Note that it is not claimed that
the MILP implementation by Lakhdar et al. (2007) is the best possible, or that it is
not possible to design an MILP formulation that circumvents or at least reduces the
impact of the time period length. However, the MILP model is the only one found
in the literature for this problem, and one of the advantages of GAs is their greater
flexibility in modelling the real world, and that solving a problem heuristically that
is close to reality can sometimes work better than a model further from reality but
solved to optimality.
All these being considered, although the GA and the MILP are attempting to
solve the same problem, the two approaches are actually solving very similar (but
not exactly the same) models. Hence, in the comparison between both approaches
they will be distinguished by calling the former ‘GA model’ and the latter ‘MILP
model’ from here on.
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Figure 4.3: Exemplary Gantt chart of a schedule generated by the GA model (top)
and MILP model (bottom), for the standard case. The profit and customer service
level (CSL) for each schedule is also indicated.
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Table 4.8: Runtime of MILP until it reached an optimality gap of 0.25%, and
runtime of GA to reach the same solution quality as was reached by MILP, for
different problem sizes, depending on problem size.
15 years 23 years 30 years
Target (RMU) 66284 90236 111229
MILP Time (s) 200.86 824.134 1332.59
GA Time (s) 0.07 0.131 0.195
Results from the MILP model and the GA model are compared in Table 4.7. As
can be seen, in the standard case as taken from Lakhdar et al. (2007), the GA model
solution has lower manufacturing costs (i.e., utilises the low-cost facilities better),
and lower storage costs. It also manages to satisfy all the demand (CSL of 100%),
whereas the MILP model chooses to backlog some of the demand. This is because
the GA tries to satisfy all the demand as first priority and only backlogs if there is no
other feasible option. The MILP model, however, has an explicit trade-off between
backlog and other costs, and backlogs if the resulting solution has a higher profit.
On the other hand, the setup costs of the GA model solution are higher. Overall,
the profit generated by the GA model solution is consistently higher, and by more
than the 0.25% optimality gap, i.e., the difference between the best solution found
and the upper bound determined by the MILP solver. This is possible because
the MILP model, due to its imposed time granularity, has an artificially restricted
search space. It can switch less often between products, resulting in lower setup
cost and higher storage cost. Also, it sometimes wastes part of a time period,
which may mean the need to use occasionally more expensive facilities, resulting
in higher manufacturing costs. These differences can be seen also by comparing
the Gantt charts of the optimal solutions found in the MILP model and the GA
model which are depicted in Figure 4.3. The Gantt chart of the MILP solution
generally shows shorter campaigns (sequences of batches of the same product),
and, especially visible on facility i4, small gaps between production in different
time periods, simply because the time period (of 90 days) is not equivalent to a
duration spanned by a multiple of batches for this product in this facility. The
schedule optimised by the GA model has longer un-interrupted idle time, which
may be advantageous if a new product is introduced to the facility or if a third
party is seeking to rent and use production capacity.
For the scenario with twice the demand, the conclusions are similar to the base
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case. However, for three times the demand, it seems backlogging becomes cru-
cial, and the MILP model approach seems better in doing that. While backlogging
reduces the products sold due to lost demand and thus reduces revenue, the sav-
ings that can be achieved in terms of manufacturing cost and setup cost seem to
outweigh this loss, and the overall profit of the MILP model approach is higher in
this scenario. Whether a slightly higher profit justifies a lower CSL is a different
issue. The GA’s construction heuristic, always tries to meet all the demand, even
if this may lead to a possibly lower profit. Finally, it can be observed that the GA
model’s solution still has lower storage cost and higher setup cost, probably due to
not being constrained by the coarse time periods.
Runtimes strongly depend on the implementation skills of the developer, the
hardware used, and software tools used, and thus have to be handled with caution.
Nonetheless, Table 4.7 also reports on the runtime of the two algorithms. For the
MILP, the stopping criterion was 600s, so the runtime remained the same, but the
optimality gap increased as the problem became more difficult by increasing the
demand and thus utilisation level. The GA was run for a fixed number of gener-
ations. The computational time still increased with increasing demand level. The
reason is that an increasing demand raises the utilisation level and the construction
heuristic is then less likely to be able to schedule a demand in steps (I) or (II), and
thus more often has to look at the other alternatives for scheduling it. This will be
explored further in the next subsection.
Also, the scaling behaviour of both optimisation methods with increasing prob-
lem sizes. To do this, the GA and MILP were run for problems with longer time
horizons of 23 years and 30 years (in addition to the 15 year-long base case). For
the longer time horizons, the demand forecasts for the years after year 15 were set
equal to the forecast for each product in year 15. To compare the two methods,
the MILP was first run for all three problem sizes with a stopping criterion of a
0.25% optimality gap, at which point, the solution quality (profit) was recorded
along with the time taken to achieve the solution. This profit value was then used
as a target for the GA. The average time over the 50 runs that it took for the GA to
match or beat those targets was recorded. The results of this experiment are shown
in Table 4.8. As can be seen, the time required for the MILP model and GA model
increases roughly linearly with problem size, however the factor by which runtime
increases when moving from 15 to 30 years is 6.6 for the MILP model, but only
2.8 for the GA model.
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Table 4.9: Breakdown of how often each part of the heuristic is used in optimised
solutions, mean ± std. error. Also detailed is the percentage of separate jobs that
are delivered late.
1 × Demand 2 × Demand 3 × Demand
(I) 71.9% ± 0.18% 70.7% ± 0.27% 64.1% ± 0.25%
(II) 20.9% ± 0.19% 16.8% ± 0.22% 12.8% ± 0.20%
(III) 0.3% ± 0.03% 2.8% ± 0.13% 4.9% ± 0.14%
(IV) 6.9% ± 0.03% 8.3% ± 0.17% 10.4% ± 0.12%
(V) 0.0% 1.3% ± 0.18% 7.7% ± 0.22%
(VI) 0.0% 0.0% 0.04% ± 0.02%
Total Backlogged Jobs 0.0% 1.8% ± 0.25% 9.2% ± 0.25%
Overall, from these results, the conclusion is that the suggested GA approach
is competitive with the MILP approach, but does not suffer from the introduction
of artificial time periods and thus is sometimes able to find better solutions than
MILP. The trend seems to be that the computation times for both optimisation
methods are going up linearly. However the increase of the GA approach is of a
smaller factor than that of the MILP optimisations. This suggests that the relative
performance of the GA is less susceptible to the detrimental impact of increasing
the scale of the problem.
4.5.2 Algorithm Components
In order to better understand the importance and robustness of the various compo-
nents of the algorithm, some additional experiments were done.
Table 4.9 examines how often the various alternatives to insert a demand are ac-
tually selected by the construction heuristic, averaged over the best solution found
in each of the 50 runs. As can be seen in the table, in the standard case, the major-
ity of demands (92.8%) are inserted by either scheduling it as late as possible (I),
or adjacent to a previous demand of the same type (II). This is reassuring, since if
such an insertion is possible, the other options are not tested, which significantly
speeds up the algorithm. Moving to the scenarios with higher demand, the percent-
age drops from 92.8% to 78.9%. This still constitutes the majority of cases, but
clearly the other insertion alternatives of the heuristic become more important.
Figure 4.4 looks at the relevance of the alternatives (III)-(VI) in terms of their
impact on profit. It shows the ratio of the obtained profit depending on whether
the construction heuristic during the GA search was limited to looking at alterna-
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Figure 4.4: The ratio in profit of the full model compared to the simple model,
optimized by the GA, shown for multiples of the base market demand as presented
in the case study. The increasing ratio indicates the increasing benefit the full model
will have in more complicated scheduling problems than the basic case study. Error
bars represent the standard error.
tives (I) + (II) (denoted as “Simple”), or all alternatives (“Full”). A profit ratio
of 1 means that the two models obtain the same profit, while a greater profit ra-
tio indicates that the full model is able to achieve higher profits than the simple
model. It confirms that the more complicated cases with splitting, backlogging and
moving previously scheduled demand are responsible for an increasing share of the
profit as the overall demand is increased. Especially once the demand is increased
to three times the original values, there seems to be a step change and the more
complicated alternatives seem to become indispensable.
Figure 4.5 shows the convergence of the GA over generations. This is com-
pared with random search using fully random permutations, and random search
using limited random permutations generated in the same way as the GA’s initial
population (i.e., when half of the permutations are only random amongst demands
of the same year, but the order on years is kept). Both random search algorithms
evaluate N points at random, where N is the product of the number of generations
and population size used by the GA. As can be seen, the results optimised by the
GA are considerably better than the results obtained by random search. The lim-
ited randomisation helps in particular for the less loaded problems (1 × Demand),
but is no longer better than fully randomised permutations for the case of 3 × De-
mand. This also makes sense, as with higher utilisation of the facilities, there is
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Figure 4.5: Convergence of profit over generations, for GA and random search.
Random search is tested with fully randomised permutations and where 50% of
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30th evaluation. RS = random search.
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Table 4.10: Comparison of profit, CSL, and other characteristics for the GA at 3×
demand with reneging turned off, and the reneging coefficients fixed or optimised.
Figures are mean ± std. error over 50 runs, and units are in RMU unless otherwise
indicated. Best mean is highlighted in bold - where the difference is not significant,
both are highlighted.
Reneging
No Reneging Fixed Optimised
Revenue 222704 ± 36.8 222492 ± 37.3 222475 ± 38.4
Manufacturing 42331 ± 56.13 41132 ± 55.36 41244 ± 58.45
Storage 1710 ± 11.8 1732 ± 9.1 1702 ± 9.9
Setup 355 ± 1.65 326 ± 1.55 330 ± 1.98
Backlog penalties 58 ± 3.0 90 ± 3.5 84 ± 3.2
Profit 178251 ± 54.2 179213 ± 34.9 179116 ± 48.2
CSL (%) 99.601 ± 0.0164 99.506 ± 0.0167 99.498 ± 0.0172
increasing need to schedule demands outside the year the demand is delivered, and
the artificial limitation of randomisation to within a year is no longer helpful.
To examine the effect of reneging on performance, the heuristic was run three
more times at the 3×Demand case. In the first, the option to renege was turned off.
In the second case, the reneging coefficients were both fixed to be 1.0. However,
in the third, the reneging coefficients were allowed to be independently optimised
by the GA. In all of these cases, any reneged or otherwise unscheduled demands
could be partly fulfilled from stored material in inventory if any was available.
The results from this are summarized in Table 4.10. As expected, with reneg-
ing, the heuristic is able to achieve higher profits than without but at the expense
of a lower CSL. This shows that the Reneging component can be an improvement
to the performance of the optimisation on the whole because it enables the GA
to explore more of the search space. Comparing the results of when the reneging
coefficients are fixed or are allowed to be optimised by the GA, it is seen that the
former approach performs better in terms of profit achieved but the difference in
CSL is not significant. This seems to suggest that, for single-objective of max-
imising profit, the best strategy in implementing a reneging rule is to choose a
common-sense value, like 1, for the coefficients and there is no apparent benefit in
trying to search for potentially more optimal values.
It is worth noting that these results are significantly better than the correspond-
ing results for the GA at 3× Demand in Table 4.7 with the ability to partly fulfil
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demands that are not scheduled (or that are reneged) which demonstrates that this
addition to the heuristic is an improvement to its performance4. Also, with reneg-
ing turned on, the GA is actually now able to produce solutions that achieve a better
profit than the optimal MILP solution though the mean profit is still slightly lower.
One of the drawbacks of heuristic methods is that they do not always guarantee
that the optimum solution can be reached. This is true of the GA and heuristic that
has been presented and evaluated here. In fact, in this case, the optimum cannot
be guaranteed to be in the search space as the heuristic cannot cover the entire
search space. For one, it excludes schedules that are not as close to their deadline
as possible or linked to another demand. Secondly (and more importantly), the
heuristic can only split a demand once. This limits the ability to spread heavy
demand loads over all available facilities. As previously shown in Table 4.9 on
page 54, the splitting mechanics — i.e., (IV) and (VI) — become more important
with increased load. Therefore, there are solutions the heuristic can never reach
even with brute-force approaches.
4.5.3 Multi-Objective Optimisation
In order to demonstrate the versatility of the algorithm in dealing with more than
one objective, it was run twice as a multi-objective problem using NSGA-II at 3
× Demand case. In both cases reneging was turned on but for one, the reneging
coefficients were fixed to be equal to 1 and in the other the coefficients were left to
be optimised by the algorithm. The parameters used by NSGA-II are as previously
described in Section 4.4.2.2 on page 48.
4.5.3.1 Bi-objective: profit and customer service level
As was seen in Section 4.5.1, at increasing demand loads a trade-off begins to ap-
pear between maximising profit and CSL. Therefore this multi-objective optimisa-
tion would enable a decision-maker to select a solution that meets their priorities.
First, the multi-objective results from fixing reneging coefficients and from op-
timised reneging coefficients were compared. In both cases, the non-dominated
final solutions (an approximation/nondominated set) from each of the 50 NSGA-II
runs were used to generate 50 attainment surfaces using the method and source
4The only difference between the ‘3×Demand - GA’ results column in Table 4.7 and the ‘No
Reneging’ results column in Table 4.10 is that the latter has this ability to partly fulfil demands that
are not scheduled (or are reneged) from material held in inventory.
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code by Knowles (2005). Figure 4.6 compares these two cases by plotting the
best and worst attainment surfaces for each. The figure shows how allowing the
NSGA-II to optimise the reneging coefficients may lead to better multi-objective
results. In the best case (i.e., the first attainment surfaces) having optimised reneg-
ing coefficients leads to a superior performance — this set largely dominates the
corresponding set for the fixed coefficients. The likely reason for this is because
fixed reneging coefficients don’t allow a wider sampling of potential solutions, i.e.,
it has a narrower search space. In the worst case (i.e., the 50th attainment surfaces),
the attainment surface corresponding to fixed reneging coefficients appears to be
dominating the optimised reneging coefficients, meaning that optimised reneging
coefficients have a larger variance across its 50 approximation sets. This obser-
vation is not surprising because, as mentioned earlier, having optimised reneging
coefficients allows for a wider search space. In either of the best cases, the attain-
ment surfaces include solutions that achieve a 100% CSL.
Then, in Figure 4.7, the single-objective results (from Section 4.5.2) were com-
pared with the multi-objective results at the 3×Demand case. This shows the first,
median, and last (worst) attainment surfaces for the multi-objective optimisation
where the reneging coefficients are allowed to be optimised plotted with the final
solutions from the single-objective case where the reneging coefficients were fixed
(to equal 1). As can be seen, the single-objective solutions clearly dominate the
multi-objective solutions with regard to profit which is unsurprising as its single
objective is to maximise profit. However, as previously mentioned, the NSGA-II
was able to capture a solution which manages to achieve 100% CSL which may be
of benefit to a decision-maker who prioritises meeting all customer demand over a
higher profit; the maximum CSL the single-objective GA can manage in its final
solutions is 99.7%. In general, the NSGA-II captures a greater spread of different
solutions whilst the GA produces a smaller cluster of similar solutions.
4.6 Summary
In this chapter, the lot sizing and scheduling problem was considered for a com-
plex biopharmaceutical production scenario featuring multiple products, multiple
facilities, and batch processing. For this challenging optimisation problem, a GA
was proposed based on an indirect permutation encoding that is decoded into a full
schedule by a novel construction heuristic tailored to the problem at hand.
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As noted, e.g., by a recent survey (Jans and Degraeve, 2008), most meta-
heuristics developed for lot sizing are validated only on artificial test data, failing
to demonstrate that they can tackle the complexities of real-world problems. How-
ever, the work in this chapter validates the proposed meta-heuristic approach on
industrial data.
A comparison with an MILP approach from the literature showed that the GA
is at least competitive, and often produces even better results than the MILP ap-
proach. The reason is that the MILP model artificially imposes a time granularity
by dividing the time into discrete periods that is not needed in the GA approach.
This shows that although GAs are heuristic methods, they can sometimes outper-
form exact methods not only in terms of running time, but also because they are
able to work with a model closer to reality. In addition, the performance of both
approaches were compared at increasing problem scale (by investigating longer
planning horizons) with the results suggesting that the relative performance of the
GA is less sensitive to the effects of increasing the problem size.
Finally, the heuristic was extended such that it was able to explore more of the
search space. As a result, it was demonstrated that this approach is easily adaptable
to multiple-objectives by optimising a set of non-dominated solutions that max-
imised profit and CSL which provides a decision-maker with a set of optimised
alternatives.
61
Chapter 5
Scheduling Strategies for
Continuous Bioprocesses
5.1 Introduction
The run time1 of a continuous operation is determined by several factors including
cell line stability, culture productivity, product quality, process economics, and
operational reliability and consistency (Ozturk, 2015). Clearly, this can have an
effect on any scheduling or capacity planning that takes place on the facility that
it is processed on. This is because there is a trade-off between short and longer
run times. As the process goes on for longer, the probability of failure increases,
which has associated costs, clean-up, and long lead-times to restart the process. On
the other hand, if the process is too short, because of the seed train, ramp-up and
changeover costs, these setup costs become dominating. That is sales of product
are not sufficient to cover these costs as not enough product is made before the
process is ended and restarted.
This is illustrated in Figure 5.1 on the following page: given the turnaround on
a bioreactor, and the seed train duration, one can choose a target batch run time
from which then follows the time (relative to the progress of the USP operation)
at which to start a new seed train so that it ends just before the bioreactor is able
to start its next batch (if the current batch runs for the target batch time). Here the
seed train takes 14 days, the target USP duration is 30 days, and the turnaround for
the bioreactor is 4 days. Therefore the stagger left for the seed train is such that the
1Alternatively: process/batch length or process/batch duration.
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seed train for the next batch (Batch 2) starts on the 21st day of the USP operation. In
the case of failure (e.g., Batch 2, Day 66), the seed train is started immediately for
the next batch. However this means that there is a greater period of downtime for
the bioreactor (a maximum of 14 days) as compared to the cases where the process
runs to completion without a failure. Given these considerations it is important to
determine the optimal cell culture duration, in a capacity planning context, for a
particular process given its process economics data, technical characteristics and
commercial targets.
Further to previous work on integrated continuous bioprocessing, the aims of
this chapter are to investigate the consequences to be considered when scheduling
and/or capacity planning for these types of processes. The optimal scheduling and
capacity planning strategy for these continuous processes that are prone to failure
are to be investigated as previous models did not aim to optimise schedules or
capacity plans.
Process configuration — i.e., the number of parallel bioreactors and the ratio
between the number of reactors and the number of DSP trains — has an impact on
the decision making. Given that all the parallel bioreactors share and are fed by the
same seed train, the trade-off between a large single reactor and multiple smaller
reactors with the same failure profiles is such that with more reactors the proba-
bility of achieving a low output is minimised. This is at the cost of also reducing
the likelihood of achieving maximum output from the process. In addition, there is
obviously increased probability of a failure event (because there are more reactors)
although each failure event has a reduced magnitude.
Thirdly, there needs to be consideration of the decision-making required after
a reactor fails in the context of multiple bioreactors or a more complex scenario
of scheduling & capacity planning for a multi-product facility. In the case of the
former, one decision is to let any reactors that haven’t failed run to its planned end
(e.g. if there are four reactors started at the same time and planned to last 60 days
but one fails before that time, the other reactors are run until the 60 days are up or
they all fail). Another decision is to stop the process early and restart it as soon as
possible. The trade-off there is that with a ‘normal’ restart, the remainder of the
batch proceeds at an indeterminate lower productivity but with the ‘early’ restart
there is an inital period of zero productivity as the reactors restart (due to the ramp-
up) but after that the productivity is back to the maximum for an indeterminate
time period (there may be another failure).
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This chapter attempts to factor scheduling and capacity planning concerns into
this decision-making while dealing with failure-prone perfusion processes and the
consequences of failure. First a model for perfusion processes that allows man-
ufacturing schedules to be simulated is developed. It comprises a new stochastic
simulation framework for evaluating operational decisions for a facility utilising
perfusion bioprocesses, as well as optimisation algorithms which may be utilised
to tune any scheduling strategy or policy as part of a larger hyper-heuristic frame-
work. Second, based on a mAb production process with peak production capability
of ca. 460 kg/annum, this chapter demonstrates that selecting the run time of the
cell culture operation based on the expected process economics of a singular batch
is inferior to decision-making that considers the expected annual demand or utilisa-
tion for a given facility and process. Third, strategies are developed and applied —
inspired by the EPQ and inventory replenishment model(s) — to simultaneously
optimise the selection of process run time and scheduling of batches. These are
compared with a standard scheduling approach at different facility utilisations in a
dynamic simulation environment. Finally, investigations on the impact of process
configuration are undertaken with respect to determining an optimal run time for
the cell culture process and any operational decisions that need to be taken after a
cell culture failure event.
In Section 5.2 the proposed modelling framework is detailed. This includes
the design of its components and their interactions as a hyper-heuristic. This is
followed by an evaluation of the bioprocess and simulation models as part of an
effort to ascertain the impact of failure rates and process configuration on optimum
process run times. Section 5.4 on page 85 evaluates the hyper-heuristic on a simple
scenario featuring a single-product facility by tuning two scheduling policies to
dictate operational decisions in the face of uncertain demand. Finally a section
summarising the work preceding it concludes this chapter.
5.2 Model Framework
The modelling framework proposed in this chapter is designed as a custom frame-
work comprising: a model for the manufacturing bioprocesses; an object-oriented
discrete-event model used to simulate the scheduling environment on the manufac-
turing facility in which the bioprocesses are operated; policies that dictate schedul-
ing decisions; and optimisation algorithms to tune the parameters of the scheduling
65
S
ch
ed
u
li
ng
 p
o
li
cy
 
d
ec
is
io
n
-m
ak
in
g
N
ew
 d
ay
G
en
er
at
e 
d
em
an
d
M
an
u
fa
ct
ur
in
g 
&
 f
ai
lu
re
 
si
m
u
la
ti
o
n
E
co
n
o
m
ic
s 
&
 
in
v
en
to
ry
 u
p
d
at
es
S
ch
ed
u
li
ng
 p
o
li
cy
 
d
ec
is
io
n
-m
ak
in
g
E
nd
 o
f 
ho
ri
zo
n
?
E
n
d
S
ta
rt
Y
es
N
o
O
p
ti
m
is
at
io
n
 A
lg
or
it
h
m
 
(G
A
/C
M
A
-E
S
)
−
D
ec
is
io
n 
va
ri
ab
le
(s
):
 P
o
li
cy
 
p
ar
am
et
er
s
−
E
v
al
u
at
or
: 
R
ep
ea
te
d 
si
m
u
la
ti
o
ns
 o
f 
m
od
el
−
O
bj
ec
ti
ve
 f
u
nc
ti
on
: 
P
ro
fi
t
In
p
ut
s
•
O
p
ti
m
is
a
ti
o
n
 a
lg
o
ri
th
m
 
p
a
ra
m
et
er
s:
•
M
ax
. 
ge
n
er
at
io
n
s
•
G
en
et
ic
 o
pe
ra
to
rs
•
E
co
n
o
m
ic
 d
a
ta
•
R
is
k
 f
ac
to
rs
•
P
ro
ce
ss
 d
a
ta
•
P
o
li
cy
 t
yp
e O
u
tp
u
ts
•
K
ey
 m
et
ri
cs
:
•
P
ro
fi
t
•
C
S
L
•
O
p
ti
m
is
a
ti
o
n
 a
lg
o
ri
th
m
 d
a
ta
:
•
C
o
nv
er
ge
n
ce
•
C
o
m
pu
ta
ti
on
 t
im
e
•
O
p
ti
m
is
ed
 p
o
li
cy
 p
a
ra
m
et
er
s:
•
In
v
en
to
ry
 t
h
re
sh
ol
d
s
•
E
x
p
ec
te
d
 p
ro
ce
ss
 d
u
ra
ti
o
ns
H
y
pe
r-
he
u
ri
st
ic
 
fr
am
ew
o
rk
S
im
u
la
ti
on
 M
od
el
−
S
ch
ed
u
li
ng
 p
ol
ic
y 
al
g
o
ri
th
m
s
−
B
io
p
ro
ce
ss
 e
co
n
om
ic
s
−
S
to
ch
as
ti
c 
si
m
u
la
ti
o
n
−
In
v
en
to
ry
 t
ra
ck
in
g
Fi
gu
re
5.
2:
O
ve
rv
ie
w
of
th
e
hy
pe
r-
he
ur
is
tic
,
sh
ow
in
g
th
e
in
te
ra
ct
io
ns
of
its
co
m
po
ne
nt
s
an
d
in
cl
ud
in
g
a
flo
w
sh
ee
t
of
th
e
si
m
ul
at
io
n
fr
am
ew
or
k.
66
policies. Figure 5.2 on the preceding page gives an overview of this framework.
Detailed descriptions of the components of the hyper-heuristic framework follow.
5.2.1 Bioprocess Model
The basis of the bioprocess used is a platform mAb manufacturing process utilising
a perfusion bioreactor with an alternating tangential flow (ATF) filtration system
for cell retention. Perfusion bioreactor systems equipped with an ATF filter have
been shown to perform well in economic analyses compared to other cell-retention
filter systems and do not suffer consequences as severe in the event of filter failure
(Pollock et al., 2013b). A flow sheet of this process is shown in Figure 5.3. In gen-
eral, the economic, operational, and technical data for the continuous process(es)
used for the bioprocess model is adapted from Pollock (2013) and summarised in
Appendix B.
For simplicity, the unit operations of the process can be grouped together into
three main steps:
• A seed train which encompasses all cell thawing and expansion operations;
• USP which is just the cell culture; and
• DSP which accounts for all unit operations from the capture chromatography
step (Protein A) to the final finish & polishing steps (UF/DF).
Processes may have more than one DSP train per bioreactor and so are not
limited to a 1:1 USP:DSP train configuration. In the case that there are multiple
bioreactors, all bioreactors are fed from the same seed train simultaneously. This
means that all the bioreactors have to be started at the same time.
The seed train takes 14 days and then the production bioreactor can be innoc-
ulated. The ramp-up time to reach the desired cell density for harvests is ten days.
In this period, no harvests are collected as the process has not yet reached steady-
state. From day 11 onwards, daily harvests are collected from the bioreactor and
then taken through DSP. Each DSP ‘batch’ then takes two days to be fully pro-
cessed and product coming out of it then can be put in inventory, sold or otherwise
delivered. Therefore, a process that has a cell culture run time of 60 days and
ramp-up time of 10 days will produce 50 separate DSP batches. The turnaround
on the bioreactor determining the earliest time it can be reused is four days and
accounts for clean-in-place (CIP) and sterilization-in-place (SIP) operations and
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Seed #1
Seed #2
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UFDF
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Suite
Viral 
Secure 
Suite
Figure 5.3: Process sequence and suite configuration for the model perfusion-
based bioprocess. CC = cell culture, ProA = Protein A chromatography, VI =
virus inactivation, Pool = daily perfusate volume pooling, CEX = cation exchange
chromatography, UFDF = ultrafiltration/diafiltration, AEX = anion exchange chro-
matography, VRF = virus retention filtration. Adapted from Pollock et al. (2013b).
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Table 5.1: Process scheduling parameters.
Parameters Value units
Seed train 14 days
Bioreactor turnaround 4 days
Ramp-up Time 10 days
DSP duration 2 days
other activities in preparation for a new cell-culture operation. As it is possible for
parts of the seed train process to use a different suite, the earliest portion of the
seed train of a product can take place concurrently with the latter days of the USP
of a previous batch (of the same or a different product). A threshold can then be
defined, in the case the facility is not idle, as the minimum time elapsed for a USP
operation before a decision on starting a new batch (i.e., a new seed train) can be
made. The seed-restart threshold is for starting a new batch of the same product
and the changeover threshold is for starting a new batch of a different product.
Process timing information is contained in Table 5.1.
The economics associated with this process are such that a seed train cost is
attributed to every seed operation that is started, and a cell culture setup cost for
the setup and prep activities that go into starting up each bioreactor in a batch.
The daily cell culture perfusion costs are accrued for every day a bioreactor is in
operation, and for every DSP batch commenced, DSP batch cost is accrued. A cost
is associated with replacing a fouled ATF filter; this is also captured in the batch
setup costs as a new ATF filter is needed for each one. Finally, if the process is
idle for more than the setup expiry period, there is a cost of re-establishing sterile
and clean holds for all equipment before another batch/campaign is started. This is
referred to as changeover costs and also captures the costs of setting up the facility
when changeover to manufacturing another product occurs.
To capture the stochastic failure events and the consequences, previous data
adapted from Pollock et al. (2013b) and Pollock (2013) was used and this is pre-
sented in Table 5.2 on the next page. Those studies used a fixed perfusion duration
of 60 days so the probability of ATF culture contamination and ATF filter failure
events were within the 60 days. As this study is looking at various process du-
rations, this requires some adjusting. Ideally, the rate of failure should be low in
the early stages of the process and be relatively high towards the end. The process
for Pollock (2013) choosing a 6% failure rate for the cell culture contamination
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Table 5.2: Process failure events, consequences, and the associated risk (adapted
from Pollock et al. (2013b).
Process Event p(Failure) Consequence
ATF culture contamination 6% Batch loss & discard two
pooled perfusate volumes
ATF filter failure 2% Replace filter & discard next
24 hours of perfusate
0
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Figure 5.4: The probability distribution functions illustrating the probability of a
failure event occurring on a particular day of the USP operation for different rates,
6−25%. These failure rates are defined as the probability of failure event occurring
within the first 60 days.
is that each addition to (or sample from) the bioreactor has a 1 in 1000 chance of
introducing contamination to the system — the 60 day batch had approximately
sixty such additions leading to the 6% chance of failure. This has the result that the
chance of failure on any specific day is independent of how far along in the process
it currently is.
It is reasoned that not only additions can cause contamination, but also equip-
ment that wears or stresses over the course of the process (such as tubing, gaskets,
valves, O-rings, filters, seals or connectors). For the equipment failure due to filter
fouling, however, Pollock chooses a probability of 2% and then weights failure to
occur at latter stages of the cell culture.
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Figure 5.5: The cumulative probabilities showing how likely the USP operation of
a certain duration will fail based on different failure rates.
To this end an exponential function of the form shown below is used to describe
the probability of a failure event occurring P(x), on a specific day x:
P(x) =
exp(x/a)−1
b
. (5.1)
Here, a is benchmarked to 60 and also represents the amount of time it takes (in
days) for the probability of failure to increase by a factor of e; and b is a scaling
constant
The significance of the difference in this assumption is illustrated in Figure 5.5
which shows the cumulative probability of a cell culture contamination event oc-
curring within the duration of a process. For profiles where the daily absolute risk
of failure is constant, the cumulative probability of failure in the early parts of
the process can be significantly larger than profiles modelled from an exponential
function.
Mainly seven failure rates were investigated for culture contamination: 6%,
8%, 10%, 12.5%, 15%, 20%, and 20%. These are defined as the probability of
failure event occurring within the first 60 days unless otherwise specified. Some
additional failure rates were also used in experiments: 10% failure within 45 and
30 days. In addition, a 2% rate is used for the ATF filter failure. The probability
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distribution functions are shown in Figure 5.4 on page 70.
5.2.2 Discrete-Event Simulation Framework
Based on the bioprocess model discussed in Section 5.2.1, a custom discrete-event
simulation model was developed in JavaTM (Oracle Corp., Redwood Shores, CA,
USA). Other software for simulating bioprocesses exist. For example, BioSolve
Process (Biopharm Services, Chesham, UK) is an Excel-based software package
that enables detailed cost analysis and scheduling for a single batch. INOSIM
(INOSIM Software GmbH, Dortmund, Germany) also allows for process design
and optimisation at the process level. Both of these software packages are not suit-
able for high-level planning and scheduling. Commercial discrete-event simulation
software such as ExtendSim (ImagineThat! Inc, San Jose, USA) could have been a
candidate as it allows for detailed simulation models to be designed and stochastic
events implemented, even if it is not generally used for capacity planning.
However, the choice was made for a custom discrete-event simulation model
so that it could be better integrated with the overall hyper-heuristic framework (and
the optimisation algorithms). These would all be developed in the same program-
ming language (i.e., Java). In addition, using these external programs for evaluating
solutions would add a considerable computation expense as they are quite complex.
It seemed reasonable to design a custom model that was detailed enough for the
purposes of this research without being a large drain on computation resources.
The model simulated the processing of batches on a facility as a multi-stage
process comprising of a seed train, USP, and DSP. In addition, based on the state of
the facility (i.e., what it is currently manufacturing), inventory levels, and stochastic
events, it evaluates the economics of operational decisions and reports key metrics,
inventory profiles, and the facility schedule of the given time horizon. Finally, it al-
lows the use of dynamic scheduling rules or policies to make operational decisions
based on the state of the simulation so these policies can react to any changes.
On each day:
• any new activities or operations are started if required whilst any existing
ones have their durations advanced by a day;
• any manufacturing takes place and the random variables (such as demand,
process failure events, or yield) are realised by sampling the associated prob-
ability distributions once each;
72
• the process economics related to the model are evaluated;
• scheduling decisions are made if necessary; and
• activities or operations are brought to an end at their target run time (or
terminated early due to equipment failure).
The timing of scheduling decisions and the set of decisions available to make are
determined by the specific type of scheduling policy or strategy (see Section 5.2.3).
Decisions made on one day are implemented and take effect the following day.
In the event a decision is made to start a batch and/or campaign, a seed train
operation is created and started up. When that is completed, it triggers the start of a
USP operation which proceeds until it reaches its natural/intended end — specified
by the process run time — or is terminated because of a process failure event.
During the course of USP but past its ramp-up, the daily harvests trigger separate
DSP operations which deposit product in the inventory when completed. Over the
course of the simulation, these operations are recorded in a local history. This is so
that at the end of the simulation, a facility schedule can be generated describing the
history of operational decisions taken, the workload of the facility, and identifying
any batches terminated early due to contamination. Similarly, the inventory levels
for each product are recorded at each time point so a decision-maker can evaluate
the impact of scheduling decisions on inventory levels.
Depending on the assumptions made for the purposes of the simulation, de-
mand constraints may be set to be periodic (yearly or monthly), or set to be contin-
uous (i.e., daily). According to the set demand frequency, any available product in
inventory is used to satisfy the demand for that period. If the inventory is not suf-
ficient, unfulfilled demand is added to backlog on which a decay function may be
applied. Also, any product that has exceeded its shelf-life is deleted from inventory
and discarded.
5.2.3 Scheduling Strategies
The scheduling strategies employed in a dynamic simulation environment are based
on control policies. They initiate new production orders (batches in this case) based
on current inventory levels as well as the state of the facility (i.e., the product cur-
rently being manufactured), m, in a make-to-stock fashion. In addition, these poli-
cies may have parameters that determine the run times of the processes.
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As previously mentioned, when decision-making takes place, the set of avail-
able decisions is determined by the type of scheduling policy or strategy imple-
mented. Generally, simpler policies make decisions at the end of a batch — either
because it has suffered process failure or because it has reached its predetermined
run time — or if the facility is idle. Specifically, because the seed train for a subse-
quent batch can be started before the completion of the current batch, the decision
epoch begins at the seed-restart threshold or the changeover threshold. These are
determined respectively by: the bioreactor turnaround time, and the changeover
time between products. As a result of the lag between the point when a decision
is required and the end of the current batch, policies will need to (implicitly or
explicitly) take into account the expected extra product that would be produced by
the end of the current batch (if the facility is not idle). In cases of those simpler
policies, the set of decisions is usually whether to start a new batch of the current
product, or to changeover to another product (in a multi-product scenario), or to
keep the facility idle. A more flexible policy would allow decision-making at any
point in the horizon. Specifically, everyday it would be able to cut short a batch
currently in production to either switch to a new product (in a multi-product sce-
nario), or to make the facility idle, or simply to start a new batch of the product
currently being produced.
5.2.4 Optimisation Algorithms
In the case that the scheduling strategies or policies required tuning, evolution-
ary algorithms (EAs) were used to optimise their parameters. These EAs include
a genetic algorithm (GA) and a Covariance Matrix Adaptation Evolution Strat-
egy (CMA-ES) implemented using the ECJ Library (Version 24) in JavaTM (Luke,
1998). The representation used for the chromosomes of the tuned policies was
tailored to each specific type of policy to enable efficient search procedure. As a
result, the EA parameters will be discussed in tandem with the specific policies
utilised.
5.3 Evaluating the Bioprocess and Simulation Model
In this section the results from experiments on determining optimal processing
run times are discussed. First the economics of a singular batch are considered,
followed by separate analyses of the effect of demand targets, capacity constraints
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and process configuration on the optimal cell culture run time.
5.3.1 Optimal Processing Run Time
5.3.1.1 Optimal run time of a typical batch without demand constraints
Given the costs for an ATF filter, cell culture setup costs, daily cell culture perfusion
batch costs, DSP batch costs, costs for the seed train, and process yields (all in rel-
ative monetary units (RMU)), the simulation could be used to assess the expected
performance — the Cost of Goods (CoG) — of each batch length for each failure
rate . Each failure rate, P(x), is the probability the batch will fail within the first 60
days. The failure rate used for the ATF units was 2%. In addition, a batch termina-
tion penalty is incorporated which was applied if the batch suffered a cell culture
contamination and was subsequently aborted. This is because when analysing the
expected performance of a single batch in isolation, the lost production time in a
manufacturing campaign discussed earlier and illustrated in Figure 5.1 on page 63
cannot be directly modelled (because there are no subsequent batches to delay). So
this batch termination penalty is used as a surrogate for this scheduling inefficiency
and is heuristically set to be roughly equal to the observed worst case CoG/g (ca.
20 RMU/kg) multiplied by the time that would be lost in a scheduling scenario in
the worst case (i.e., 10 days). The values for the process economics parameters are
listed in Table 5.3 on the next page.
Optimal process run time at different failure rates The simulation environ-
ment was set up to start a seed train (at the beginning of the simulation horizon)
which eventually triggered a USP operation. This operation was run until it ended
either by reaching its target duration or termination due to process failure. The
simulation environment would then be terminated after the completion of the last
DSP operation. The process economic data and process failure statistics would be
captured as well as how much product was made. This procedure was replicated
10,000 times to evaluate the metrics for each process run time.
From this it is possible to ascertain the most cost-effective process duration in
isolation by evaluating the CoG/g. In this scenario, CoG/g is calculated by dividing
the amount of product manufactured by the costs associated with operating the
process. This is illustrated in Figure 5.6 which shows the trend of CoG/g decreasing
to an optimal point, increasing after it and then plateauing with increasing process
duration. At very short process durations, the ratio of costs to material produced
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Table 5.3: Process economics parameters. Only the first seven parameters are used
for evaluating the Cost of Goods (CoG) in Figure 5.6 and Table 5.4. The remaining
parameters are used in the experiments that take into account demand.
Parameters Value Units
Replacement ATF filter cost 16 RMU
Cell culture setup cost 29 RMU
Daily cell culture perfusion cost 3 RMU/day
DSP batch cost 12 RMU
Seed train cost 5 RMU
Batch termination penalty cost 200 RMU
Process yield 1.55 kg/DSP batch
Sales price 100 RMU/kg
Inventory cost 0.01 RMU/kg/day
Waste cost 5 RMU/kg
Changeover cost 35 RMU
Backlog decay 0.25
Backlog decay period 1 year
Backlog penalty 0.1 RMU/kg/day
Setup expiry period 30 days
Shelf-life 720 days
is heavily dominated by the fixed costs involved in operating a batch, hence the
high CoG/g. Batch failures are unlikely at these process durations. As the process
duration is increased, so does the amount produced which offsets those fixed costs
and leads to lower CoG/g. However, an increasing likelihood of batch failure and
associated penalty cost tempers this decrease in CoG/g up to the optimum duration
where the trend reverses and an increasing CoG/g is observed. The CoG/g value
stabilises and remains more or less the same at very long process durations where
the probability of batch failure is practically 100%. In addition, one can see that the
optimum decreases with increasing failure rates and also that the CoG/g in general
increases with more failure-prone processes.
Sensitivity analysis The process run time with the lowest CoG/g for each failure
rate2 is shown as well as results of a ±50% sensitivity analysis in Table 5.4 on the
following page.
Looking at the base case, intuitive results are observed where the optimum
2The values for the optimum process run time are the average of the process lengths that have
CoG/g values within the standard error of the lowest CoG/g value.
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Figure 5.6: Expected CoG/kg for differing process run times and contamination
rates
cell culture duration gets smaller with increasing probability of failure — from an
average of 97.9 days at a 6% failure rate to 85.5 days at 10% failure rate and the
extreme of 61 days when the probability of failure is one-in-four within the first 60
days of the process.
Table 5.4 also shows that the optimal batch duration was not affected by the cost
of a replacement ATF filter and was also barely sensitive to variations in the cost
of the seed train. The cost of the replacement ATF filter has no impact because it is
only applied in the event of a filter failure (which does not terminate the process)
and is not very likely3. Similarly, the cost of the DSP batches does not affect the
optimum batch durations when varied. The daily cell culture perfusion and cell
culture setup costs have a moderate positive effect on the optimum when compared
to the bioreactor failure penalty cost which has the greatest but opposite effect on
process duration. That is to say, a decrease in the cell culture setup cost or daily
perfusion cost reduces the optimum process duration while an increase would make
it longer while the inverse relationship applies to the failure penalty cost.
3Although the cost of an ATF filter is used in deriving the value of the cell culture setup cost, in
the sensitivity analysis the knock-on effect the ATF filter would have on the cell culture setup cost
— and consequently the optimal process duration — is not considered. Instead, for ease and clarity
in determining dependencies, each parameter is treated independently of the others in this analysis.
Otherwise, increasing the cost of an AFT filter would increase the optimum process duration.
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One can explain these trends by considering these parameters as either de-
pending on how much product is manufactured or independent of the output. For
example, the cell culture setup is applied regardless of how much is produced, so
the higher its value, the more product has to be manufactured (and consequently
the longer the process duration has to be) to offset this cost. Conversely the total
DSP cost is more or less a function of how much is manufactured. One of the con-
sequences of process contamination is that product is discarded. This discarded
product may have been in the middle of DSP processing and thus accrue DSP costs
regardless. A larger DSP batch cost exacerbates this inefficiency and so a shorter
batch would be better as the chance of process contamination is lower. Clearly,
this particular effect was not large. These effects apply to the cell culture perfusion
cost because it is applied during the ramp-up period as well as during the produc-
tive period of the process; in this scenario the former effect is more significant. The
effect of the bioreactor penalty cost is more obvious — if there is a larger direct
penalty for process failure, longer processes that are more likely to fail become
more costly.
Although the differences in the optimum process duration are reduced when
comparing the 6% and 25% failure rates, there does not seem to be an overall trend
when considering all the other failure rates examined. In fact, these differences are
not strictly monotonic (as a function of changing failure rates) even as the reported
optimum durations are. This observed behaviour is due to the simulation noise
and the shape of the CoG/g curves which means that the average of the process
lengths within the standard error of the minimum CoG/g value can be skewed.
With increasingly failure-prone processes, there may be a limit to how much the
parameters can affect the optimum process duration. If this is true, it would be at a
failure rate that is higher than those considered here and so would be unrealistic in
a real-world scenario.
5.3.1.2 Optimal duration with demand targets or time constraints
In comparison, when examining a scenario that takes into account demand require-
ments over the course of years, or one where there are capacity constraints on the
manufacturing facility (or both) the optimal process duration changes. The differ-
ence between this and previous analysis is that here, sequences of batches (rather
than isolated batches) are examined.
Another way of describing this difference is that in the previous analysis, for
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each process run time that is tested, the facility is assumed to have infinite time
available to schedule a fixed number of batches, after which the average economic
statistics of the average batch is analysed. In the following analysis, however, for
each process run time tested, this facility has a finite fixed time available so as many
batches as possible need to be manufactured in that time frame to either maximise
production output or meet a demand target. Hence, the consequence of process
failure is captured as a loss in available production time instead of relying on an
explicit failure penalty cost4.
Time constraints This is first illustrated with time constraints by Figure 5.7 on
the next page which shows the expected throughput for each process run time if
the facility was run at maximum utility — i.e., the objective was to maximise the
amount of product manufactured within a time horizon of five years. The trend
observed for all failure rates is such that with increasing process duration, the pro-
ductivity increases until it peaks, goes down a little and then plateaus shortly after-
wards. This is because at one extreme, if the process is very long, it will always
fail well before it reaches its ‘threshold’ where the seed train for the next batch is
started. So there is always wasted time equal to the difference between the seed
train duration and turnaround time. As the process duration gets smaller (towards
the optimum) the failure will tend to happen after its threshold but before the sched-
uled run time. For example, if a 130-day process will fail on its 127th day (wasting
the last three days), it is more productive to have scheduled a 129-day process as
there is only two days wasted, which is less productive than a 128-day process,
and a 127-day process would be better still. A 126-day process would be best as
the 127-day process would require previous days’ harvests to be discarded making
it as productive as a 125-day process. Processes shorter than 126 days would be
increasingly less productive.
From this figure, the maximum throughput achievable by the facility is deter-
mined to be 456 kg when the process duration is 126 days at a failure rate of 10%
within 60 days. This means that the maximum fraction of productive days is 81.9%
in that time horizon. Comparing with the longest batch possible of 180 days and a
perfect process (i.e., there is no failure) the facility has a peak productivity of about
89% of its capacity. The figure also shows the profiles for 10% failure within 30
and 45 days where the maximum throughputs are 378 kg if the process duration
4Therefore, bioreactor failure penalty cost is not used in cost calculations from this point onward.
80
 0
 100
 200
 300
 400
 500
 0  20  40  60  80  100  120  140  160  180
Y
ea
rly
 th
ro
ug
hp
ut
 (k
g)
Process duration (days)
P(F) = 10%
60 days
45 days
30 days
Figure 5.7: Productivity of processes with different cell culture failure rates: 10%
within 30, 45, and 60 days.
is 64 days, and 429 kg at 96 days respectively. Compared to the previous analy-
sis, this suggests that at a 10% failure rate within 60 days, the most cost-effective
processes (those minimising costs) are shorter than the most productive processes
(those maximising production) — i.e., ca. 85 days vs. 126 days).
Demand targets To demonstrate this also with demand targets, a simulation of
a facility with one product over an extended time horizon (fifty years in this case)
and yearly deterministic demand (i.e., demand is delivered from inventory once
each year at the end of the year) was carried out.
To determine when the campaigns to meet the demand each year were started, a
simple heuristic was implemented. This heuristic starts campaigns at the latest
possible date (for a perfect process) so that enough product is made to meet the
demand at the end of the year whilst taking into account any product already in
inventory and the expected production of any batches that are currently in progress.
A consequence of the demand being delivered at the end of each year and the shelf-
life of inventory being measured in days is that during a year, a lot of product may
expire before the end of the year if it was not delivered at the end of the previous
year. This means that there would be material in inventory accruing storage costs
that would never be used. To deal with this, at the end of each year, material
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Table 5.5: The optimal process durations at various yearly demand targets and
10% contamination rate for different objectives: maximising profit and minimising
CoG/g. The values for the optimum process length are the average of the process
lengths that have profit or CoG/g values within the standard error of the highest
profit or lowest CoG/g value respectively.
Best process run time (days)
Demand (kg) Profit CoG/g
30 49 49
75 42 43
155 67 63.5
230 94 64
310 84 81.5
455 119.5 120
that will expire before the next delivery date is thrown away to avoid unnecessary
storage costs.
In a real-life bioprocess scenario, facilities and the processes they house are
designed to maximise utilisation. This means it is unrealistic and inefficient to pro-
duce a small fraction of the facility’s maximum output. However, if it is assumed
that the different demand targets represent different products that can be manufac-
tured in a multi-product facility, a ball-park estimate of an efficient choice when
deciding the processing length for such products can be determined.
Different processing lengths for the given parameters in Table 5.3 were sim-
ulated and performance captured at various yearly deterministic demand targets.
The demand targets investigated were 30, 75, 155, 230, 310, 465 kg per annum
and the cell culture contamination rate was 10% (per first 60 days) while the ATF
fouling rate was 2%. The processing lengths with the best profit and CoG/g perfor-
mances are listed in Table 5.5. Profit is calculated as the difference between rev-
enues (product of sales price and amount sold) and the total costs which is sum of
inventory costs, waste costs, and manufacturing costs (replacement ATF filters, cell
culture setup, daily cell culture perfusion, DSP batches, seed train costs). CoG/g,
meanwhile is calculated as the total costs divided by the amount of product sold.
From these results, it is observed that when considering demand targets, the
optimal process duration is not necessarily the same as when demand is not taken
into account. Although the trend shows that the best process duration when judged
based on the overall profit and the CoG/g is going up with increasing demand, at
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various points there appears to be some interaction of different factors causing the
optimal process duration based on either performance measure to fluctuate. This
is partly due to a lot-sizing trade-off between long and short process durations.
With a long(er) batch, setup costs are minimised and enough is made for each year
without needing to store much for the next year or that is wasted. However it
is more susceptible to failure leading to uncompleted demand. On the other hand,
multiple (i.e., more than one) shorter batches are less likely to fail and miss demand
but incur greater setup costs. This explains the drop in optimal process duration
from 30 kg to 75 kg and again from 230 kg to 310 kg with respect to profit. In
addition, at 230 kg, the optimal process durations with respect to profit and CoG/g
are significantly different.
The best process duration for a minimal CoG/g may be significantly different
from that which gives maximum profit. This is because the CoG/g measures the
ratio of total costs to the amount of product made (or in this case, sold) while
profit is simply the difference between revenues and total costs. A low CoG/g
may indicate an ‘efficient’ process but does not reveal the whole story as it is also
possible that not enough product was sold. For this reason, it is better to use profit
as a metric rather than relying solely on the CoG/g measure. Finally, given these
assumptions and process, really short batches (less than three to four weeks) are
always sub-optimal.
5.3.2 Process Configurations and Multiple Bioreactors
In investigating the impact of multiple reactors in determining an optimal runtime
for the cell culture process, process configurations with one to four parallel reac-
tors were investigated. The processes that utilised multiple parallel reactors were
designed such that they were comparable to the scenario with one reactor. This
means that absent failure, the productivity of each configuration would be identi-
cal. So taking the single reactor case as a basis, if that reactor can produce a daily
yield of Y , a process configuration comprising n reactors would have a daily yield
per reactor of Y/n. The parallel reactors all share the same seed train, i.e., they are
innoculated from the same seed source so they always start at the same time. In
addition, the harvest from all reactors are pooled together and fed into one single
downstream train so DSP is identical in all process configurations. Table 5.6 con-
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Table 5.6: Process economics parameters for multiple parallel bioreactor scenarios
in RMU. The replacement ATF filter cost is per bioreactor in the configuration
while the other costs represent the entire process configuration.
Number of parallel reactors
2 3 4
Seed costs 5 5 5
Cell culture setup costs 52 68 54
Daily cell culture perfusion costs 3 3 3
Replacement ATF filter 16 16 7
DSP batch costs 12 12 12
tains the process economics parameters for the three new process configurations5.
Firstly, the performance and productivity of the multi-bioreactor configurations
was assessed and compared with the base case of a singular bioreactor. To do this,
a five year horizon was simulated for each configuration without any demand or
shelf-life constraints and recorded the total inventory at the end of the period. The
purpose of this was to measure how much can be manufactured in each design
scenario. This simulation was carried out over 10,000 replications and the mean
amount of product manufactured was captured for each process duration from 14 to
180 days inclusive at a 10% cell culture contamination rate and a 2% ATF fouling
rate.
In event of a cell culture contamination event, two different strategies were
employed. In the normal case, the next seed train would only be started at the pre-
determined threshold point unless all the bioreactors had become contaminated and
failed — a normal seed restart. The second strategy/response was such that if a
bioreactor became contaminated and failed, a new seed would be started immedi-
ately and the current cell culture operation would be terminated early so as to turn
around the bioreactors and prepare them to receive the innoculum from this new
seed train. This is referred to as an immediate or early seed restart. The results
from these are shown in Figure 5.8 on page 86.
This shows that a process configuration that utilises only one bioreactor is able
to manufacture more than the other process configurations that comprise multiple
5The cell culture setup costs increase in a non-monotonic manner because the single use biore-
actors (SUBs) come in discrete set sizes of 2000, 1000, and 500 litres which cost about 9.8, 8.3,
and 5.5 RMU respectively. The one-reactor process needs just one 2000L SUB; the two-reactor and
three-reactor processes require identical 1000L SUBs; the process with four parallel reactors needs
its SUBs to be only 500L each.
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bioreactors. In fact, a trend can be observed such that with increasing number of
reactors, the maximum output of the process reduces across all process durations.
In addition, when comparing the normal seed restart decision to the early or im-
mediate seed restart decision, it is clear to see that the latter strategy is superior
to the other. This indicates that the trade-off does not favour a prolonged period
of indeterminate low(er) production as compared to an interval with no production
followed by an indeterminate period of maximum production.
Some of the insights from Figure 5.8 are made clearer in Figure 5.9. For in-
stance, one can see that the gap between the multiple reactors and a single reactor
widens with increasing process duration. With the normal seed restart this trend
holds true for the entire scope of process durations examined. However, when
the seed is restarted immediately upon a failure, this is only true until a process
duration of about 130 days at which point the trend reverses and the difference
in productivity begins to narrow. This is because at higher process durations, the
single reactor process starts to decline in productivity whilst the productivity of
configurations with multiple reactors merely plateaus.
In addition, the marginal difference in productivity reduces with increasing re-
actors is observed. That is to say that, at any given process duration, the difference
in productivity between one reactor and two reactor configurations is larger than
that between two reactors and three reactors which is larger than between three re-
actors and four. This is evident with normal seed restart decisions and more muted
with immediate restart decisions. This observation may be useful in the case of
facility retrofitting if there is a decision to make about adding more bioreactors to
the USP suite(s) in order to increase the scale or capacity of the facility.
5.4 Single-Product Scheduling Strategies
Here, control strategies for a single-product facility are introduced and evaluated.
These strategies are based on simple stock replenishment policies that determine
when to order a new batch (by starting a new seed train) and how much to order
(by setting the process run time).
5.4.1 The (s,B) Inventory Policy
One of the approaches to dealing with stochastic uncertain demand is by trying to
sustain strategic inventory levels at a certain amount. In other words, some safety
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stock is maintained as a buffer to mitigate fluctuations in actualised demand, and
in this case, failure-prone processes.
In this case two decision variables are defined:
1. The re-order level, s
2. The size of batches in the campaign, B
The logic for determining when to start a new seed train is detailed in Algo-
rithm 2. This essentially says that each day the inventory is compared with the
re-order level and will attempt to start a new seed train to start the following day if
the amount in inventory is less than that. Obviously, a new seed train is not started
if one already exists in operation, or if there is an existing USP process that has not
been in operation for as long as the threshold time.
Algorithm 2 Pseudocode of the (s,B) strategy.
1: procedure NEW SEED TRAIN(current time t)
2: STt = the existing seed train at time t
3: USPt = the existing USP operation at time t
4: T ST = the seed train run time
5: T USP = the USP run time
6: T USPt = time elapsed in USP operation at time t
7: T BT = time required to turnaround bioreactor
8: T THD = threshold
9: T THD = T USP+T BT −T ST
10: if STt == {} then
11: It = the inventory level at time t
12: if USPt == {} OR
(
USPt 6= {} AND T USPt ≥ T THD
)
then
13: if It ≤ s then
14: Start seed train, STt+1
15: end if
16: end if
17: end if
18: end procedure
With this policy, s has to be sufficiently high so that stock-outs do not occur but
must not be too high such that large inventory holding costs are not accrued. This
must be balanced with an optimal B which if too small would mean more batches
would be needed and lead to an increase in setup costs.
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5.4.2 The (s1,s2,B) Inventory Policy
The second inventory policy was designed to be a potential improvement on the
(s,B) policy by including a third parameter. All three decision variables are identi-
fied below:
1. The re-order point, s1
2. The size of batches in the campaign, B
3. The campaign re-order point, s2
The significance of the campaign re-order point, s2, is such that it (instead of s1)
is compared with inventory in the case where a potential new batch would be part
of the current campaign (i.e., the time between the USP of the latest batch and the
USP of the new batch does not exceed the setup expiry period) to determine if a new
seed train should be started. The reasoning for this policy especially in contrast to
the (s,B) policy is that the new parameter s2 is an attempt to allow the optimisation
to choose values for the policy parameters so that batches can be linked together
or manufactured in close proximity to each other in order to minimise changeover
costs that apply if there is a sufficiently long idle time between two consecutive
batches.
These three decision variables were optimised using a GA for the objective of
maximising expected profit. The logic for determining when to start a new seed
train is detailed in Algorithm 3.
5.4.3 Evaluation of the Scheduling Strategies
Next, the performance of the scheduling strategies previously devised were anal-
ysed. These strategies would identify the best way to schedule batches in the face
of imperfect processes and stochastic demand by determining an optimum process
duration and the right time to start a new seed train (and ultimately a new cell
culture operation). They would be applied in a simulation environment similar to
previous experiments but with a few differences.
Firstly, and most importantly, the demand is due daily and (as previously men-
tioned) is stochastic. The random variable of daily demand is defined as a Normal
distribution, N(µ,(σ)2), where µ is the expected demand and σ is its standard de-
viation; sampled demand is truncated and not allowed to be negative. In practice,
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Algorithm 3 Pseudocode of the (s1,s2,B) strategy.
1: procedure NEW SEED TRAIN(current time t)
2: STt = the existing seed train at time t
3: USPt = the existing USP operation at time t
4: T ST = the seed train run time
5: T USP = the USP run time
6: T USPt = time elapsed in USP operation at time t
7: T BT = time required to turnaround bioreactor
8: T SEP = the setup expiry period
9: T SEPt = the time elapsed in setup expiry period
10: T THD = threshold
11: T THD = T USP+T BT −T ST
12: if STt == {} then
13: It = the inventory level at time t
14: if T SEPt +T ST > T SEP AND It ≤ s1 then
15: if USPt == {} OR (USPt 6= {} AND T USPt ≥ T THD) then
16: Start seed train, STt+1
17: end if
18: else if T SEPt +T ST ≤ T SEP AND It ≤ s2 then
19: if USPt == {} OR (USPt 6= {} AND T USPt ≥ T THD) then
20: Start seed train, STt+1
21: end if
22: end if
23: end if
24: end procedure
this means that:
µ =
yearly demand
360
(5.2)
and,
σ = 0.025× yearly demand√
360
. (5.3)
In addition, the inventory cost is 0.6 RMU/kg/day and since demand is delivered on
a daily basis, material is only discarded when it has reached the end of its shelf life.
The backlog decay is also applied daily at a pro rata rate of the yearly value. This
is detailed in Equation (5.4) where ∆t is the amount of product that is undelivered
at time t, θ is the daily backlog decay rate, Dt is the observed demand at time t,
and St is the product sales at time t.
∆t = θ∆t−1+Dt −St , ∀ t. (5.4)
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Meaning that each day, any outstanding demand is multiplied by the equivalent
of 360
√
0.25 and the product of that is carried over to the next day. Otherwise, the
parameters used are as detailed in Table 5.3 & 5.6, the cell culture contamination
rate is 10%, and the ATF fouling rate is at 2% (both rates are per the first 60 days).
5.4.3.1 Genetic algorithm parameters
In order to evaluate the performance of the two strategies, they were tested at vari-
ous demand rates. This was also to determine if there were any discernible trends
dependent on the facility utilisation (i.e, the demand).
A GA was designed to tune the parameters in each strategy and its parameters
are as follows: The number of generations was set to be 100, the population size
was 30 with elites of six. The chromosome was made up of three genes for the
(s1,s2,B) strategy: the first two representing s1 and s1 respectively are real-valued
whilst the third representing B is integer. In the case of the (s,B) strategy, there are
two genes — the first for s and the latter for B. The selection process for individ-
uals to be crossed over was a tournament with a size of two. The probability of
crossover being applied was 0.9 and the crossover operator was uniform crossover.
Probability of a gene being mutated was 0.3 and 0.5 for the (s1,s2,B) strategy and
(s,B) strategy, respectively. Gaussian mutation was used (with a standard deviation
of 10) for the real-valued genes whilst the integer gene used (±1) random walk as
its mutation operator with the probability 0.9 that the walk continues. Random
walk mutation performs a random walk starting at the current value of the gene. At
each step in the walk it sets a variable k to either 1 or −1 (with uniform probabil-
ity). It then attempts to add k to the current value. Then with a probability value
of 0.9 it iterates another step, or else it immediately quits the walk. At the end of
the walk, the gene is set to the current value, as was modified during the walk. The
minimum and maximum values for the genes in the chromosome are detailed in
Table 5.7.
For both strategies, the GA was run for 50 independent runs and the results
which are described and analysed below are based on averages of these runs unless
otherwise specified.
5.4.3.2 Comparison of scheduling strategies
As well as being compared to each other, the strategies were also compared with
two ‘standard’ strategies, SSH1 & SSH2. These are based on the (s,B) strategy but
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Table 5.7: The minimum and maximum values for genes in the chromosome.
Parameter Type Min. value Max. value
s continuous 0 100
s1 continuous 0 100
s2 continuous 0 100
B integer 14 120
Table 5.8: Comparing the profit (in RMU) for the different strategies at various
annual demand targets. Demand is a random variable which follows a Normal
distribution as previously described where the values in this table correspond to
µ . Values reported are mean ± std. error, and in the case of the GA optimised
strategies are over 50 runs. Bold indicates best performance.
Demand (kg) (s1,s2,B) (s,B) SSH1 SSH2
220 95661 ± 2.0 95650 ± 2.0 93893 ± 8.0 94185 ± 7.8
250 109102 ± 1.9 109095 ± 1.8 107364 ± 9.0 107471 ± 8.9
280 122607 ± 1.9 122612 ± 2.5 120814 ± 9.9 120837 ± 10.2
310 136179 ± 2.7 136182 ± 2.0 134247 ± 11.1 134300 ± 11.1
340 149738 ± 2.2 149732 ± 3.0 147486 ± 12.2 147784 ± 12.3
370 163191 ± 2.6 163187 ± 3.4 161083 ± 13.6 161275 ± 13.4
400 176427 ± 4.1 176430 ± 2.2 174615 ± 15.4 174743 ± 14.9
440 192979 ± 3.1 192973 ± 3.5 185191 ± 27.0 192379 ± 18.5
in both of these cases, s is set so that there is not more than a 5% probability of
a stock-out during the lead time. Then for SSH1, B is chosen to be 60 days and
for SSH2, the optimal B is chosen via an enumerative search. To evaluate SSH1 &
SSH2 at the different demands, the strategies were simply simulated 20,000 times
with the same random number seeds used to evaluate the performance of the final
solutions evolved by the GA. The results of these experiments and comparisons are
summarised in Table 5.8.
From these results, one can see that the (s,B) and (s1,s2,B) strategies are more
or less similar in terms of overall performance. This would mean that the extra
parameter in the (s1,s2,B) strategy does not offer any advantages in achieving a
superior performance. Also, the ‘standard’ strategies are seen to perform worse
than the other strategies. SSH2 performs better than SSH1 across all demand scales
which adds more merit to the idea of selecting process durations based on the
demand faced, especially at high demands. In Table 5.9 the values of parameters
for the best (s,B) policy and ‘standard’ strategies are directly compared over the
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Table 5.9: Summary of GA evolved parameters for the (s,B) policy compared with
that of the ‘standard’ strategies. Units for parameter s and annual demand are in kg
and in days for parameter B. Values for (s,B) are the out of all GA runs. Note that
SSH1 and SSH2 share the same values for s.
(s,B) SSH1 SSH2
Demand s B s B B
220 11.6 52 28.2 60 46
250 14.6 53 32.1 60 53
280 16.7 56 36.0 60 59
310 19.2 62 39.8 60 61
340 20.7 70 43.7 60 71
370 23.7 84 47.5 60 85
400 26.4 103 51.4 60 105
440 35.4 106 56.5 60 110
different demand scales. The parameter s is always larger in the SSH1 & SSH2
case and with increasing demand load, the difference becomes larger. However,
there is a step jump at 440 kg where that difference narrows slightly. The run times
for SSH2 are generally similar to that of the (s,B) policy. On the other hand, at 310
kg and 280 kg, the value of B for the (s,B) policy almost equals that of the SSH1
strategy and exceeds it by a wide margin at larger demand loads. These higher
demands require greater productivity which are achieved by longer run times.
The implications of this are that a facility operating at 75% or higher of its
maximum capacity6 requires increasingly longer run times for its cell culture and
using a ‘standard’ run time would mean the facility is being run inefficiently. Be-
low that but above 50% of max. capacity, the variance in optimum run times over
different demands is much smaller and a more moderate run time should be im-
plemented. However, it remains important that this is paired with a good reorder
level, otherwise performance (profit) will suffer.
In order to determine the importance of each parameter to the performance of
the strategy, a ‘rough’ visualisation of the (s,B) search space was generated. This
is presented in Figure 5.10 for an expected annual demand of 440 kg. It shows
that for shorter process run times, B, the reorder level, s does not affect the perfor-
mance. This is because shorter processes are not as productive and so inventory
is perpetually below the reorder level meaning that new batches are always being
6Maximum capacity here is defined as the maximum throughput (or productivity) of 456 kg per
annum as shown in Figure 5.7 on page 81.
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Table 5.10: Summary of GA evolved (s,B) policy parameters for the various
USP:DSP process configurations. Units for parameter s in kg and in days for pa-
rameter B. The best policy out of all GA runs is reported for each configuration.
Number of reactors s B
1 35.3 113
2 34.9 107
3 40.7 109
4 42.3 116
ordered. Past process durations of 55 days or so, the reorder level becomes in-
creasingly more significant to the point that process duration has minimal effect
on profit. Here, the reorder level has to be large enough to keep inventory levels
sufficiently high.
5.4.3.3 Comparison of parallel-bioreactor process configurations
The (s,B) strategy was used to compare the different process configurations at a
mean yearly demand of 440 kg — processes with multiple parallel bioreactors are
compared with a configuration with just one larger reactor. The purpose of this is
twofold. The first is to determine the optimal economic performance of each pro-
cess configuration. The second is to observe if there is a difference in the optimised
strategy parameters. On one hand, because the configurations with fewer reactors
have a higher productivity at comparatively shorter process run times, configura-
tions with more reactors will need longer run times to compensate especially at a
high demand load. However, with more consequential failures in configurations
with fewer reactors, the safety stock needed to mitigate stock-outs would need to
be larger.
Fifty runs of the GA were therefore run for each of the process configurations
and the results over these optimisations are reported below. In the cases with mul-
tiple reactors, the ‘early/immediate seed restart’ response (as described previously
in Section 5.3.2 on page 83) is used if the cell culture fails before its scheduled
end. The GA parameters are identical to previously described except the minimum
value for B was increased to 60 days and the number of generations was set to 50.
This was done to focus the search on the space illustrated in Figure 5.10 on the
preceding page.
Table 5.11 on the next page summarises the performance of each configura-
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Table 5.11: Profit and other characteristics for the (s,B) strategy at the various
USP:DSP process configurations. Figures reported are in RMU (apart from CSL)
stated and are an average over 50 runs. White background indicates best per-
formance and darker shades denote worse performance for each metric; figures
highlighted in colour are the differences between the best and performance in that
scenario.
1:1 2:1 3:1 4:1
Profit 192977 -1713 -3188 -4564
Revenue 217793 -475 -1417 -2975
Total costs 24816 1238 1771 1589
Seed 85 11 16 23
USP 5310 602 1032 830
Replacement ATF filters 19 15 31 8
Cell culture setup 491 505 880 671
DSP 17086 622 607 457
Changeover 19 6 2 36
Storage 611 439 254 870
Backlog penalties 690 119 345 705
Wastage 109 69 145 205
CSL (%) 99 -0.22 -0.65 -1.35
tion. This shows the single-reactor configuration performing better than the other
process configurations and a trend of decreasing profit with more parallel reactors.
This difference in profits is mainly driven by high(er) USP costs, especially in the
3:1 configurations. This is most likely due to the fact that SUBs get comparatively
cheaper the larger they are (i.e., a 2000L SUB costs less than two 1000L SUB). At
the 4:1 process configuration, the difference is due to significantly lower revenue.
It is possible that this is because with four reactors, there are often failures, causing
lower production/productivity which leads to more lost sales (reflected by much
higher backlog penalties).
Meanwhile Table 5.10 reports the best optimised (s,B) parameters for each of
the process configurations. It is worth noticing that generally, the reorder level
— and consequently the amount of safety stock required — increases with more
reactors in the process configuration. This is contrary to what was initially pre-
dicted; it appears instead that more safety stock is needed because these processes
are less productive. The process duration also somewhat follows this trend; al-
though the two- and three-reactor configurations have slightly lower duration than
that of the 1:1 process, the run times increase when going from 2:1 to 4:1 config-
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urations. It may be that at 2:1 and 3:1 configurations, the need to mitigate process
failure dominates the lower productivity but at 4:1 configurations a longer run time
is required to compensate for lower productivity exacerbated by a large demand
load. Multi-reactor process configurations have more process failures and are less
productive which necessitates longer run times to compensate and meet demand.
However, with longer durations the risk of failures increases even more and may
require higher safety stock levels to mitigate stock-outs (or higher reorder levels to
increase the frequency of batches).
5.5 Summary
This chapter set out to investigate the scheduling considerations of operating perfu-
sion cell culture processes prone to failure especially through the prism of process
run times. This involved exploring the economics of the perfusion cell culture
process, identifying appropriate scenarios for using short or long batches, as well
as determining the impacts of process configuration and scheduling strategies and
policies.
To achieve this, a custom object-oriented simulation framework modelling con-
tinuous bioprocesses in a scheduling environment was first proposed and devel-
oped. In addition to a bioprocess and scheduling model, its components include a
custom discrete-event simulation engine, and modules for implementing schedul-
ing policies and optimisation algorithms to tune them.
Utilising this framework, the work in this chapter found that given the assump-
tions made, optimum run times are very sensitive to demand and process failure
rates. Despite this, really short batches (i.e., less than three weeks) are sub-optimal
even in high failure or low demand scenarios. Utilising parallel reactors, which
may offer flexibility, is less productive than one equivalent larger reactor. This
difference, however, heavily depends on the response to a reactor failing. The su-
perior option is to implement an immediate seed restart response — this limits the
dip in productivity in a 4:1 configuration, for example, to just above 95% of the 1:1
configuration as compared to normal seed restart which can go as low as around
76%.
There is no major difference between the (s,B) and (s1,s2,B) strategies for
scheduling continuous bioprocessing and anticipating stochastic events. So the
former strategy would be preferred as it is simpler and requires less effort to tune.
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Comparing the (s,B) policy with ‘standard parameters’ revealed that operating the
facility at more than 75% of maximum capacity would require run times signifi-
cantly longer than the ‘standard’ 60 days otherwise performance would suffer; it is
also necessary to pair the run time with a good value for the reorder level.
While this chapter focused entirely on a single product, the following chapter
will, using the framework presented here, tackle a scenario with a multi-product
scenario. There, scheduling decisions or policy parameters for each product cannot
be ‘greedy’ but have to be complementary to the others in the portfolio.
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Chapter 6
Dynamic Scheduling for
Continuous Bioprocesses in a
Multi-Product Facility
6.1 Introduction
Prior scheduling or planning frameworks for bioprocesses are static, determinis-
tic, and almost exclusively consider fed-batch processes. Those that model any
continuous processes either do not account for uncertainty — either in demand,
process/equipment failure, and/or process titres and yields — or do not intend on
optimising facility schedules. As previous models did not aim to optimise sched-
ules or capacity plans (Pollock et al., 2013b; Farid et al., 2014), there is a research
gap in investigating optimal scheduling and capacity planning strategies for these
continuous processes. Similarly, deterministic planning models (Siganporia et al.,
2014) did not focus on uncertain events — so require complete re-optimisation
after stochastic events.
Take, for example, a scheduling & capacity planning scenario for a multi-
product facility where two products are scheduled and are to be manufactured. In
the event a batch of the first scheduled product fails, restarting another batch would
lead to the schedule running late and demand (of that product and/or the subse-
quent product) being delivered late. This raises the question of what the optimal
rescheduling strategy is. One can simply carry on the campaign until the demand
target is met, thereby moving back everything else scheduled later. Conversely,
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one may decide to reschedule the manufacturing campaign(s). Deciding when to
reschedule and how to implement a strategy is another question. An alternative
approach to constant re-optimisation and rescheduling is to have a dynamic policy
that does not prescribe an entire schedule ahead of time. Instead it makes just-
in-time scheduling decisions, reacting to and anticipating changes such as failed
batches, fluctuating titres & yields, and uncertain demand.
For most perfusion processes, the duration of the cell culture operation (the
process run time) is fixed for each batch. However it may be optimal to allow the
duration to be flexible. That is to say, if a 60 day batch produces 20 kg, and the
yearly demand is 24 kg, instead of running two 60 day batches it may be better to
run either a single longer batch or run two or more smaller batches. So the relevant
question is to determine how beneficial is it for the batches to be of flexible duration
and how best that is implemented.
In addition, it is worth noting that the reviewed literature on the SLSP with
maintenance schedules (see Chapter 3) is not exactly transferable to the problem
considered in this chapter. This is because ‘maintenance scheduling’ is inextrica-
bly linked to lot-sizing decisions in this case while the previous literature considers
them as separate decisions. Equipment failure in this chapter is an increasing func-
tion of process run-time and therefore lot-size, so a decision on lot-size may be
seen as implicitly scheduling preventive maintenance. However it seems prudent
to consider process run-time as only a lot-sizing decision and treat its preventive
maintenance and process restorative properties as a side-effect.
This chapter has multiple aims. The first is to evaluate the previously de-
scribed model (Chapter 5 on page 62) on a multi-product facility. The second is to
adapt and develop dynamic scheduling policies that make operational decisions in
a multi-product facility. These policies anticipate and react to changes in the simu-
lation environment (such as uncertain demand and process failure events). Finally,
the relative benefits of a scheduling policy capable of implementing batches with
flexible process run times is investigated.
To achieve this, a hyper-heuristic is utilised to tune the parameters of policies
tailored to the problem of scheduling multiple perfusion products on a facility. The
policy search comprises a simulation-optimisation approach which uses an EA as
an optimisation algorithm and a custom stochastic bioprocess scheduling model to
evaluate performance of candidate policies. The use of scheduling policies allows
natural reactions to demand changes and process failure even if no firm schedule is
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generated in advance.
As a result, existing policies from the SELSP or SCLSP literature are tailored
to the peculiarities of biopharmaceutical manufacturing, in particular the semi-
continuous operation of perfusion processes. In addition, it proposes a novel policy
with a custom look-ahead heuristic which enables better performance on the test
problem. Third, process run times are optimised for each product in the portfo-
lio. Finally, a neural network representation is proposed and implemented for a
scheduling policy that adapts process run times based on the current state of the
environment.
The remainder of this chapter consists of the problem statement and descrip-
tion in Section 6.2 followed by detailed descriptions of the scheduling policies
and representations in Section 6.3 on page 102, and the EAs used as optimisation
algorithms for parameter tuning in Section 6.4. The case study on which the hyper-
heuristic is evaluated is laid out in Section 6.5, which is followed by a report and
discussion of the empirical evaluation in Section 6.6 on page 117.
6.2 Problem Domain
6.2.1 Problem Description
The problem that this chapter considers is a variant of the SELSP applied to bio-
pharmaceutical manufacturing. It involves a facility and a set of drug products
PF , each associated with a bioprocess which, when operated, manufactures the
corresponding product. The state of the facility, m, refers to the product, p, whose
bioprocess is currently in operation on the facility or is 0 (zero) if idle. The biopro-
cesses are comprised of the same multiple stages (unit operations) and are operated
in a semi-continuous manner — the bioprocess has to be operated in multiples of a
pre-defined batch length (i.e., process duration or run-time) but processed material
is made available over the course of the batch and not just at the end. In general, no
more than one bioprocess may be in operation in the facility at any time to avoid
cross-contamination issues and ease the validation burden, though there is some
exception to this which allows the earlier stages of a subsequent process to be in
operation simultaneously with the latter stages of the previous process.
In addition to stationary stochastic demand, the manufacturing process is prone
to equipment failure of differing types, risks, and consequences without the ability
to explicitly carry out preventive maintenance (PM) per se. Equipment failure is a
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function of process duration so ending a batch may, in a sense, be construed as PM
but process duration is primarily a lot-sizing decision and treated as such. Finally
this implementation uses a finite time horizon and discrete-time periods of one day
each which is effectively continuous time given the time-scales of the bioprocesses
and the stochastic events.
The objective is to maximize the overall profit, calculated as total revenue mi-
nus the costs for production, storage, process changeover, wastage, and backlog
penalties given a facility with different manufacturing yields and manufacturing
costs for the different products.
6.2.2 Notation
The indices p and t denote individual products and discrete time points respec-
tively. The subset characterising the facility being considered is PF , the set of
products produced by the facility.
Parameters
αp lead time for production of first DSP batch of product p, days
δp unit cost charged as penalty for each kilogram of unfulfilled demand of
product p, RMU per kilogram per day
ζp shelf-life of product p, days
µDp mean daily demand of product p, kilograms
ρp unit cost for each stored kilogram of product p, RMU per kilogram
σDp standard deviation of daily demand of product p, kilograms
θ daily backlog decay rate
υp unit sales price for each kilogram of product p, RMU per kilogram
ψp changeover cost for starting a campaign of product p, RMU
Ap sum of all costs incurred up till the end of ramp-up for first batch in cam-
paign of product p, RMU
brp bioreactor yield per daily perfusion harvest, kilograms
ydp overall process yield, %
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State variables
∆pt amount of product p which is late at time t, kilograms
Dpt observed demand of product p at time t, kilograms
Ipt the amount of product p stored at time t, kilograms
mt the product being manufactured on the facility at time t, 0 if idle
st the state of the system at time t
Spt the amount of product p sold at time t, kilograms
Z(i)t the set of products p, such that Ipt ≤ Y (i)p
Decision variables (policy parameters)
B run time of perfusion cell culture batch, days
Q(i) product cycle sequence
w neural network connection weights
Y (1) reorder point, kg
Y (2) order-up-to level, kg
Y (3) can-order point, kg
Y (4) can-order-up-to level, kg
Y (5) reorder point, kg (BSP3)
6.3 Scheduling Policies
The scheduling policies laid out here are tailored for the problem described in
Section 6.2. These policies can be grouped into three main representations: a fixed
cyclic policy, a base-stock policy, or an Artificial Neural Network (ANN).
6.3.1 Fixed Cycle Policies
These policies function on the basis that the facility will manufacture batches ac-
cording to the sequence associated with the specific policy. The main parameter
for this type of policy representation is a product sequence and process run times.
Depending on the complexity, it may optionally include parameters for inventory
levels to determine how many batches to order. In each policy, one sequence is
defined while the process run times and inventory parameters are defined for each
product in the scenario the policy is designed for. Three of these fixed cycle poli-
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cies are laid out here.
6.3.1.1 Basic fixed cycle policy (FCP1)
This policy ensures that the manufacturing facility follows a fixed sequence of
batches. The decision variables for this policy are:
1. The sequence of product batches, Q(1)
2. The process run time of batches in the campaign, B
The sequence is made up of a number elements which can be one of any p in PF
which indicates that a single batch of product p is to be manufactured with a run
time of Bp. In addition, any element in the sequence may be zero (0) which indi-
cates that the facility should be made idle. This policy is implemented by cycling
through each element in the sequence, producing a batch of the product the item
corresponds to, and then moving to the next element in the sequence — when it
gets to the end of the sequence, it starts from the beginning again. Consecutive
identical but non-zero elements in the sequence mean that consecutive batches of
that product are produced. However, consecutive zeroes in the sequence are pruned
down to one instance1 which means that the length of sequences |Q| can be vari-
able. The time the facility spends being idle is determined by the inventory levels
of the products. Specifically, idle time is ended when any product’s run-out time
falls below 90 days. At that point, the facility will then move on to the next prod-
uct in the sequence. Also, if a batch ends prematurely due to process failure, the
facility will move to the next element in the sequence.
6.3.1.2 Fixed cycle with order-up-to level (FCP2)
In addition to a sequence and process run time, this policy also has a third set of
decision variables. The decision variables are defined below:
1. The sequence of product campaigns, Q(2)
2. The order-up-to level, Y (2)
3. The process run time of batches in the campaign, B
1A sequence with a leading and trailing zero will have the leading element preserved and the last
element deleted.
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Instead of a sequence of product batches in FCP1, this policy has a sequence of
product campaigns. The difference being that each element in the sequence of
campaigns commits the facility to produce at least one batch (with run time of Bp)
of the associated product. The facility will move on to the next product in the
sequence after the batch that brings the inventory of the currently manufactured
product past its order-up-to level. The facility does not go idle until all products
in the sequence are above their respective order-up-to levels. However, if product
Q(2)(i+2) mod |Q| is below its order-up-to level but the product in the sequence preced-
ing it Q(2)(i+1) mod |Q|, is not, the facility will still need to produce at least a batch of
Q(2)(i+1) mod |Q| before proceeding to Q
(2)
(i+2) mod |Q|. Again, when the facility reaches
the end of the sequence, it returns to the start and begins the sequence again in a
cyclical fashion. Each element in the sequence can be any p in PF but consecutive
identical elements in the sequence are pruned down to one instance (in the same
manner as consecutive zeroes in FCP1) so the sequences can be of variable length.
6.3.1.3 Fixed cycle with skip-ahead (FCP3)
This policy, adapted from Lo¨hndorf and Minner (2013), is an improvement to
FCP2. The decision variables are:
1. The sequence of product campaigns, Q(2)
2. The order-up-to level, Y (2)
3. The process run time of batches in the campaign, B
FCP3 is identical to FCP2 apart from the fact that it can skip ahead in the sequence.
What this means is that if a facility is to move on to Q(2)(i+2) mod |Q| but the product is
already above its order-up-to level, it does not need to manufacture that product so
it skips ahead to the next element in the sequence that has its inventory below its
order-up-to level.
6.3.2 Base-Stock Policies
Three base-stock policies (BSPs) are presented here, two of which are adapted from
Lo¨hndorf and Minner (2013), and the third is a novel development. The adapta-
tions from the versions presented in that previous work are necessary because the
problem in this chapter introduces processes that can fail and which consist of a
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fixed sequence of multiple batch (and semi-continuous) unit processes. In addi-
tion, there is a need to identify an optimum run time for one of the constituent unit
processes — the perfusion cell culture in this case. Therefore this problem setting
differs from that in Lo¨hndorf and Minner (2013) because here, there are batches
that require their run times optimised. Also, since the processes here are composed
of multiple stages, the decision to make the next batch has to be made before the
current batch is over. This means that the amount of product made and delivered
in that time lag needs to be estimated and taken into account.
In this case, because the seed train for a subsequent batch can be started be-
fore the completion of the current batch, the decision epoch begins at the seed-
restart threshold or the changeover threshold. These thresholds are determined by
the bioreactor turnaround time, and the changeover time between products respec-
tively. Decisions are also made once the cell culture is contaminated and fails or
if the facility is idle. As a result of the lag between the point when a decision
is required and the end of the current batch, the policies presented here will take
into account the expected extra material that would be produced by the end of the
current batch (if the facility is not idle). So, γ is set to be the estimated net produc-
tion (i.e., material produced minus expected demand) in the interval between the
decision-making time point and the end of the batch. Decision epochs end when a
decision to start a batch (of any product) has been made or selected.
6.3.2.1 Simple base-stock policy (BSP1)
This is the first of the policies adapted from Lo¨hndorf and Minner (2013). In this
case, there are three decision variables defined for each product:
1. The reorder point, Y (1)
2. The order-up-to level, Y (2)
3. The process run time of batches in the campaign, B
The logic for determining when to start a new seed train is detailed in Algo-
rithm 4. This states that if the facility is idle and there is a product p with inventory
below its Y (1), a new batch — with a cell culture run time of Bp days — for this
product is initiated. If there is more than one product to which this applies, the
product selected to be manufactured next is the one with the smallest run-out time
— i.e., time till product runs out of stock, Ip/µp, where Ip is inventory of product
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Algorithm 4 Pseudocode of BSP1.
1: procedure BSP1(current time t)
2: PF = the set of products manufactured
3: mt = the product manufactured at time t, 0 if idle
4: Ipt = the inventory level of product p at time t
5: γpt = the estimated net output of p between t and end of its batch
6: µp = the expected demand of product p
7: Zt = {p : Ipt ≤ Y (1)p } ∀p ∈ PF
8: if mt > 0 AND Imt + γmt < Y
(2)
m then
9: Start new seed train of product mt
10: else if Z(1)t 6= {} then
11: Start new seed train of product argmini∈Zt{Iit/µi}
12: else if ∀p : Ipt > Y (1)p then
13: Keep facility idle
14: end if
15: end procedure
p and µp is its expected demand. Once the facility is manufacturing a product,
it does not go idle or switch products (changeover) until it has reached Y (2). The
drawback of this is that if the inventory of another product is falling critically low,
the facility cannot be switched to the critical product to prevent a stock-out.
6.3.2.2 Can-order base-stock policy (BSP2)
This policy was designed to be an improvement on BSP1 by including two more
parameters. This allows the control policy to interrupt a campaign (a set of consec-
utive batches of the same product) if the inventory of another product falls critically
low. The decision variables for each product are identified below:
1. The reorder point, Y (1)
2. The order-up-to level, Y (2)
3. The can-order point, Y (3)
4. The can-order-up-to level, Y (4)
5. The process run time of batches in the campaign, B
The logic for determining when to start a new seed train is detailed in Algo-
rithm 5. If the facility is idle and there is a product p with inventory below Y (3), a
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Algorithm 5 Pseudocode of BSP2.
1: procedure BSP2(current time t)
2: PF = the set of products manufactured
3: mt = the product manufactured at time t, 0 if idle
4: Ipt = the inventory level of product p at time t
5: γpt = the estimated net output of p between t and end of its batch
6: µp = the expected demand of product p
7: Z(1)t = {p : Ipt ≤ Y (1)p } ∀p ∈ PF
8: Z(3)t = {p : Ipt ≤ Y (3)p } ∀p ∈ PF
9: if mt > 0 AND Imt + γmt < Y
(4)
m then
10: Start new seed train of product mt
11: else if Z(1)t 6= {} then
12: Start new seed train of product argmin
i∈Z(1)t {Iit/µi}
13: else if mt > 0 AND Imt + γmt < Y
(2)
m then
14: Start new seed train of product mt
15: else if Z(3)t 6= {} then
16: Start new seed train of product argmin
i∈Z(3)t {Iit/µi}
17: else if ∀p : Ipt > Y (3)p then
18: Keep facility idle
19: end if
20: end procedure
new batch for this product is started. The campaign cannot be interrupted until the
inventory of that product exceeds Y (4). When this occurs, changeover to another
product is allowed if its inventory level is less than Y (1) — again any ties are set-
tled by picking the product with the smallest run-out time. However, if there are
no products with inventory below their reorder points, the campaign may continue
until it exceeds Y (2).
So the facility does not go idle until all products are above their can-order
points. In this manner, this policy works similarly to BSP1 but with the can-order
point and the can-order-up-to level it enables interruptions. In general, Y (1) ≤
Y (3) ≤ Y (4) ≤ Y (2) and BSP1 can be considered a special case of BSP2 where
Y (1) = Y (3) and Y (4) = Y (2). The disadvantage of this policy is that with more
parameters (compared to BSP1 for example), it requires a greater computation
effort in searching for good parameters. In addition, due to the ability to interrupt
campaigns, this policy may introduce more product changeovers which require
substantial operational and validation effort in practice.
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6.3.2.3 Forecasting base-stock policy (BSP3)
This policy is a novel contribution proposed here and utilises a ‘look-ahead’ heuris-
tic. The following decision variables are identified:
1. The reorder point, Y (5)
2. The process run time of batches in the campaign, B
Algorithm 6 Pseudocode of BSP3.
1: procedure BSP3(current time t)
2: PF = the set of products manufactured
3: mt = the product manufactured at time t, 0 if idle
4: Ipt = the inventory level of product p at time t
5: γpt = the estimated net output of p between t and end of its batch
6: µp = the expected demand of product p
7: Z(5)t = {p : Ipt ≤ Y (5)p } ∀p ∈ PF
8: CE(pi) = the estimated cost of manufacturing a permutation, pi
9: if Z(5)t 6= {} then
10: S(Z(5)t ) = all permutations of products in Z
(5)
t
11: Select cheapest permutation, pi∗ = argminpi∈S(Z(5)t ){CE(pi)}
12: Start new seed train of product pi∗1
13: else if ∀p : Ipt + γpt > Y (5)p then
14: Keep facility idle
15: end if
16: end procedure
When the inventory of a product p falls below the reorder point during a deci-
sion epoch (i.e., during idle time, or after a batch ends or is contaminated), a new
batch of that product is started with cell culture run time of Bp. However, if there
is more than one product with inventory below Y (5), the heuristic first generates
all possible permutations of manufacturing a single batch of each of the products
with inventory less than Y (5). Next the heuristic estimates the costs of each per-
mutation. This estimated cost is the projected sum of inventory costs, lost sales
penalties, and any changeover costs assuming that the processes will be ‘perfect’
and the demand realised is equal to the mean or mode of its probability distribution
— other manufacturing costs will be the same regardless of manufacturing permu-
tation. Cost estimation is done by generating a function describing the piecewise
linear estimation of each product’s inventory before, during, and after production
of its corresponding batch within the permutation time frame. The inventory cost
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for each product is the product of the inventory rate and the absolute value of the
sum of positive integrals of the function; and the lost sales penalty is the product
of the backlog penalty cost and the absolute value of the sum of negative integrals
of the function. The permutation of batches that has the lowest estimated cost is
selected and a batch of the first product in the permutation is started.
It should be noted that this policy does not automatically schedule the entirety
of the sequence of cheapest permutation but at the next decision time, the heuristic
generates a new set of permutations, evaluates them, and then makes a decision
based on the new evaluations. The logic of this policy is laid out in Algorithm 6.
The drawbacks of this policy include the need to enumerate all permutations of
elements in Z(5) which, in the worst case, gives the policy a complexity of O(n!)
where n is the number of products. In addition, the cost estimation is not exact and
does not anticipate or account for the possibility of process failure.
6.3.3 Artificial Neural Network Policy
This policy type is made up of an Artificial Neural Network (ANN) representation
of a priority rule. For each decision available to the neural network to make, a
priority value is computed using state variables. The decision that has the highest
computed priority is then chosen and implemented. The decision-making that is
available to this policy is flexible because decisions are made at very regular deci-
sion epochs. These decision epochs are generally each day — the exception being
during the early stages of a new batch.
Every day, this calculates priority values for these set of decisions:
1. Keep/make the facility idle
2. Continue the current batch (if there is one) for another day
3. Start a new batch of product pi ∀i
The network is structured as a fully connected feed-forward neural network
with a single hidden layer. This ANN representation has been shown to give
good results when computing priority indices in a stochastic dynamic environment
(Branke et al., 2015). The network’s input layer comprises information on the state
of the system and a bias node that is always set with the value of 1. Apart from
the bias node, there are 2n+ 2 input nodes, where n is the number of products.
Of those nodes, n+ 1 reflect the state of the facility m: one for each p, plus one
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Figure 6.1: Illustration of ANN representation of priority rule for a scenario with
two products and three available decisions. Both input and output layers have three
nodes and the hidden layer has two nodes (the bias node and its connections are
not shown in this figure).
for when the facility is idle. The node corresponding to the observed state of the
facility is set to an input value of +1 while the others are set to −1. Another n
nodes correspond to the inventory or run-out times of the different products. The
last input node represents how long the current batch has been in operation. Every
node in the hidden layer is connected with every node in the input layer. The out-
put layer comprises n+2 nodes and every node in that layer is connected with all
the nodes in the hidden layer. Each of the output nodes corresponds to one of the
decisions mentioned previously.
Each neuron computes the function described below in Equation (6.1) as its
output value.
out(z,w) = tanh
(
N
∑
i=1
wizi
)
. (6.1)
Here, N is the number of incoming edges, the vector z contains the activation levels
(i.e, output values) with an incoming connection to the neuron, and w is the weight
vector specifying a weight for each incoming connection. This means that in the
case of the neurons in the input layer, w and z will each have one element and the
element in w will be equal to 1.
As a result, the number of weights in this network can be calculated as in
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Equation (6.2). Where Noutput is the number of neurons in the output layer, Ninput is
the number of neurons in the input layer (excluding the bias node), and Nhidden is
the number of nodes in the hidden layer.
Noutput+Nhidden(Ninput+Noutput+1). (6.2)
Therefore the priority value for any given decision corresponding to its output node
u is calculated as:
priority(u,s) = tanh
(
wBOu +
Nhidden
∑
h=1
wOu,h tanh
(
wBHh +
Ninput
∑
i=1
tanh
(
wHu,h,isi
)))
. (6.3)
In Equation (6.3): s is the vector containing the attributes that describe the state
of the system; wO is the weight matrix for the connection weights from the hidden
layer to the ouput layer; wH is the weight array for the connection weights from
the input layer to the hidden layer; wBO is the vector of connection weights from
the bias node to the output layer; and wBH is the vector of connection weights
from the bias node to the hidden layer. Therefore, it is these weights (i.e., wO, wH ,
wBO, wBH) that determine the policy (and its quality) and what the optimisation
algorithm will search for during its procedure.
This neural network approach implicitly optimises process run times but also
means that they can be flexible — i.e., each batch of the same product does not
have a fixed run time. This means a batch can be cut short in order to change over
to a more critical product in reaction to a change in the state of the environment.
Figure 6.1 shows an example of a neural network structure.
6.4 Optimisation Algorithms
Evolutionary algorithms were used to tune the parameters of the scheduling poli-
cies. Specifically, the performance of a GA and a CMA-ES was compared for
the optimisation of the FCP and BSP parameters; for the ANN, only a CMA-ES
is used. These were implemented in JavaTM using the ECJ Library (Version 24)
(Luke, 1998).
The genomes used to represent BSPs were designed to deal with the constraints
on policy parameters. For example, a BSP1 policy needs to have its parameters
such that Y (1) ≤ Y (2) and a BSP2 policy needs its parameters so Y (1) ≤ Y (3) ≤
Y (4)≤Y (2). This is illustrated in Figure 6.2, where instead of the genome represent-
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Figure 6.2: (a) Structure of a BSP2 policy chromosome for a facility manufacturing
three drug products where the process run times are simultaneously optimised.
(b) Structure of an FCP2 or FCP3 policy chromosome with max. sequence length
of 12, and three products where run times are optimised.
ing the inventory thresholds directly, the difference between adjacent parameters is
encoded. The ranges for the gene encodings are detailed in Table 6.1.
All results reported are an average of 50 runs unless otherwise stated. The
parameters of the two EAs deployed are detailed below.
6.4.1 Genetic Algorithm
A GA was designed to optimise the parameters in each BSP and FCP strategy. The
GA parameters chosen are as follows: the number of generations was set to be
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200, the population size was 30 with elitism2. The genomes were determined by
the sub-type of policy and the number of products.
So, for the BSPs, if the policy did not simultaneously optimise process run
time, the length of the chromosome would be the number of parameters in the
policy multiplied by the number of products. In the case where the policy was to
also optimise the process duration, then additional genes for each product would
be added to the chromosome. The first segment of the chromosome representing
the policy parameters for each product were real-valued whilst the last few genes
representing the process duration were integer (see Figure 6.2).
If process run times were not optimised, the length of the chromosome repre-
senting an FCP1 policy was the maximum sequence length. For FCP2 and FCP3,
genes for each product for the order-up-to levels are added. And in the case that
run times are also optimised, additional genes for each product would be added
to the chromosome. The first segment of the chromosome coding for the prod-
uct sequence and the third segment representing the process run times are integer.
The middle segment coding for the policy parameters for each product, meanwhile,
were real-valued (see Figure 6.2).
The selection process for individuals to be crossed over was a tournament3
(with replacement) with a size of two. The probability of crossover being applied
was 0.9, and the crossover operator was uniform crossover for the BSPs or two-
point crossover in the case of the FCPs. Probability of a gene being mutated was
the inverse of the chromosome length (i.e., 1/chromosome length). Gaussian muta-
tion was used (with a standard deviation of 6) for the real-valued genes. The integer
genes representing process run times used random walk (±1) as its mutation oper-
ator with the probability 0.9 that the walk continues. For the segment encoding the
sequence, shift mutation was used which entails removing the element in the se-
quence and re-inserting it in a new random position. The minimum and maximum
values for the genes in the chromosome are detailed in Table 6.1.
6.4.2 Covariance Matrix Adaptation Evolution Strategy
As previously described in Chapter 3, the CMA-ES algorithm is a state-of-the-art
EA for difficult black-box optimisation problems in continuous domain. Here, a
2The elitism implemented was such that the fittest six individuals in the population each genera-
tion (the elites) are carried over to the next generation automatically.
3This was used instead of stochastic universal sampling (SUS) because SUS does not work with
the negative fitness values that some solutions produced.
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Table 6.1: The minimum and maximum values for the genes in the chromosome.
Gene Type Min value Max value
Y (i), Y (i)−Y ( j) continuous 0 60
Q(1)i integer 0 n
Q(2)i integer 1 n
B integer 14 120
population of λ new candidate solutions is sampled at every generation from a
multi-variate normal distribution. The mean of the distribution is updated by tak-
ing a weighted average of selected points from the current sample. The covariance
matrix is also incrementally updated using a self-adaptation strategy to improve
the likelihood of successive search steps. As part of the covariance matrix adapta-
tion, the algorithm implements step-size control. This is to ensure longer steps are
taken instead of more but smaller steps in the same direction, or that shorter steps
are taken instead of longer steps that cancel out each other. The aim of this is to
prevent premature convergence but allow fast convergence to an optimum by mak-
ing the expected consecutive movements/steps of the distribution approximately
orthogonal.
The CMA-ES does not have many user-specified parameters, as a lot of them
are calculated based on the chromosome specified. As a result the default settings
were used (Hansen and Ostermeier, 2001). The population size λ is by default
4+ b3ln |x|c where |x| is the size of the genome x; a weighted average of bλ/2c
individuals is used to update the distribution mean; and the initial covariance matrix
is set to the identity matrix.
The chromosome for each FCP or BSP policy has the same structure as previ-
ously discussed but with the values of the encoded genes normalised to fall between
[−1,+1]. These values are then transformed to the actual policy parameters at the
point of fitness evaluation. To enable comparison with the GA, the CMA-ES was
set the same budget of 6,000 fitness evaluations and the starting point for the search
was set randomly in the decision space.
To tune the ANN policy, the chromosome used consisted of a vector of all the
weights for the neural network. These weights are encoded directly onto the chro-
mosome with values in the interval [−1,+1]. The search for the neural network
weights was allocated a budget of 12,000 fitness evaluations.
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Table 6.2: Process economics parameters for products in relative monetary units
(RMU) unless otherwise stated.
p1 p2 p3
Seed cost 4.6 5.2 5.1
Daily cell culture cost 3.4 3.2 3.6
Cell culture batch setup cost 26 26.9 33.7
ATF replacement cost 17.8 14.6 15.7
DSP batch cost 10.7 11 14.2
Sales price (RMU/kg) 150 95 100
Backlog penalty cost (RMU/kg/day) 0.25 0.1 0.1
Annual demand (kg) 60 120 115
Reactor yield (kg) 2.03 2.25 1.38
6.5 Case Study Description
To evaluate the scheduling policies, a biopharmaceutical industrial case study was
designed. The data comprises anticipated market demand and manufacturing fa-
cility characteristics. This problem features multiple products to be produced in a
single facility with different efficiencies, yields and costs, perishable inventory, and
backlogging and lost sales allowed. The processes to manufacture these products
are all based on a platform mAb process as described in Chapter 5.2.1.
The demand forecast is made up of three different products (p1− p3) to be
manufactured over a period of seven years. The demand forecast shows the ex-
pected annual demand which is stationary (i.e., does not change from year to year)
but is stochastic and is sampled either daily, monthly, quarterly, or annually (Ta-
ble 6.2). The different constituents of the manufacturing costs are also listed in that
table as well as the reactor yields, the sales price per kilogram of each product, and
the periodic penalty cost for each unit of unfulfilled demand. The reactor yield in-
dicates how much product is in each daily harvest from the bioreactor. The product
of this and the overall process yield is how much material is deposited in inventory
after each DSP batch. For all products, the overall process yield is 69%.
Changeover cost is accrued when switching between two different products or
after the setup expiry period lapses between batches of the same product. Changeover
and turnaround times are defined as the minimum time between two USP opera-
tions for different and same product respectively. Therefore the seed-restart thresh-
old for a product’s process is the sum of its cell culture run-time and turnaround
time minus its seed run time. Likewise, the changeover threshold is cell culture
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Table 6.3: Case study parameters
Parameter Value Unit
Shelf life 720 Days
Backlog decay 0.5 Per 180 days
Inventory rate 0.01 RMU/kg/day
Bioreactor turnaround 4 Days
Changeover time 10 Days
Wastage rate 5 RMU/kg
Setup expiry 30 Days
Number of reactors 1
Changeover cost 35 RMU
Overall process yield 69 %
run-time plus changeover time minus seed train run time of the subsequent prod-
uct. There is also a daily backlog decay on unfulfilled demand so that it becomes
less important over time. This is detailed in Equation (6.4) where for product p,
∆pt is the amount of product p that is late at time t, θ is the daily backlog decay
rate, Dpt is the observed demand of product p at time t, and Spt is the amount of
product p that is sold at time t.
∆pt = θ∆p,t−1+Dpt −Spt , ∀ p, t. (6.4)
This means that if 1kg of product is undelivered at time t, the amount due at time
t + 1 is (1× 180√0.5) kg plus whatever new demand arrives at t + 1 less any sales
at t +1. Each product has a maximum period of time (its shelf-life) that it can be
stored for before it perishes. Any product that has to be thrown away because it
has exceeded its shelf-life or as a consequence of process failure will also accrue
a wastage penalty per kilogram. These parameters are specified in Table 6.3. It is
assumed that processes utilise a single reactor so that the process configuration is
a 1:1 USP:DSP ratio.
The case study is designed so that each of the three products has a particular
characteristic. The first product, p1, is high-value and low-demand; p2 is high-
demand and high-yield; and p3 is high-demand and low-yield. So the trade-off
between p1 and p2 is that the former commands a higher sales price per kilogram
manufactured but also a larger penalty per kg of unfulfilled demand. On the other
hand, comparing p3 to p2, we see that p3 has a similar demand profile as p2 but
its yield is a third lower.
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This case study will be the basis of simulation optimisation experiments per-
formed and reported in the following section.
6.6 Results and Discussion
To evaluate the performance of the policies, optimisation runs were carried out
in the manner described in Section 6.4 on page 111. This section presents and
discusses the scenarios investigated and their results.
6.6.1 Description of the Standard Policy
In addition to the proposed policies, the performance of a standard policy is also
reported. This policy serves as a baseline to compare the optimised policies. It
takes the form of the simple base-stock policy where the parameters are heuristi-
cally chosen by the Doll & Whybark heuristic (Doll and Whybark, 1973) adapted
by Gascon et al. (1994) and used as an initial guess in the direct policy search by
Lo¨hndorf and Minner (2013). This policy is denoted as BSP0. This heuristic at-
tempts to construct a schedule by producing products in repetitive cycles. So each
product is manufactured once every certain period of time (that may be unique to
each product) where each of these periods is a multiple of a fundamental cycle pe-
riod or a common cycle time. The values of the parameters of the standard policy
are based on common cycle time and the method to calculate these values is as
follows: Let Tˆ be the common cycle time and k be the safety factor.
Tˆ = max
{√√√√√ 2 ∑∀p∈PF Ap
∑
∀p∈PF
ρpµDp (1−µDp /(brpydp))
,
∑
∀p∈PF
αp
1− ∑
∀p∈PF
µDp /(brpydp)
}
, (6.5)
k =Φ−1
(
δp(1+θ Tˆ )/2
δp(1+θ Tˆ )/2+ρp
)
. (6.6)
Where µDp is the expected daily demand; σDp is the standard deviation of the daily
demand; αp is the process lead time which in this case is the sum of the seed train
time, the ramp-up time, and the DSP time; brp is the amount harvested from the
daily perfusate of the bioreactor; ydp is the process yield; δp is the lost demand
penalty cost; θ is the daily backlog decay rate; ρp is the inventory holding cost;
and Ap represents all setup costs associated with the first batch of a campaign prior
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to its first perfusion harvest, i.e., the sum of the changeover cost, seed cost, cell
culture setup cost, and the perfusion costs in the ramp-up period.
Then, the reorder level and order-up-to point are, for each product p, set to:
Y (1)p = max
{
µDp αp+ kpσ
D
p
√
Tˆ , 0
}
, (6.7)
Y (2)p = Y
(1)
p +max
{
µDp (1−µDp /(brpydp))Tˆ , 1
}
. (6.8)
In this standard policy, the process run time for each product is set to 60 days.
6.6.2 Evaluation of Optimised Policies
The policies were optimised twice: once with the process durations fixed to 60
days, and a second time where the optimisation algorithm is free to optimise the
process duration. These are differentiated by the suffixes appended to the policy
name. Where the process duration is fixed, the suffix is ‘A’ and if the process
duration is optimised, the suffix is ‘B’.
For the base-stock policies (BSP1-3), the results reported are averaged over 50
independent runs of the GA — the results were similar to that of the CMA-ES
so those were reported. For FCP1, the reported results are from GA runs as
these results outperformed the CMA-ES. The opposite is true of FCP2 and FCP3;
CMA-ES results are reported for those policies. The ANN results (using the
CMA-ES) are also an average of 50 independent runs like the other tuned poli-
cies.
The optimisations were run on the case study data previously described for
a time horizon of seven years (with a year comprising 360 days). Initially, the
first two years of the horizon served as a warm-up period but this was changed
because it caused unrealistic artefacts in the inventory profiles of simulations of
ANN policy solutions. During the EA optimisation, the fitness evaluation uses the
average performance of 500 simulations as this was found to give a good estimate
without making computation time(s) too long. The stochastic demand for each
product follows a Normal distribution, N(µ,(σ)2), where µ is the yearly forecast
demand (Table 6.2) and σ is 0.025µ . The demand frequency is set to be daily
which means that during each simulation, demand is sampled, is due, and can be
delivered everyday; sampled demand is truncated and not allowed to be negative.
This means the distribution describing the daily demand is N(µD,(σD)2) where
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µD = µ360 and σ
D = σ√
360
. Failure rates were set such that the probability of cell
culture contamination was 10% in 60 days and the probability of ATF filter failure
was 2% in 60 days too. Finally, each simulation was started with each product
having an initial inventory equal to a quarter of the expected yearly demand.
6.6.2.1 Policies with standard run-times
Here, the ‘A’ sub-types of the base-stock and fixed cycle policies are compared
with the standard policy.
Base-stock policies Table 6.4 compares the performance characteristics of the
standard policy (BSP0) to those tuned base-stock policies (BSP1-3) where the pro-
cess run times are fixed to 60 days. The performance characteristics for BSP0 were
evaluated from 20,000 simulations of the policy and the same was done (on the
same random number seeds) for each optimised solution from all runs of BSP1A,
BSP2A, and BSP3A. The table shows that the tuned base-stock policies outper-
form the standard policy in terms of the expected profit generated. This is driven
primarily by differences in the revenue (and consequently, backlog penalties and
CSL) and storage costs. By scrutinizing the seed costs and the cell culture setup
costs, it appears that both the standard and the optimised base-stock policies start
a similar number of batches so the advantage of the optimised base-stock policies
is due to the sequence or timing of the batches ordered. It is worth pointing out
that BSP0 does outperform the optimised policies in one metric, changeover costs.
This means that although the overall timing and sequencing of batches in BSP0 is
sub-optimal in terms of the overall objective, it is able to schedule batches of the
same product together in longer campaigns thereby reducing changeover costs and
potentially making the operation of the facility more straightforward with fewer
manufacturing switches between products.
Differences in performance between the optimised policies are much smaller
when compared to the standard policy; between the optimised policies, BSP1A is
the worst, with BSP2A performing a bit better, and BSP3A best. That ranking is
the same when looking at revenue but is reversed with regards to the total costs.
The only other major differences between them is that BSP2A appears to have
on average at least two fewer product changeovers than the other policies. This
is however offset by it having larger storage costs than BSP1A and BSP3A. Any
differences between two policies in total seed, USP or DSP costs are due to a policy
119
having marginally fewer or more batches started than the other, since they all have
the same process run times.
Fixed cycle policies As with the base-stock policies, the performance of the stan-
dard policy is compared with the fixed cycle policies with process run times fixed to
60 days. This is shown in Table 6.5. Comparing BSP0 with the tuned fixed cycle
policies, similar trends to the base-stock policies are observed. The tuned poli-
cies are again substantially superior to the standard policy in terms of maximising
profit and revenue, and minimising total costs. The standard policy appears to start
slightly fewer batches than the other policies and although the FCPs have lower
changeover costs than the BSPs, they are still a lot higher than the standard pol-
icy. It is also worth noting that the best FCP performs worse than the worst BSP
(FCP3A vs. BSP1A).
Comparing the individual FCPs, the differences between them are again less
substantial than when compared to the standard policy. However these differences
are larger than observed between the tuned BSPs. FCP3A performs best and of the
other two, FCP1A is worse. This ranking is mostly driven by the number of batches
that FCP1A and FCP2A have to start and run as well as the higher inventory levels
they maintain. Also, though FCP1A has higher seed and cell culture setup costs
than FCP3A, its changeover costs are lower which indicates that FCP1A schedules
in multi-batch campaigns more often than FCP3A. Similarly, since FCP2A has to
make at least a batch of each product in the sequence between its current position
and the product that has just fallen below its order-up-to level, it will start and run
a large number of batches compared with FCP3A. Changeover costs for FCP2A
are also lower than for FCP3A (and also lower than for FCP1A too). This may
seem counter-intuitive because FCP2A may have to start campaigns and accrue
changeover costs that are not necessary in order to get to a critical product in the
sequence. But this means that if the critical product is far away enough on the
sequence, by the time the facility gets to that product, multiple batches would be
required to bring it above its order-up-to level.
6.6.2.2 Policies with optimised run-times
In Table 6.6 and Table 6.7 the performance characteristics of the best performing
FCP and BSP policies that had a fixed process run time — FCP3A and BSP3A
in this case — are compared with the fixed cycle policies and the base-stock poli-
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Table 6.4: Profit, costs, customer service level (CSL), and other performance char-
acteristics for the three BSPs with process duration fixed to 60 days as well as the
standard heuristic (BSP0) solution. Mean ± std. err. are listed of 50 runs each and
values reported are in RMU apart from CSL values. Statistically best values are
highlighted in bold.
BSP0 BSP1A BSP2A BSP3A
Profit 179015 ± 20.9 189589 ± 1.6 189651 ± 4.5 189711 ± 1.7
Revenue 214690 ± 17.9 222908 ± 6.8 222996 ± 6.0 223075 ± 7.5
Total costs 35676 ± 5.7 33319 ± 7.1 33345 ± 6.1 33363 ± 8.0
Seed 179.0 ± 0.04 181.3 ± 0.03 181.7 ± 0.02 181.9 ± 0.03
USP 8059 ± 0.9 8155 ± 1.1 8173 ± 1.1 8181 ± 1.5
Replacement ATF filters 10.3 ± 0.09 10.5 ± 0.01 10.6 ± 0.01 10.6 ± 0.01
Cell culture setup 1064.6 ± 0.22 1076.9 ± 0.15 1079.6 ± 0.15 1080.7 ± 0.21
DSP 21022 ± 2.5 21265 ± 2.8 21313 ± 3.1 21342 ± 4.2
Changeover 478.0 ± 0.24 1132.5 ± 0.44 1053.1 ± 4.00 1150.1 ± 1.11
Storage 3065 ± 1.0 2253 ± 5.0 2315 ± 4.7 2210 ± 4.7
Backlog penalties 2827.3 ± 5.24 285.3 ± 1.70 263.8 ± 1.55 251.8 ± 1.74
Wastage 44.9 ± 0.16 45.8 ± 0.02 45.9 ± 0.02 45.9 ± 0.02
CSL 95.88% ± 0.007 99.50% ± 0.003 99.54% ± 0.004 99.58% ± 0.004
Table 6.5: Profit, costs, customer service level (CSL), and other performance char-
acteristics for the three FCPs with process duration fixed to 60 days as well as the
standard heuristic (BSP0) solution. Mean ± std. err. are listed of 50 runs each and
values reported are in RMU apart from CSL values. Statistically best values are
highlighted in bold.
BSP0 FCP1A FCP2A FCP3A
Profit 179015 ± 20.9 186544 ± 14.9 188044 ± 41.6 189445 ± 3.5
Revenue 214690 ± 17.9 221708 ± 21.5 222529 ± 24.3 222816 ± 6.1
Total costs 35676 ± 5.7 35164 ± 33.4 34485 ± 46.5 33371 ± 6.7
Seed 179.0 ± 0.04 185.3 ± 0.12 184.8 ± 0.15 181.4 ± 0.03
USP 8059 ± 0.9 8346 ± 5.4 8309 ± 8.3 8161 ± 1.5
Replacement ATF filters 10.3 ± 0.09 10.9 ± 0.02 10.7 ± 0.02 10.6 ± 0.01
Cell culture setup 1064.6 ± 0.22 1100.0 ± 0.68 1096.5 ± 0.96 1077.7 ± 0.20
DSP 21022 ± 2.5 21736 ± 13.7 21644 ± 19.9 21281 ± 4.6
Changeover 478.0 ± 0.24 1091.9 ± 12.17 1064.4 ± 7.94 1100.0 ± 2.26
Storage 3065 ± 1.0 3114 ± 25.6 2815 ± 29.6 2291 ± 7.0
Backlog penalties 2827.3 ± 5.24 642.8 ± 7.82 419.4 ± 10.03 310.8 ± 1.78
Wastage 44.9 ± 0.16 47.8 ± 0.09 47.2 ± 0.13 45.9 ± 0.02
CSL 95.88% ± 0.007 98.96% ± 0.009 99.36% ± 0.009 99.46% ± 0.004
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Table 6.6: Profit, costs, customer service level (CSL), and other performance char-
acteristics for the three BSPs with process durations optimised by the GA com-
pared to the best performing BSP and FCP with fixed process duration. Policy
names with a suffix of ‘A’ are for optimisations with process duration fixed to 60
days while those with suffix ‘B’ have process duration optimised by the EA. Mean
± std. err. are listed of 50 runs each and values reported are in RMU apart from
CSL values. Statistically best values are highlighted in bold.
FCP3A BSP3A BSP1B BSP2B BSP3B
Profit 189445 ± 3.5 189711 ± 1.7 189972 ± 6.3 190016 ± 13.9 190125 ± 1.9
Revenue 222816 ± 6.1 223075 ± 7.5 223101 ± 9.2 223123 ± 9.4 223240 ± 7.3
Total costs 33371 ± 6.7 33363 ± 8.0 33129 ± 6.8 33107 ± 10.2 33116 ± 7.2
Seed 181.4 ± 0.03 181.9 ± 0.03 182.2 ± 0.72 178.8 ± 0.86 185.8 ± 0.36
USP 8161 ± 1.5 8181 ± 1.5 8148 ± 8.3 8110 ± 9.5 8178 ± 5.0
Replacement ATF filters 10.6 ± 0.01 10.6 ± 0.01 11.1 ± 0.11 11.5 ± 0.09 11.3 ± 0.07
Cell culture setup 1077.7 ± 0.20 1080.7 ± 0.21 1065.7 ± 4.34 1043.1 ± 4.87 1077.0 ± 2.68
DSP 21281 ± 4.6 21342 ± 4.2 21248 ± 3.6 21282 ± 5.7 21256 ± 4.0
Changeover 1100.0 ± 2.26 1150.1 ± 1.11 1211.1 ± 4.13 1150.5 ± 6.02 1249.5 ± 1.63
Storage 2291 ± 7.0 2210 ± 4.7 2050 ± 8.2 2102 ± 12.6 2002 ± 6.1
Backlog penalties 310.8 ± 1.78 251.8 ± 1.74 243.5 ± 2.26 235.3 ± 3.04 197.8 ± 2.06
Wastage 45.9 ± 0.02 45.9 ± 0.02 46.9 ± 0.39 48.4 ± 0.36 46.4 ± 0.19
CSL 99.46% ± 0.004 99.58% ± 0.004 99.60% ± 0.004 99.61% ± 0.004 99.66% ± 0.004
Table 6.7: Profit, costs, customer service level (CSL), and other performance char-
acteristics for the three FCPs with process durations optimised by their EA com-
pared to the best performing BSP and FCP with fixed process duration. Policy
names with a suffix of ‘A’ are for optimisations with process duration fixed to 60
days while those with suffix ‘B’ have process duration optimised by the EA. Mean
± std. err. are listed of 50 runs each and values reported are in RMU apart from
CSL values. Statistically best values are highlighted in bold.
FCP3A BSP3A FCP1B FCP2B FCP3B
Profit 189445 ± 3.5 189711 ± 1.7 186585 ± 127.1 189234 ± 39.5 189910 ± 3.3
Revenue 222816 ± 6.1 223075 ± 7.5 221389 ± 73.8 222733 ± 25.8 223047 ± 6.1
Total costs 33371 ± 6.7 33363 ± 8.0 34804 ± 99.5 33499 ± 17.2 33137 ± 7.2
Seed 181.4 ± 0.03 181.9 ± 0.03 172.2 ± 3.72 188.7 ± 0.84 179.0 ± 0.72
USP 8161 ± 1.5 8181 ± 1.5 8128 ± 36.3 8231 ± 10.2 8102 ± 8.4
Replacement ATF filters 10.6 ± 0.01 10.6 ± 0.01 13.5 ± 0.36 11.1 ± 0.12 11.5 ± 0.07
Cell culture setup 1077.7 ± 0.20 1080.7 ± 0.21 1004.9 ± 21.24 1096.9 ± 5.16 1041.7 ± 4.33
DSP 21281 ± 4.6 21342 ± 4.2 21602 ± 44.8 21293 ± 6.7 21265 ± 4.3
Changeover 1100.0 ± 2.26 1150.1 ± 1.11 1119.2 ± 21.22 1230.2 ± 6.92 1180.9 ± 4.55
Storage 2291 ± 7.0 2210 ± 4.7 2998 ± 96.7 2152 ± 13.8 2107 ± 10.6
Backlog penalties 310.8 ± 1.78 251.8 ± 1.74 721.5 ± 21.33 357.8 ± 8.64 254.8 ± 1.78
Wastage 45.9 ± 0.02 45.9 ± 0.02 62.6 ± 3.41 46.2 ± 0.45 47.7 ± 0.25
CSL 99.46% ± 0.004 99.58% ± 0.004 98.83% ± 0.035 99.44% ± 0.012 99.57% ± 0.003
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cies that also optimised the process run time. First, one can observe that the FCP
policies — apart from FCP3B — are always worse than the base stock policies re-
gardless of process run time optimisation. This suggests that utilising a rigid fixed
schedule in an uncertain environment is sub-optimal compared to policies reactive
to changes. In general, the ‘B’ policy variants are better than their corresponding
‘A’ counterparts across the board. The only exception to this is FCP1 which does
not seem to show improvement when optimising the run-times as well. This is
likely due to the FCP1B expending its computation budget before fully converg-
ing. On the other hand, the greatest improvement observed from optimising the
run-times is seen going from FCP2A to FCP2B.
The ranking of the ‘B’ policies carries over from the ‘A’ policies. For the BSPs,
BSP3B is best followed by BSP2B then BSP1B. The pattern is similar for the FCP
policies: FCP1B is worst, FCP2B performs better than that, and FCP3B is best.
Because the run-times are different between the policies and among the individual
solutions within each policies, it is harder to draw insights or conclusions based on
the performance characteristics than with policies with standard run-times.
6.6.3 Policy with Flexible Process Duration
To ascertain the benefit of a policy that allows for flexible process run-times, the
ANN policy was compared with the previously evaluated polices.
The implementation of this policy, as previously described, means that on every
day, a batch can be cut short even if it was just started the previous day. To exclude
very bad solutions, a constraint on a minimum process run-time was enforced. This
meant that upon making a decision to start a batch, no new decisions could be made
until the cell culture reached a specified duration milestone. If this lower bound is
small, it means that there is a larger search space which increases the scope for
flexibility but also makes the search for a good solution harder. A large lower
bound improves computation time but means some batches may be unnecessarily
long. As a result, some duration lower bounds were tested: lower bounds of 14, 20,
30, 40, and 45 days for all of the products, and ‘optimised’ lower bounds where the
EA searched for individual lower bounds for each product in addition to the neural
network weights. Table 6.8 reports the results of that experiment and shows that
setting the lower bound to 30 days for all products is best, so that strategy was used
for the rest of the following analysis.
Although the ANN policy is substantially better than the standard policy, it
123
Table 6.8: Profit performance (in RMU) for tuned ANN policies utilising different
minimum process run-times.
Process run-time lower bound
14 days 20 days 30 days 40 days 45 days ‘Optimised’
Profit 188983 ± 365.6 189315 ± 39.6 189421 ± 42.3 188842 ± 100.9 188709 ± 48.1 189147 ± 31.5
Table 6.9: Profit, costs, customer service level (CSL), and other performance char-
acteristics for the ANN, the best of each of FCP-B and BSP-B, and the overall
worst ‘B’ policy variant. Mean ± std. err. are listed for 50 runs each and values re-
ported are in RMU apart from CSL values. Statistically best values are highlighted
in bold.
FCP1B FCP3B BSP3B ANN
Profit 186585 ± 127.1 189910 ± 3.3 190125 ± 1.9 189421 ± 42.3
Revenue 221389 ± 73.8 223047 ± 6.1 223240 ± 7.3 222833 ± 28.2
Total costs 34804 ± 99.5 33137 ± 7.2 33116 ± 7.2 33412 ± 20.5
Seed 172.2 ± 3.72 179.0 ± 0.72 185.8 ± 0.36 200.6 ± 0.38
USP 8128 ± 36.3 8102 ± 8.4 8178 ± 5.0 8367 ± 4.0
Replacement ATF filters 13.5 ± 0.36 11.5 ± 0.07 11.3 ± 0.07 11.3 ± 0.14
Cell culture setup 1004.9 ± 21.24 1041.7 ± 4.33 1077.0 ± 2.68 1160.7 ± 2.62
DSP 21602 ± 44.8 21265 ± 4.3 21256 ± 4.0 21223 ± 7.8
Changeover 1119.2 ± 21.22 1180.9 ± 4.55 1249.5 ± 1.63 1385.2 ± 4.96
Storage 2998 ± 96.7 2107 ± 10.6 2002 ± 6.1 1843 ± 13.4
Backlog penalties 721.5 ± 21.33 254.8 ± 1.78 197.8 ± 2.06 346.2 ± 9.28
Wastage 62.6 ± 3.41 47.7 ± 0.25 46.4 ± 0.19 46.8 ± 0.49
CSL 98.83% ± 0.035 99.57% ± 0.003 99.66% ± 0.004 99.52% ± 0.012
fails to compete with the other optimised BSPs — even the BSP policies where the
process run-time is not optimised. Table 6.9 compares the performance of the ANN
policy and other policies with optimised process run-times. It is slightly worse than
FCP3A but it outperforms the FCP1 and FCP2 policies. By inspecting the expected
profit values, the simulated performance appears to vary much more than the other
policies (apart from the two FCP1 policies). This policy starts on average more
batches than the others compared in Table 6.9 and also accrues more changeover
costs; if the ratio between DSP costs and seed costs (or cell culture setup) for each
policy is compared it suggests that in addition to having more batches, the ANN
has shorter batches.
6.6.4 Tuned Policy Parameters
Table 6.10 lists the parameters in the optimised base-stock policies as well as the
calculated parameters for the standard base stock policy and Table 6.11 reports the
parameters for the FCP policies. This data represents the overall best solution for
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each policy from all the EA runs.
The striking difference between the standard policy and the optimised BSPs is
that the standard policy has much higher order-up-to levels. Coupled with slightly
lower reorder points, this means that batches are more likely to be ordered in cam-
paigns of the same product instead of the facility switching more frequently be-
tween products. Conversely, the optimised policies have their inventory parameters
in much narrower ranges which means that campaigns are more likely to have just
one batch — the amount produced per batch is much larger than the difference be-
tween the inventory parameters — and subsequently more product changeover(s).
In fact, with BSP1, the best policies have Y (1) and Y (2) parameter values almost
equal which suggests that the second parameter is not particularly useful. This
would mean that the policy could be replaced by one with just Y (1) (much like how
BSP3 only has Y (5)) which would require less effort tuning it — i.e., if it were to
be run again but with one parameter it should give faster convergence but similar
results. This assumption has been confirmed experimentally.
The reason that the optimised Y (1) values are higher than that of the standard
policy is most likely due to the fact that the optimised policies implicitly account
for the fact that the product changeovers can only happen after the end of a batch of
a predetermined run time. This means it can maintain higher levels of safety stock
and reduce the likelihood of stock-outs. And with the narrower ranges of the inven-
tory parameters, more frequent product changeovers help avoid product inventories
from falling critically low. The standard base-stock policy is based on heuristics
that do not model batch or semi-continuous production; this highlights how pre-
vious approaches to lot-sizing approaches don’t easily apply to biopharmaceutical
manufacturing contexts.
The best FCP1 solutions also highlight that campaigns of multiple batches are
seemingly sub-optimal at this problem load. Though these policies can schedule
consecutive batches of the same product, the best solutions do not implement that
strategy. The best FCP1 sequences are longer than the other fixed cycle policies
partly because the set of possible elements in the sequence is larger and the se-
quences attempt to encode idle times and length of manufacturing campaigns. The
fixed cycle policies with standard process run times tend to have p1 less frequently
in their sequences compared to the other products. This is due to its low demand —
all of a year’s demand can be produced in a 60 day batch. Apart from FCP1B, the
best FCPB policies have sequences that are shorter than their ‘A’ counterparts —
125
Table 6.10: Policy parameters for p1-p3 in each of the base-stock policies and the
ANN policy. The best solutions (i.e., the best solution out of all EA runs for each
tuned policy) are reported. For the ANN, the mean ± std. err. of batch run-times
over several simulations is reported; the run-times for batches that were terminated
due to process failures or those that had not been completed by the end of the
simulation horizon were not included in these calculations.
p1
Y (1) Y (2) Y (3) Y (4) Y (5) B
BSP0 6.2 52.5 – – – 60
BSP1A 16.4 16.7 – – – 60
BSP1B 18.7 19.9 – – – 47
BSP2A 10.5 27.5 15.2 16.2 – 60
BSP2B 12.8 20.3 15.0 17.1 – 43
BSP3A – – – – 16.3 60
BSP3B – – – – 16.3 43
ANN – – – – – 33.7 ± 0.00
p2
Y (1) Y (2) Y (3) Y (4) Y (5) B
BSP0 11.1 93.6 – – – 60
BSP1A 28.8 28.9 – – – 60
BSP1B 25.1 25.5 – – – 58
BSP2A 23.5 38.4 25.3 26.1 – 60
BSP2B 22.4 31.5 23.4 25.3 – 59
BSP3A – – – – 23.8 60
BSP3B – – – – 29.2 51
ANN – – – – – 49.4 ± 0.01
p3
Y (1) Y (2) Y (3) Y (4) Y (5) B
BSP0 10.7 77.5 – – – 60
BSP1A 23.8 23.9 – – – 60
BSP1B 21.0 21.6 – – – 65
BSP2A 19.1 39.9 21.3 21.5 – 60
BSP2B 6.6 36.4 18.8 19.9 – 74
BSP3A – – – – 28.8 60
BSP3B – – – – 19.2 79
ANN – – – – – 71.9 ± 0.02
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Table 6.11: The optimal sequence and process run times for the fixed cycle policies
overall from all EA runs.
Sequence Y (2)p1 Y
(2)
p2 Y
(2)
p3 Bp1 Bp2 Bp2
FCP1A 1-3-2-3-0-3-0-2 – – – 60 60 60
FCP1B 2-0-1-3-0-2-3-0-1-0-2-3 – – – 42 48 73
FCP2A 1-3-2-3-2-3 45.3 25.0 12.5 60 60 60
FCP2B 2-1-3 15.3 40.6 22.5 37 55 87
FCP3A 1-2-3-1-2-3-2-3-2 17.7 24.3 26.1 60 60 60
FCP3B 2-3-2-1-2-3 21.4 22.3 22.9 47 58 74
an extreme being FCP2B which is just a simple permutation of the three products.
Observed solutions for process run times are based on striking a balance be-
tween the process yields and demand forecasts of each product as well as the in-
creasing risk of process failure with longer process duration. It is intuitive, based
on the specifics of the case study, that p1 would have a shorter process run time
than the other products because it has much lower demand. By the same token, it
makes sense that p3 has a longer process run time than p2 because it has similar
demand but the yield of its manufacturing process is a third lower.
There are no major differences in the optimised process run times between
the different base-stock policies apart from p2 in BSP3B and p3 in BSP1B where
the run times are significantly lower than that of the other tuned BSPs. The same
cannot be said for the FCPs where the optimised run times vary substantially be-
tween the best policy solutions. The ANN policy, as predicted by inspecting the
cost breakdowns, has significantly lower expected run times compared to all the
other policies. This indicates that this policy suffers from reduced efficiency —
more time is spend setting up batches or changing over between different products
which reduces the facility’s productivity.
All the optimised durations deviate from the ‘standard’ process run time of 60
days especially with p1 and p3. It is interesting to note that the optimised policies
tend to have process run times that cannot produce all of the expected demand for
a year in a single batch even if it is possible — process durations of 53 and 88 days
would suffice for p1 and p2 respectively. As previously mentioned, the factors
determining these decisions are the need to mitigate process failure and the ability
to changeover to other critical products. It is not clear which role each of those
factors play in each case but it is fair to say that mitigating process failure is more
influential for p2 than it is for p1.
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Figure 6.3: Exemplar schedules from a single simulation run with the same ran-
dom number generator seed for the standard, FCP1B, ANN, FCP3B, BSP3A, and
BSP3B scheduling policies.
6.6.5 Production Schedule(s) for the Facility
Although the Gantt charts in Figure 6.3 are just for one scenario and simulation
run, many of the points previously discussed are illustrated here. The Gantt charts
shown are for BSP0 and the best performing solutions for FCP1B, FCP3B, BSP3A,
BSP3B, and the ANN.
BSP0 schedules batches of the same product together so that campaigns have
multiple batches and minimises changeover costs as a result. As a result of these
sustained campaigns, the inventory will be built up and incur higher storage costs.
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Moving from BSP0 to BSP3A and then to BSP3B, the number of multi-batch cam-
paigns decreases with BSP3B not scheduling any two batches of the same product
together in this particular scenario — this also applies to FCP1B and the ANN. For
FCP1B the sequence does not include any consecutive batches of the same prod-
uct. With increasing number of product changeover, there is more production time
lost due to the fact that changeover between batches of different products requires
more setup time than the turnaround between two batches of the same product.
This is why the BSP0 chart appears to be less utilised. Scheduling of idle time on
the facility are decisions directly available to the ANN and FCP1B policies, but it
is these policies that actually have the least amount of idle time. In the case of the
ANN, there is none scheduled at all.
What these charts also illustrate is a disadvantage of FCP1B: although it is
able to dictate a schedule ahead-of-time, it is not able to find a ‘good’ decision to
make when the environment changes. This is true especially in the event of pro-
cess failure where it will move on to the next batch in the sequence regardless of
any critically low inventory levels. On the other hand, while the BSPs cannot fix a
schedule in advance or determine an absolute decision to make when process fail-
ure occurs, they can implicitly react to changes by deciding at each point whether
to continue with that product, go idle or switch to another product. Similarly, al-
though FCP3B is based on a ‘fixed’ sequence which should help mitigate planning
nervousness, it is often the case that production skips ahead by one or more ele-
ments in the sequence. In this respect, this policy is more alike to the BSP policies
than a rigid schedule or manufacturing sequence.
6.6.6 EA Performance and Statistical Analysis
Statistical testing on the performance of the policies was carried out, the results of
which are presented in Table 6.12 on the next page. It contains a matrix of p-values
from Mann-Whitney U tests comparing the profits of the final solutions from each
policy. It indicates that in terms of performance, the assertion that ANN < BSP1A
< BSP2A < BSP3A < BSP1B < BSP2B < BSP3B is statistically significant (at
the level of 0.05) when looking at pairwise comparisons between each policy and
the rest. Similarly, FCP1 < FCP2A < FCP2B < ANN < FCP3A < FCP3B. It also
shows that the difference between both FCP1 policies is not significant.
Figure 6.4 on page 131 shows the convergence of the optimisations of the ANN
with different minimum process run times and Figure 6.5 on page 132 shows that
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Figure 6.4: Convergences of the ANN optimisations runs with different lower
bounds on process run time. LB14 = minimum run time of 14 days for all prod-
ucts; LB30 = minimum run time of 30 days for all products; LBOPT = minimum
run time optimised for each product.
for the BSPs. Across all the BSP policies both optimisation algorithms tested (i.e.,
the GA and the CMA-ES) deliver essentially the same quality of final solutions.
However, the more state-of-the-art CMA-ES converges faster than the GA. This
gets more pronounced the more decision variables the problem has — e.g., BSP2
which has four inventory parameters per product — and with the policies that have
to optimise process durations in addition to the inventory parameters. In addition,
these EAs were compared with random search and it is shown that the EAs perform
significantly better on most of the policies. The exceptions to this are the BSP3
policies where there is no statistical difference between the performance of random
search and the EAs. This suggests that BSP3, by virtue of its in-built forecasting
heuristic, is able to make good scheduling decisions during simulation. It also
helps that the policy has very few decision variables to optimise (six at most and
as few as three when process run times are fixed) so the search space is smaller.
To test the benefit of the forecasting heuristic, the BSP3 policies were com-
pared with BSP1 policies where Y (1) = Y (2). This constraint is to ensure that both
policies work in the same way except that the BSP3 policies break ties with the
forecasting heuristic and the BSP1 policies break ties by comparing run-out times.
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So for both the BSP3 and the constrained BSP1, 2,000 policies were randomly
generated and evaluated. The mean performance (± standard error) of the BSP3
policies was 167933± 850 RMU and the performance of the constrained BSP1
policies was 166709± 855 RMU. A two-tailed Mann-Whitney U test was per-
formed on the policies and indicated that the increase in performance of the BSP3
policies was statistically significant (observed significance level of <0.001).
The ANN convergence plot demonstrates how much more of a computation
effort is required to find a good policy — at least when compared with the BSPs.
Lower bounds on the process run time significantly affect the speed of convergence;
while a lower bound of 14 days on average converges to values close to the others, it
takes substantially more fitness evaluations to get there. While more parameters to
tune usually means slower convergence, the optimised lower bounds converge with
the least fitness evaluations with lower bound of 30 days slightly worse. This is due
to the ability to exclude bad policies which schedule inefficiently short batches.
In Table 6.13 on the following page, the computation times for the differ-
ent EA optimisations are reported. These values are from one run each of the
hyper-heuristic for each policy type. This experiment was carried out on an Intel R©
CoreTM i5-7500 Quad-core 3.40GHz processor, with 8GB RAM running Microsoft
Windows 10 64-bit. In cases where both the GA and CMA-ES are used, generally,
the latter is slower. This is due to the updates of the covariance matrix carried out
within the CMA-ES algorithm. The considerably longer CPU times needed by the
ANN can be explained by two reasons. First, the ANN tuning was given a bud-
get of fitness evaluations that is twice that of the BSPs and FCPs. Secondly, the
implementation of this policy dictates that decisions are made almost every day in
the simulation which requires querying the neural network any time a decision is
required. This is a significantly larger computation load. For example, if all pro-
cess run times are 60 days, a base-stock policy would make decisions on around
40 days of the seven-year simulation. In contrast, an ANN policy with run time
lower bound of 14 days would need to make over 1,000 days of decisions in order
to have its process durations also be 60 days in a simulation horizon of the same
length. This explains why increasing the run time lower bounds (or allowing them
to be optimised) gives a considerable increase in speed. In fact, the CPU time of
the ANN with optimised lower bounds, if interpolated to 6,000 fitness evaluations,
is comparable to the FCPs (and to a lesser extent the BSPs) which use the CMA-ES.
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Table 6.13: CPU times (in seconds) for a single run of each EA for the scheduling
policies. ANNLB-14 and ANNLB-30 are ANN policies with minimum process run
time fixed to 14 days and 30 days respectively. ANNLB-OPT is ANN policy with
optimised process run time lower bounds for each product.
GA CMA-ES
BSP1A 817 906
BSP1B 812 830
BSP2A 839 793
BSP2B 839 952
BSP3A 836 784
BSP3B 830 937
ANNLB-14 – 6474
ANNLB-30 – 4590
ANNLB-OPT – 1923
FCP1A 822 769
FCP1B 818 924
FCP2A 808 931
FCP2B 804 929
FCP3A 801 943
FCP3B 797 940
Overall, these analyses have shown that it is beneficial to tune parameters
for the scheduling policies instead of relying on estimated parameters or a fixed
schedule or sequence of batches. Furthermore, optimising process run times offers
additional advantages as it allows the policy to schedule batches so that product
changeover can occur when inventory falls to critical levels and also select run
times with efficient productivities and an acceptable risk of process failure. Thirdly,
there does not appear to be any benefit of utilising flexible process run times com-
pared to the BSPs or the more complex of the fixed cycle policies — at least in
this scenario and specific neural network implementation. In addition, intelligent
choice of process run time lower bounds may help improve speed of convergence
and minimise computation time. Finally, the choice of optimisation algorithm, for
the BSPs at least, does not play a significant effect in the quality of final solution.
However, as the number of decision variables increases, a more efficient algorithm
such as CMA-ES, can contribute to a faster convergence (with regards to fitness
evaluations).
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6.6.7 Evaluating the Sensitivity of Optimised Policy Solutions
The case study that the policies have been optimised for and evaluated on has a
demand forecast which is stochastic but is a known and defined distribution. In
reality, it is not easy to accurately predict or forecast demand in advance — which
is why the demand is defined as a probability distribution with a mean based on
targets and market research (and variance based on estimated margin of error in
predictions). However, as actual demand is being realised it can be difficult to
determine whether the observed demand actually is sampled from the same distri-
bution as the one predicted. So the observed demand could potentially be from a
distribution with a different mean and/or variance. This section aims to determine
the behaviour of the previously obtained solutions on slightly different problem
instances to the one they were trained on.
With those considerations, some of the policies were tested at different de-
mand scales. Specifically, the best solution from each of FCP3B, BSP1B, BSP2B,
BSP3B, and the ANN as well as the previously estimated BSP0 solution were eval-
uated over 20,000 simulations on demand load cases in the range of ±15% of the
standard case. As before, the demand due in each year is stochastic and described
by a Normal distribution, N(µ,(0.025µ)2). Apart from the change in demand load,
all the other model and problem parameters were unchanged from those in the case
study description or those used in Section 6.6.2.
Results of the sensitivity tests are shown in Figure 6.6 on the next page where
the performances are compared relative to BSP0. From the figure one can observe
that the best solution of BSP3B is better than the rest at the standard demand case
with BSP2B, BSP1B, FCP3B, and the ANN following in that order. However, the
BSP3B solution does not maintain its ranking when looking at demand cases be-
low and above the standard case, dropping into second place in cases 85% to 95%
of the standard demand while BSP2B replaces it at the top. At the 95% demand
case, though the mean of BSP2B is greater than that of BSP3B, the difference is
not statistically significant to say that either policy is better than the other. The per-
formance of the ANN falls away rather quickly either side of the standard demand
case to the point that at 85% it is actually worse than the standard policy. BSP2B
remains the best performing policy solution above the standard demand case —
closely followed by FCP3B — apart from in the most loaded problem instance
where it falls into third place. In that case, BSP3B and BSP1B perform similarly
and the difference between them is not statistically significant. At this demand
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case, FCP3B is only better than the ANN.
Relative to the standard policy, which has its parameters heuristically chosen,
the performances of the tuned policies generally decline as one moves away from
the standard demand case. For the tuned BSPs and FCP3B this effect is more pro-
nounced at the demand loads less than the standard case. For the BSPs, a partial
explanation for this trend is that at less loaded problems, sub-optimal decisions in-
cur less harsh penalties. For example, the main driver for the difference between
BSP0 and the tuned policies at the standard demand case is backlog penalties. So
with lower observed demand, clearly this becomes less important and the differ-
ence decreases. A more general explanation applicable to all policies is that tuning
it exploits the specific structure and characteristics of the problem instance it is
trained on which means it loses its applicability to moderately different or more
general problems — this is referred to as overfitting.
Overall what can be observed from this testing is that BSP2B is the best per-
former across all slightly different demand scale instances apart from the most
loaded problem. This is despite BSP3B being best at the problem it was trained
on. The implication is that one will need to check the sensitivity of best solutions
to demand case changes instead of automatically taking the best policy solution
trained on the current problem.
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6.7 Summary
This chapter considered the stochastic economic lot scheduling problem (SELSP)
in the context of a biopharmaceutical manufacturing scenario consisting of multi-
ple products on a single facility utilising semi-continuous perfusion processes that
are prone to various types of process failure which have significant operational
consequences. To deal with the challenges that this problem poses, a simulation-
optimisation approach was developed and implemented.
First, to complement the previously developed custom discrete-event simula-
tion framework, a few dynamic scheduling policies were adapted from the litera-
ture to fit the problem being investigated. In addition to this, a novel policy with
a forecasting heuristic was proposed. These policies were then tuned on a syn-
thetic case study using evolutionary algorithms (EAs) in what amounts to a hyper-
heuristic search.
Evaluation of these policies and further comparison with a heuristically deter-
mined standard policy as well as policies based on a fixed sequence demonstrated
the benefit of tuning parameters and utilising policies that use the current state of
the scheduling environment to make decisions. Further tuning of process run times
led to improved performance as this enables better lot-sizing decisions which may
allow hedging against process failure by utilising a shorter run time.
In addition to these policies, a flexible policy based on an Artificial Neural
Network (ANN) representation was proposed and compared with tuned policies.
This comparison showed that, in the scenario examined in this chapter, the imple-
mentation of a policy capable of flexible process run times did not improve on the
performance of the best tuned fixed cycle policies and base stock policies.
Finally, it is recommended that a potential decision-maker evaluate the policies
at different demand loads in order to determine their behaviour and sensitivity. This
is because relative performance may differ when presented with slightly different
problems than it was trained on.
138
Chapter 7
Conclusion and Future Work
7.1 Summary and Contribution of Thesis
Over the course of this thesis, deterministic and stochastic variants of lot sizing
and scheduling problems have been considered within the context of the biophar-
maceutical industry. The main contributions lie with the decision tools that were
introduced here.
First, a meta-heuristic approach for a capacity planning problem for fed-batch
processes was proposed. Compared to mixed-integer linear programming (MILP),
it avoided simplifying assumptions on the discrete time periods and as a result is
able to model reality more accurately. In addition, it demonstrated better scaling
properties (computation time grows slower than the MILP with increasing problem
size) and could easily be adapted to multi-objective problems with the implementa-
tion of a multi-objective evolutionary algorithm such as the non-dominated sorting
genetic algorithm II (NSGA-II).
After that there was a change in focus to processes incorporating perfusion
unit operations. Though there is existing literature on capacity planning models
that include perfusion processes and there are tools evaluating the economics of
utilising perfusion processes while taking into account their increased failure rates,
there was no evidence of tools or models that focused on scheduling whilst also
considering these processes’ greater propensity for failure. In other words, no pre-
existing literature attempted to determine optimal schedules for these perfusion
processes whilst anticipating or expecting they would fail and asking the question
of what the best decision(s) to make after process failure events.
The result of this was the development of a custom model to simulate semi-
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continuous bioprocesses in a scheduling system which was sensitive to the conse-
quences of failure events attributed to the perfusion cell culture and its cell retention
system. This was used to evaluate process design decisions such as the cell culture
run time and process configuration(s).
Eventually, this became part of a larger novel hyper-heuristic framework which
was utilised to determine optimal process run times and scheduling decisions for
single-product and multi-product facility scenarios. For the former, simple inven-
tory replenishment-type strategies were examined and for the latter, rule represen-
tations included base-stock policies, fixed-cycle policies, and an Artificial Neural
Network (ANN).
7.2 Future Work
There are several avenues for extending the work presented in this thesis. This
shall be discussed in relation to the chapters in this thesis that cover the work to be
extended. However, in general, the work in this thesis would benefit from further
validation on more case studies and different problem instances.
7.2.1 Chapter 4
First, in reality, demand is estimated and uncertain, so the approach can be adapted
to deal with stochastic problems. Since subsequent chapters have dealt with stochas-
ticity in a dynamic fashion, the more suitable approach with this meta-heuristic is
to conduct scenario analysis on the products or facilities in the scenario which are
deemed to be critical or seemingly more susceptible to uncertainty.
This would also be a good juncture to investigate different instances of the
problem solved in this work. This may involve smaller or larger problems or prob-
lems with different cost structures. For example, sequence-dependent setup costs
and times could be incorporated into a different problem, as well as explicit costs
associated with facility overheads, transportation, and using CMOs. In addition
facility-build or retrofit decisions may be added to the set of decision variables.
With regards to multiple objectives, it is possible to extend the optimisation to
consider alternative or additional objectives (e.g., utilsation of in-house or CMO
facilities). Suffice to say, there are numerous permutations of different problems to
which the tool may be applied to within biopharmaceutical manufacturing.
Third, it may be useful to extend the splitting mechanism to increase the search
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space so that it is more likely that the optimal schedule is indeed contained in
the search space of the search algorithm. Finally, one might explore also other
optimisation methodologies to solve this problem such as constraint programming
(Laborie, 2009) or hybrid approaches (Blum and Raidl, 2016). In addition, it may
be worth comparing this method to recent work by Jankauskas et al. (2019) which
uses a GA approach on a similar biopharmaceutical problem by utilising a dynamic
chromosome structure to directly encode the solution.
7.2.2 Chapter 5
The work in this chapter focuses on processes that utilise single-use technology in
the upstream part of the process. As a result, there is scope to extend the model so
that it considers the use of conventional stainless-steel equipment for its upstream
processing (USP). This obviously would require a slightly different cost model
since the current cost structure of the model is solely based on single use bioreac-
tors (SUBs). This would mean including the costs of fixed capital investment (FCI),
labour costs, and all direct and indirect costs in general.
Second, in order to assess the optimum process run times, the bioreactor vol-
umes, chromatography column sizes and resin volumes, and the process design in
general are fixed. This means that shorter process run times have an upper bound
on productivity and longer process run times have a lower bound on productiv-
ity. In reality, the USP and DSP design can be optimised around a selected run
time (by changing bioreactor volumes, column sizes, pooling strategy, etc.) to
meet a productivity target. Process design is not trivial and it would be exhaustive
to optimise process design for every possible run time and demand combination.
However, it may be worthwhile exploring a few process run times with the process
redesigned to examine what aspects of the process need to be re-optimised and also
what the knock-on effect on scheduling performance is. Alternatively, commercial
software that is designed for process design and simulation could be coupled with
expensive-optimisation algorithms as another approach.
Finally, combining the previous points, existing literature on assessing the ben-
efits (in fed-batch processes) of multiple reactors compared to a larger single reac-
tor has rested on the trade-off between equipment costs of the reactors and consum-
able costs related to chromatography resins and viral filters in DSP. The investiga-
tion into process configuration in this chapter does not capture this as the costs of
individual SUBs dominate and the DSP remains the same. However, since SUBs
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are currently limited to 2000L, there is scope to compare a large stainless-steel
perfusion process with multiple parallel 2000L SUBs (even if both DSPs are iden-
tical) as this not only captures the trade-off between frequent but smaller failures
vs. fewer but more significant failures, but also the trade-off between conventional
equipment and disposable equipment. Also, multiple reactor configurations can be
compared where reactors share one common seed train vs. where each has its own.
7.2.3 Chapter 6
There are a few possible ways to extend the work presented in this chapter. The
obvious one is to apply this method to different case studies. For example, a clinical
manufacturing scenario will likely have less established processes and therefore
probably higher error, failure rates, or a larger variance in probability distributions
describing the stochastic processes in general. In addition and complementary to
this, instances may have process yields and cell culture titres also uncertain and
stochastic. In addition, problems that also mix different bioprocessing modes (i.e.,
fed-batch and perfusion cell cultures) together would represent a good extension to
this work as it would introduce sequence-dependent changeover times.
Second, one can extend the problem tackled so that it is able to deal with mul-
tiple facilities. The scope of that problem is much larger and requires heuristics
and/or policies that not only need to coordinate facilities in terms of what they
manufacture at any time instant, but also potentially anticipate the future work-
load of critical facilities within the network. This will require careful considera-
tion of strategies to deal with expensive evaluations and noise as the problem size
increases such as meta- and surrogate-modelling (Jin and Branke, 2005; Branke,
2018). In fact, such methods could be used to manage the computation time of the
optimisation procedure as it is now and are worth exploring even without the added
computational burden and load of additional facilities.
Finally, there is potential to consider product attrition or project selection in
an R&D perspective. The decision variables may be adapted to select an initial
portfolio out of an initial set of alternatives with different attrition rates and market
potential and the objective function would be to maximise expected net present
value (NPV) or risk-adjusted NPV.
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Figure A.1: Exemplary Gantt chart of a schedule generated by the GA for the 2 ×
demand case. The profit and customer service level (CSL) is also indicated..
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Figure A.2: Exemplary Gantt chart of a schedule generated by the MILP, for the 2
× demand case. The profit and customer service level (CSL) is also indicated.
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Figure A.3: Exemplary Gantt chart of a schedule generated by the GA, for the 3 ×
demand case. The profit and customer service level (CSL) is also indicated.
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Figure A.4: Exemplary Gantt chart of a schedule generated by the MILP, for the 3
× demand case. The profit and customer service level (CSL) is also indicated.
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Appendix B
Chapter 5 Appendix
B.1 Bioprocess Model Parameters
Calculation of Bioprocess Economics Parameters
The basis and rationale for determining the cost parameters for different aspects
of the process is laid out in this section. Figures, estimates and assumptions are
based on guideline values used by or suggested by Felo et al. (2013), Farid et al.
(2014), Pollock et al. (2013b), or Pollock (2013). The dollar amounts have been
transformed such that 1,000 USD ≈ 1 RMU.
There are six different types of costs attributed to the bioprocess as defined in
Section 5.2.1. These costs are attributable to direct costs including materials and
consumables and do not take into account labour, indirect or other fixed investment
costs unless otherwise stated or indicated. It is assumed that the process utilises
disposable/single-use equipment and is capable of meeting an annual demand of
ca. 450 kg with a 1:1 USP:DSP train ratio and whole process yield of 69%.
Seed Train Costs This is representative of the direct material costs accrued from
operating the seed train (Seed #1 and Seed #2 in Figure 5.3). To estimate this, the
costs for a 100L Wave bag, a 200L SUB (Single Use Bioreactor), and media costs
are summed up — it is assumed that there are no additions during the batch and
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the volumetric efficiency is 80% for both reactors. Media costs $ 3.15/L.
100L Wave+200L SUB+80% of 300L×Media Cost
= 420+4200+240×3.15
= $ 5376
So, about 5.4 RMU.
Cell Culture Setup Costs This takes into account the ATF filter, the SUB and
the initial media within it. The bioreactor used is a 2000L SUB with a volume
efficiency of 50% utilising an ATF 10 system.
1000L × Media Cost + ATF filter + 2000L SUB
= 1000×3.15+16300+9800
= $ 29250
This comes to roughly 29.3 RMU.
Cell Culture Daily Costs Media costs for daily perfusion are the only compo-
nent represented here; the perfusion rate is 1 vessel volumes per day (vv/day) in
terms of the liquid working volume.
Perfusion rate × working volume × Media Cost
= 1×1000×3.15
= $ 3150
Cell culture daily costs are therefore estimated to be 3.2 RMU.
ATF Filter Replacement Cost Simply the cost for a new filter for the ATF 10
system. This is stated to be $ 16300 per unit and therefore a cost of 16.3 RMU is
used.
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DSP Batch Costs Includes the process steps from the Protein A step to the final
UF/DF. The costs of the chromatography resins are amortised over the number
of batches it takes to meet five years’ worth of demand which take into account
repurchases when the resin has exceeded its lifetime (re)uses. The parameters of
which can be found in Table B.1.
Amort. ProA +2×Amort. IEX +VRF +Amort. UF +Bags & Liners
= 1742+2×302+6500+100+2×453+7×360
= $ 12372
As such, the Cost of each DSP batch is estimated to be 12.4 RMU.
Campaign/Changeover Costs Estimated from QCQA batch release costs being
$ 35000 (Pollock, 2013) to therefore be 35 RMU.
B.2 Tables
Table B.1: Parameters, inputs and outputs for estimating costs of the Protein A and
the two ion-exchange (IEX) resins.
Parameters ProA IEX Unit
Inputs
Columns 1 1
Resin DBC 50 30 g/L
Bed height 20 20 cm
No.of cycles 1 1
Linear velocity 450 600 cm/h
Lifetime reuses 120 180
Resin cost 8000 2000 $/L
Outputs
Column diameter 40 40 cm
Cycle time 173 130 minutes
Amortised resin cost 1742 302 $/batch
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Table B.2: Summary of GA evolved (s,B) policy parameters for the various
USP:DSP process configurations. Units for parameter s and annual demand are
in kg and in days for parameter B.
1 reactor 2 reactors 3 reactors 4 reactors
s B s B s B s B
mean 34.8 110.9 38.3 105.0 41.7 109.4 47.4 110.0
s.d. 1.86 4.55 1.93 3.16 2.89 3.04 5.2 2.56
median 111 105 109 110
mode 111 107 106 110
B.3 Figures
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Figure B.1: Mean convergence over 50 GA runs for the (s,B) scheduling strategies
at the four process configurations investigated.
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scheduling strategies at various demand targets.
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C.1 Tables
Table C.1: Sensitivity of the optimised policies to different demand scales at
monthly demand frequency. Figures reported are expected profit values (in RMU)
± std. err. Best performance for each demand case is in bold.
Demand case BSP1B BSP2B BSP3B ANN
50% 90985 ± 4.5 91833 ± 4.7 91489 ± 4.6 67738 ± 5.7
75% 140314 ± 5.9 140592 ± 5.9 140552 ± 6.0 128846 ± 8.1
80% 150060 ± 6.3 150409 ± 6.4 150217 ± 6.3 141164 ± 8.4
85% 159970 ± 6.8 160058 ± 6.8 160016 ± 6.7 153263 ± 8.6
90% 169796 ± 7.0 169911 ± 7.2 169869 ± 7.1 165227 ± 9.1
95% 179480 ± 7.6 179574 ± 7.5 179576 ± 7.5 177260 ± 9.3
100% 189225 ± 8.1 189261 ± 8.2 189343 ± 8.0 188540 ± 11.7
105% 197807 ± 10.8 197899 ± 10.8 197589 ± 11.1 189258 ± 32.6
110% 202071 ± 17.9 202073 ± 17.8 201003 ± 18.2 182174 ± 33.9
115% 203112 ± 20.8 203071 ± 20.6 202013 ± 20.4 174785 ± 34.0
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Table C.3: Optimised parameters for p1-p3 in each of the scheduling policies. The
mean ± std. deviation of the 50 best solutions (i.e., the best solution in each EA
run) are reported.
p1
Y (1) Y (2) Y (3) Y (4) Y (5) B
BSP0 6.2 52.5 - - - 60
BSP1A 16.4±1.0 18.7±2.2 - - - 60
BSP1B 19.4±1.6 21.3±1.9 - - - 43.4±3.1
BSP2A 10.8±2.4 24.3±5.1 15.6±1.1 17.7±2.0 - 60
BSP2B 12.4±3.9 24.8±3.2 18.1±1.8 20.1±1.9 - 44.1±8.6
BSP3A - - - - 16.0±0.9 60
BSP3B - - - - 17.4±1.2 43.2±0.9
ANN – – – – – 34.1±1.88
p2
Y (1) Y (2) Y (3) Y (4) Y (5) B
BSP0 11.1 93.6 - - - 60
BSP1A 27.6±1.8 29.5±2.2 - - - 60
BSP1B 26.6±2.9 28.6±3.2 - - - 58.4±4.5
BSP2A 22.0±4.8 33.6±4.0 26.5±2.1 27.8±5.0 - 60
BSP2B 20.5±6.3 34.0±5.0 26.7±3.3 28.2±2.9 - 58.4±6.4
BSP3A - - - - 25.2±1.6 60
BSP3B - - - - 30.1±2.0 51.7±1.9
ANN – – – – – 51.3±2.75
p3
Y (1) Y (2) Y (3) Y (4) Y (5) B
BSP0 10.7 77.5 - - - 60
BSP1A 23.8±0.7 23.9±0.7 - - - 60
BSP1B 20.3±2.6 20.9±2.5 - - - 72.4±7.2
BSP2A 14.6±4.9 38.3±5.1 21.4±1.3 21.5±1.3 - 60
BSP2B 10.7±4.7 31.0±6.0 19.2±1.6 19.9±1.5 - 75.5±6.6
BSP3A - - - - 28.1±1.6 60
BSP3B - - - - 20.6±2.0 77.0±4.7
ANN – – – – – 73.2±6.14
165
Table C.4: Matrices of observed significance level of Mann-Whitney tests compar-
ing the mean profit of the best solution of each policy at different demand scales.
The p-values are for the test that 〈row〉 > 〈column〉.
Demand case ×0.85
BSP1B BSP2B BSP3B
BSP1B - 1.00E+00 1.00E+00
BSP2B 4.71E-33 - 1.01E-10
BSP3B 8.78E-09 1.00E+00 -
Demand case ×0.90
BSP1B BSP2B BSP3B
BSP1B - 1.00E+00 1.00E+00
BSP2B 2.25E-76 - 7.17E-02
BSP3B 1.23E-65 9.28E-01 -
Demand case ×0.95
BSP1B BSP2B BSP3B
BSP1B - 1.00E+00 1.00E+00
BSP2B 9.63E-21 - 3.06E-01
BSP3B 5.87E-19 6.94E-01 -
Demand case ×1.00
BSP1B BSP2B BSP3B
BSP1B - 1.00E+00 1.00E+00
BSP2B 4.63E-17 - 9.95E-01
BSP3B 1.76E-28 5.10E-03 -
Demand case ×1.05
BSP1B BSP2B BSP3B
BSP1B - 1.00E+00 9.90E-01
BSP2B 3.40E-110 - 4.29E-90
BSP3B 9.59E-03 1.00E+00 -
Demand case ×1.10
BSP1B BSP2B BSP3B
BSP1B - 1.00E+00 5.58E-35
BSP2B 1.94E-24 - 1.36E-111
BSP3B 1.00E+00 1.00E+00 -
Demand case ×1.15
BSP1B BSP2B BSP3B
BSP1B - 1.79E-30 6.15E-01
BSP2B 1.00E+00 - 1.00E+00
BSP3B 3.85E-01 9.56E-40 -
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Figure C.1: Exemplar inventory profiles over scheduling horizon from the simula-
tion run in Figure 6.3 on page 128 for the standard and FCP1B scheduling policies.
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Figure C.2: Exemplar inventory profiles over scheduling horizon from the simula-
tion run in Figure 6.3 on page 128 for the ANN and FCP3B scheduling policies.
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Figure C.3: Exemplar inventory profiles over scheduling horizon from the simula-
tion run in Figure 6.3 on page 128 for the BSP3A and BSP3B scheduling policies.
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